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1. Introducción 
Streptococcus pneumoniae (neumococo) es un patógeno humano que puede colonizar el 
tracto respiratorio superior o puede causar infecciones invasivas como neumonía, meningitis y 
empiema, y no invasivas como otitis media, sinusitis y bronquitis, principalmente en niños, 
ancianos e inmunodeprimidos. Es la principal causa de muertes en niños menores de 5 años a 
nivel mundial, sobre todo en los países en vías de desarrollo. 
Existen más de 90 serotipos diferentes de acuerdo a la composición de la cápsula 
polisacarídica y, aunque existen vacunas comerciales basadas en la cápsula, su eficacia es 
limitada y son caras. Así, tanto por la reciente aparición de cepas multirresistentes a 
antibióticos como por fenómenos derivados de la introducción de las vacunas polisacarídicas 
gracias a la gran capacidad de adaptación del neumococo es de urgente necesidad 
desarrollar nuevas, más eficientes y más baratas vacunas serotipo-independientes.  
Esta nueva vacuna debe ser de base proteica para reducir el coste de producción, y los 
candidatos, estar expuestos en superficie, antigénicamente conservados, presentes en los
serotipos más prevalentes, altamente expresados, su función debe ser esencial en 
patogenicidad y ser capaces de estimular repuesta celular. Con el fin de descubrir nuevos
candidatos proteicos, tanto con fines vacunales como para el desarrollo de herramientas de 
diagnóstico rápido, durante la presente tesis se ha desarrollado dos líneas de trabajo 
principalmente: La digestión superficial de células vivas con proteasas (1) y la producción y 
caracterización de vesículas extracelulares.
2. Contenido de la investigación
En primer lugar se llevó a cabo la optimización de la técnica del “pelado” de células vivas de 
neumococo con proteasas (2), tras lo cual se aplicó a una batería de aislados clínicos de adultos (3) 
y de niños con el fin de describir los “pan-surfomas” (conjunto de proteínas de superficie presentes 
en una batería de distintas estirpes), confirmando a esta técnica como una rápida y potente 
aproximación para la identificación de proteínas de superficie (4, 5). Por 
otro lado, la reciente descripción de la producción de vesículas extracelulares en organismos
Gram-positivos, nos llevó a caracterizar las vesículas de neumococo debido a que dichas 
estructuras están enriquecidas, presuntamente, en proteínas de membrana.
Así, 40 aislados clínicos (correspondientes a 29 diferentes ST) sin relaciones evolutivas, además de 
las estirpes de referencia R6 y TIGR4, se analizaron mediante la aproximación de la 
digestión superficial de células vivas. Además, otros 4 serotipos, relacionados con diferentes 
capacidades de invasión (serotipos 1, 6B, 8 y 23F), se usaron para la caracterización de las
vesículas derivadas de la membrana. Todo ello permitió seleccionar 95 proteínas, cuya 
inmunoreactividad se probó frente a sueros de pacientes enfermos y sanos (algunas de ellas, 
mediantes diferentes técnicas). Esto nos permitió seleccionar un conjunto de pocas
proteínas (Spr0561, Spr0247, Spr1431, Spr1754 and Sph_0062) para desarrollar un test de 
enfermedad neumocócica rápido, fiable, barato y fácil de usar  en niños de 0->5 años, que
resolvería los problemas de los métodos de diagnóstico usados hasta el momento.
Por otro lado, se llevaron ensayos de supervivencia usando una estirpe virulenta del serotipo 8 
como agente de infección, lo cual nos permitió describir la capacidad protectora de 7 nuevas 
proteínas. Además, se demostró que las vesículas de membrana producidas por este mismo 
serotipo conferían un alto grado de protección a los ratones inmunizados.
3. Conclusión 
Las principales conclusiones que se pueden destacar de esta tesis doctoral son: 
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First, optimization of "shaving" of live pneumococcal cells with proteases (2) was carried out 
and then it was applied to a set of clinical isolates from adult (3) and children in order to 
describe the "pan-surfome" (set of surface proteins present in a collection of different strains). 
This confirmed this technique as a rapid and powerful approach to surface protein 
identification (4, 5). Furthermore, the recent description of the production of extracellular 
vesicles in a Gram-positive bacteria, prompted us to characterize pneumococcus vesicles 
because such structures are enriched, presumably, in membrane proteins.
So, 40 clinical isolates (corresponding to 29 different ST) without evolutionary relationships, as 
well as reference strains R6 and TIGR4, were analyzed by the “shaving” approach. In addition, 
other 4 serotypes, with different capabilities of invasion (serotypes 1, 6B, 8 and 23F) were used for 
the characterization of the extracelluar vesicles (5, 6). All of this allowed to select 95 proteins and 
tested their immunoreactivity against sera of convalescent and healthy patients (some of them, 
1. El “pelado” de células vivas con proteasas es posible en Streptococcus pneumoniae, aunque la
lisis celular se confirma como un hecho intrínseco y debido a la manipulación experimental 
(Capítulos I, II y III) 
2. El “pan-surfoma” de una colección de aislados clínicos provee, además de candidatos para
vacunas, antígenos que se pueden usar para desarrollar test serológicos (Capítulos I, II y III).
3. La inmunización de ratones con proteínas individuales seleccionadas a partir de los análisis del 
“pelado” de células vivas de aislados clínicos de pneumococo de adultos y niños no es suficiente 
para conferir inmunidad frente a la infección por el serotipo 8 de Streptococcus pneumoniae
(Capítulo III).
Streptococcus pneumoniae (pneumococcus) is a human pathogen that can colonize the upper 
respiratory tract and can cause invasive infections such as pneumonia, meningitis and 
empyema, and noninvasive as otitis media, sinusitis and bronchitis, especially in children, the 
elderly and immunocompromised. It is the leading cause of death in children under 5 years 
worldwide, especially in developing countries.
There are more than 90 different serotypes described according to the composition of the 
polysaccharide capsule and, although there are commercial capsule-based vaccines, their 
effectiveness is limited and are expensive. Thus, both the recent emergence of multidrug-
resistant strains to antibiotics such as phenomena arising from the introduction of the 
polysaccharide vaccines, thanks to the adaptability of the pneumococcus, is an urgent need to 
develop new, more efficient and cheaper vaccine serotype-independent.
This new vaccine should be protein based to reduce the cost of production, and candidates, 
surface-exposed, antigenically conserved, presents in the most prevalent serotypes, highly
expressed, its function must be essential for pathogenicity and capable of stimulating cellular 
response. In order to discover new protein candidates, both for vaccination and for the 
development of rapid diagnostic tools purposes, during this thesis two lines of work were 
developed: The surface digestion with proteases of living (“shaving”) (1) and production and 
characterization of extracellular vesicles.
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4. La combinación de 4 proteínas (LytA, PrtA, PulA y PblB) resultó ser la mejor para el
diagnóstico de neumonía neumocócica con una sensibilidad del 100% y una especificidad del
87,5% con los sueros usados (Capítulo III).
5. Streptococcus pneumoniae produce vesículas extracelulares derivadas de la membrana que son 
capaces de transportar factores de virulencia, así como modular la respuesta inmune del 
hospedador y proteger de la muerte a ratones inmunizados (Capítulos IV y V).
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The main conclusions that can be highlighted in this thesis are: 
1. “Shaving” live cells with proteases of Streptococcus pneumoniae is possible, although cell
lysis is is both intrinsic and due to experimental manipulation (Chapter I, II and III). 
2. The “pansurfome” of a collection of clinical isolates provides, in addition to vaccine
candidates, antigens that could be used to develop serological tests (Chapter I, II and III).
3. Immunization of mice with individual proteins selected from the analysis of “shaving” 
digestion of live cells of a set of pneumococcal clinical isolates from adults and children is not 
sufficient to confer immunity to infection by Streptococcus pneumoniae serotype 8 (Chapter III).
4. Combination of 4 proteins (LytA, PrtA, PulA and PblB) proved as the best for the diagnosis of
pneumococcal pneumonia with a sensitivity of 100% and a specificity of 87.5%. (Chapter III)
5. Streptococcus pneumoniae produces membrane-derived vesicles that are able to
transportvirulence factors as well as modulate host immune response and protect from death to
immunized mice (Chapter IV and V).
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Conclusions
 tested their immunoreactivity against sera of convalescent and healthy patients (some of them, 
by different techniques). With this, a set of few proteins (spr0561, Spr0247, Spr1431, Spr1754 
and Sph_0062) were select to develop a rapid, reliable, inexpensive and easy to use test of 
pneumococcal disease in children aged 0 - > 5 years, that would solve the problems of 
diagnostic methods used so far.
Furthermore, survival assays were carried using a virulent strain serotype 8 as infecting agent, 
which allowed describing the protective capacity of seven new proteins. Furthermore, it was 
shown that the membrane vesicles produced by the same serotype conferred a high degree of 
protection to immunized mice. 
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1. Streptococcus pneumoniae 
Streptococcus pneumoniae (Pneumococcus) is lancet-shaped, gram-positive, aerotolerant, 
facultative anaerobic organisms. Pneumococci are typically observed in pairs (diplococci) but 
may also occur singularly or in short chains. Almost all pneumococci are encapsulated, their 
surfaces being composed of complex polysaccharides. Encapsulated organisms are pathogenic 
for humans and laboratory animals, whereas organisms without capsular polysaccharides are 
not. Capsular polysaccharides are the primary basis for the pathogenicity of the organism. 
They are antigenic and their seroreactivity is the criterium for classifying pneumococci in 
serotypes. The bacterium was first isolated by Pasteur in 1881 from the saliva of a patient with 
rabies. The association between the bacterium and lobar pneumonia was first described by 
Friedlander and Talamon in 1883, but pneumococcal pneumonia was confused with other 
types of pneumonia until the discovery of the Gram stain in 1884. From 1915 to 1945, the 
chemical structure and antigenicity of the pneumococcal capsular polysaccharide, its 
association with virulence, and the role of bacterial polysaccharides in human disease were 
explained. More than 80 serotypes of pneumococci were described by 1940.  To date, ninety-
four serotypes have been identified, based on their reaction with type-specific antisera, 
although this number is continuously increasing (1-10). Most S. pneumoniae serotypes have 
been shown to cause serious disease, but only a few serotypes produce the majority of 
pneumococcal infections.  
Efforts to develop effective pneumococcal vaccines began as early as 1911. However, with the 
advent of penicillin in the 1940s, interest in the vaccine declined, until it was observed that 
many patients still died despite antibiotic treatment. By the late 1960s, efforts were again 
being made to develop a polyvalent pneumococcal vaccine and the first pneumococcal vaccine 
was licensed in the United States in 1977. (Extract from Pneumococcal Disease. Epidemiology 
and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook - 12th 
Edition Second Printing (May 2012) From Centers for Disease Control and Prevention (CDC)). 
2. Pneumococcal interaction with humans 
Pneumococcal infections occur throughout the world.  Humans are almost the exclusive 
targets of pneumococcus (some strains have been isolates from pets/zoo animals (11, 12) and 
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more recently to lethal disease in wild chimpanzees (13). The human nasopharynx of 
asymptomatic human carriers is the reservoir, being those most frequently found in carriers 
who are most often responsible for causing disease. Transmission occurs as the result of direct 
person-to-person contact via respiratory droplets and by autoinoculation in persons carrying 
the bacteria in the secretions of their upper respiratory tract as long as the organism appears.  
Within a family or household, the spread of the organism is influenced by factors such as 
crowding, season, and the presence of upper respiratory infections or pneumococcal disease 
such as pneumonia or otitis media. Pneumococcal infections are more common during the 
winter and in early spring when respiratory diseases are more prevalent.  
Under certain circumstances, pneumococcus is pathogenic. Thus, the bacteria may interact 
with the host by two ways: First, it can simply colonise the nasopharynx, remaining 
asymptomatic; or second, it may cause disease, either locally or invasive. 
2.1. Colonization
Carriage is essential for the propagation of pneumococcal diseases, and its epidemiology 
is important. Pneumococcal colonization may be influenced by multiple factors and 
although these factors are not entirely clear, there is no doubt that the local host immune 
response plays an important regulatory role in the trafficking of pathogens in the 
nasopharynx. Poorly immunogenic serotypes tend to colonise for longer periods, and the 
low carriage rates in adults suggest the existence of immunological protection after previous 
exposure (14). Pneumococcal carriage occurs early in life, usually with a prevalence of 
about 30%-60% in infants and 1%-10% in adults (15). In some cases, more than 95% of 
children can be colonised with up to six different serotypes by the age of two (16). The 
prevalence of co-colonization by multiple serotypes was estimated to range from 1.3% to 
48.8% between 2004 and 2009 in Switzerland (17, 18). Geographical factors, study 
population, and different detection techniques may be responsible for this variation (18) 
the epidemiology and clinical significance of co-colonization needs better clarification. As 
children become older the prevalence of pneumococcal carriage decreases and, probably 
related to shortened duration of carriage, the distribution of colonizing serotypes changes to 
those found in adults. Before the age of nine, the carriage rate is maintained above 
30%-40%, but it declines progressively afterward (Figure 1) (19-21).  However, the carriage 
rate is quite variable according to the local epidemiology, trending toward higher carriage 
rates in impoverished communities with low vaccination rates.  
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Figure 1. Pneumococcal carriage rate by age group. Global estimates (Young Song 2013, Infectious Diseases, Microbiology and 
Parasitology (22)). 
Studies by Mackenzie et al. and Hill et al. showed remarkably high carriage rates (≥ 30%), even 
in young adults (23, 24). For example, in Korea, the pneumococcal carriage rate was estimated 
to be 34.3% among children aged 5 years or younger. Considering the difference in study 
populations, there is a limitation to comparing the results of these two studies (25). 
Common colonizing serotypes differ between young children (< 5 years) and 
adolescents/adults. Before the introduction of the first vaccine for children, serotypes 19F, 6A, 
6B, and 23F were prevalent in young children aged less than 5 years, while serotypes 3 and 23F 
were relatively common in adolescents and adults (19, 20, 26).  
The duration of colonization can range from days to months and depends on the serotype (27). 
Serotype 1 is rarely found to colonise the nasopharynx, and serotypes 4, 5, and 7F also 
colonise to lesser degrees (28, 29). These serotypes are able to initiate colonization of the 
nasopharynx, but colonization may be much shorter in duration compared to other serotypes. 
Sleeman et al. (29) estimated the duration of pneumococcal carriage among common 
colonizing serotypes. The duration ranged from 5.9 weeks for serotype 15C to 19.9 weeks for 
serotype 6B.  
Causative mechanisms of carriage rate remain unclear. Several mechanisms have been 
postulated, most of which depend on interactions between the bacteria and host immune 
defenses. Serotype-specific polysaccharide capsules protect against immune-mediated 
clearance in several ways, including blocking the deposition and function of opsonins (30), 
trapping by neutrophil extracellular traps (NETs), and clearance by mucus (31, 32). Both the 
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prevalence of carriage and virulence potential appear to be directly related to the degree of 
encapsulation.  
2.2. Invasive disease potential
Some serotypes commonly colonise the nasopharynx, thereby having a greater 
temporal opportunity for invasion. In comparison, some serotypes are more likely to cause 
invasive dis-ease with each episode of colonization. Pneumococcal capsule types are 
known to be associated with many important pathogenic processes, including 
complement deposition, inflammation, and binding to the C-type lectin of host phagocytes 
(33, 34). In an animal study by Briles et al. (35), a very strong association was demonstrated 
between capsular serotype and virulence (the ability of an isolate to kill mice and the length 
of time between inoculation and death). In mice, serotypes 3, 4, 6A, and 6B were 
virulent; serotype 1 isolates were marginally virulent; and serotypes 14, 19, and 23 were 
avirulent. Clinically, global surveillance demonstrates that a limited number of capsular 
serotypes cause more than 70%-80% of IPD (36), and the invasive property of pneumococci 
seems to be determined by capsular serotype rather than genotype, as determined by 
multilocus sequence typing (MLST) (37), although genetic elements contribute to the 
heterogeneity of invasive disease potential among the same serotype (38).
Table 1 summarizes studies about the relationship between pneumococcal serotype and 
invasive disease potential. Some serotypes (1, 4, 5, 7F, 8, 12F, 14, 18C, and 19A) 
were considered highly invasive, while others (6A, 6B, 11A, 15B/C, and 23F) were 
generally less invasive in most studies. Serotype prevalence was variable between studies, 
which may be due to geographic and epidemiologic differences. Serotype 6B was highly 
invasive according to the report by Hanage et al. (39), but was so invasive in other studies. 
Also, reports of the invasive disease potential of serogroup 9 (9A, 9V, 9N, and 9L) showed 
some variation. Except for the study by Yildirim et al. (40), all the studies of Table 2 were 
conducted before the widespread use of the first pneumococcal vaccine.  
3. Pneumococcal disease 
Different pneumococcal serotypes are known to be associated to different clinical 
presentations of pneumococcal diseases. Pneumococcus causes mucosal diseases, such as 
acute  otitis  media  (AOM),  sinusitis  and can  more occasionally  enter  into  the  bloodstream 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
43 
Country of study UK UK Finland Portugal Israel Switzerland Venezuela USA
Highly invasive serotypes, 
statistically significant
1, 4, 14, 18C, 1, 4, 5, 7F, 8, 
9V, 9A, 12F, 
14, 18C, 19A
6B, 14, 18C, 
19A
1, 3, 4, 5, 7F, 
8, 9N, 9L, 
12B, 14, 
18C, 20
1, 5, 12F 1, 4, 5, 7F, 8, 
9V, 14
1, 5, 7F, 18 3, 7F, 18C, 
19A, 22F, 
33F
Highly invasive serotypes, 
insignificant
7F, 9V, 19A - 4, 7F, 9V, 38 - 9V, 18C, 
19A, 19F
19A 3, 14, 19F -
Less invasive serotypes, 
insignificant
3, 6B, 
15B/C, 19F
- 3, 9N, 10, 
15, 19F, 22, 
23F
- 3, 6A, 6B, 
11A, 14, 
15A, 15B/C, 
21, 23F, 35B
6B, 9, 22, 
23F
6A, 6B, 19A, 
23F
11A, 15A, 
15B/C, 19F, 
35F
Less invasive serotypes, 
statiscallly significant
23F 3, 6A, 6B, 
9N, 10A, 
11A, 16F, 
15B/C, 19F, 
20, 21, 22F, 
23A, 23F, 
33F, 35F, 38
6A, 11A, 35F 6A, 6B, 11A, 
15B/C, 16F, 
19F, 23F, 34, 
35F, 37
- 3, 7, 10, 11, 
15, 19F, 23
- 6C, 23A, 35B
Table 1. Serotype distribution in patients with pneumococcal pneumonia (From Young Song 2013_Infectious Diseases, 
Microbiology & Parasitology (25)). 
leading to a generally more severe invasive disease, called invasive pneumococcal diseases 
(IPD), which mainly includes primary bacteraemia, meningitis, osteoarticular infections, 
mastoiditis, pleural empyema or bacteremic pneumonia. In globally historical records, se-
rotypes 3, 6A, 6B, 9V, 14, 19A, 19F, and 23F were reported to cause AOM in young children, 
according to a recent review (33). Serotypes 3, 11A, and non-typeable (NT) pneumococci are 
associated with acute conjunctivitis (34). Regarding IPD, serotypes 1, 5, and 7F usually affect 
healthy young adults with a low mortality rate, while serotypes with low or intermediate 
invasive potential are more likely to affect the elderly with underlying comorbidities (28, 41, 
42). Serotypes 1, 7F, and 8 are associated with lower mortality, whereas serotypes 3, 6A, 6B, 
9N, and 19F are associated with increased mortality (43). 
Pneumonia 
S. pneumoniae is the most common cause of community-acquired pneumonia (CAP) in 
children and adults (44). CAP is pneumonia acquired from community as opposed to being 
acquired during hospitalization (hospital-acquired pneumonia). In CAP, individuals who have 
not recently been hospitalized develop an infection of the lungs (pneumonia). CAP is a 
common illness and can affect people of all ages. CAP often causes problems like difficulty in 
breathing, fever, chest pains, and cough. CAP occurs because the areas of the lung which 
absorb oxygen (alveoli) from the atmosphere become filled with fluid and cannot work 
effectively. 
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While the majority of pneumococcal pneumonia cases are non-bacteremic (60%-80% in adults 
and > 95% in children), bacteremic pneumonia is more severe (45-47). Bacteremic and non-
bacteremic pneumonia are considered to be different clinical entities. In mice, several 
thousand colony-forming units (CFUs) of S. pneumoniae of serotypes 2 or 3 in the lungs result 
in bacteremia and death, whereas S. pneumoniae of serogroup 19 is unable to induce 
bacteremia after lung infection and results in a non-progressive course unless tens of millions 
of CFUs are inoculated (48).  According to a recent meta-analysis, pneumococcal serotype 14 
was the most prevalent etiologic agent of pneumococcal CAP, followed by serotypes 1 and 5, 
in Latin America and the Caribbean (49). In US, mortality rates in in-hospital patient have been 
reported to be as high as 18%, being the pneumococcus the most frequently identified 
pathogen in CAP (50). In Spain, the cases of CAP in immunocompromised and non-
immunocompromised patients admitted to five public hospitals of three different Spanish 
regions showed that, of 320 cases studied, 36% occurred in immunocompromised patients and 
pneumococcus was the most common causative organism in both groups (29% vs. 21%) (51). 
Necrotizing pneumonia is a complicated pneumococcal infection, which is associated with a 
significant increase in morbidity and mortality. In the pre-antibiotic era, studies of autopsy 
cases described a necrotizing change in about 5% (0.7%-27%) of cases, and a recent large-
series study (using computed tomography) reported its occurrence in 6.6% of adult pneumo-
coccal pneumonia cases (52). Serotype 3 strains have been recognized as the most common 
etiologic agents (52-54). 
Pleural empyema 
An empyema is a collection of pus within a naturally existing anatomical cavity, such as the 
lung pleura. It must be differentiated from an abscess, which is a collection of pus in a newly 
formed cavity. In empyema, serotypes 1, 3, 7F, 14, and 19A are known to be associated with 
pneumococcal pneumonia complicated with pleural empyema (55-58). Empyema was 
considered rare in children, but it has been increasing worldwide over the last decade (55, 59-
61). Lee et al. (62) evaluated 62 Korean children with empyema, being the most frequently 
identified (46.2% of pneumococcal empyema). In a recent US study of 49 cases of pediatric 
empyema, serotypes 3 (26.5%) and 19A (22.4%) were the most common etiologies, followed 
by serotypes 7F (14.3%) and 1 (12.2%) (63). In Spain, the incidence of empyema seems to have 
increased both in children and adults in the past decades, mainly in healthy young adults and 
in the elderly. The etiology of pleural infection is changing as well. In children, the most 
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common microorganism that causes empyema continues to be Streptococcus pneumoniae 
(64), although community-acquired methicillin-resistant has emerged in recent years as a 
predominant pathogen in pleural empyema in certain areas of US (65). 
Meningitis  
Meningitis is the inflammation of the protective membranes covering the brain and spinal 
cord, known collectively as the leptomeninges (66). The inflammation may be caused by 
infection with viruses, bacteria, or other microorganisms, and less commonly by certain drugs 
(67). Meningitis can be life-threatening because of the inflammation's proximity to the brain 
and spinal cord; therefore, the condition is classified as a medical emergency (66, 68). 
S. pneumoniae is estimated to cause worldwide annually more than 60,000 meningitis-
associated deaths and long-term disabilities in children ≤ 5 years of age (69). The incidence of 
pneumococcal meningitis is highest in children under one year of age, but data on the serotype 
distribution remain insufficient in Asian countries. According to surveillance in Ugandan 
children aged less than five years, the most common serotype was 6A/6B (40%), followed by 
22A, 23F, 14, and 19A (70). Previously, serotypes 1, 3, and 5 were rarely reported in cases of 
meningitis (49). However, recent studies in the African meningitis belt revealed that 60%-80% 
of pneumococcal meningitis was caused by serotype 1, with higher incidence and case fatality 
ratios compared to meningococcal meningitis (71). Compared to USA and Europe, where a 
bimodal age distribution is observed, the pneumococcal meningitis epidemiology of the 
African meningitis belt is quite different. Serotype 1 is predominant, and older children and 
working-age adults are more likely to be infected, with a high case fatality rate. Such 
differences might be due to the properties of the African lineage of serotype 1, rather than the 
general characteristics of serotype 1 (72). MLST has identified three clonal lineages of serotype 
1, and these were geographically segregated.  
Peritonitis 
Peritonitis is an inflammation of the peritoneum, the thin tissue that lines the inner wall of the 
abdomen and covers most of the abdominal organs. Peritonitis may be localized or 
generalized, and may result from infection (often due to rupture of a hollow organ as may 
occur in abdominal trauma or appendicitis) or from a non-infectious process. In healthy adults, 
pneumococcal peritonitis is unusual, but it typically occurs in young women as a result of 
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serotype 1 pneumococci (73, 74), causing pelvic abscesses or other reproductive tract 
infections. Pneumococci are still common etiologic agents of spontaneous bacterial peritonitis 
in cirrhotic patients. 
Hemolytic uremic syndrome 
Hemolytic-uremic syndrome (or haemolytic-uraemic syndrome), abbreviated HUS, is a disease 
characterized by microangiopathic hemolytic anemia (anemia caused by intravascular 
destruction of red blood cells), acute kidney failure (uremia), and a low platelet count 
(thrombocytopenia). S. pneumoniae-associated HUS (SP-HUS) occurs after bacterial infection, 
and although similar to typical HUS, the clinical outcomes are worse than typical HUS, with a 
higher dialysis requirement (82% vs 42%) and mortality rate (< 11% vs < 5%) (95). SP-HUS is 
known to occur exclusively in children after IPD, with a low incidence rate (0.4%-0.6%) (75, 76).  
Considering the pathogenic mechanism, SP-HUS development may not be dependent on the 
capsule serotype. Limited data suggest a weak association of SP-HUS with specific serotypes (1, 
3, 6A, 7F, 12F, 14, 19A, 22F, and 23F), as well as a high concurrence with pleural empyema (77, 
78). 
4. Current state 
Although the death rate of invasive pneumococcal infections decreased by 100 fold in 
one century, this was due mainly to antibiotic use and multiple attempts at 
antipneumococcal vaccinations. However, this was true only for developed countries, so 
the pneumococcus remains the cause of part of pneumonia and another pneumococcal 
disease. This is the leading infectious cause of child mortality worldwide (around 1.9 million 
(or 19%) of the estimated 10 million child deaths each year) and neumococcal disease is 
the second leading cause of childhood meningitis deaths as well as the leading of 
child pneumonia deaths. In fact, according to Bhutta 2013 (79), 18.3% of vaccine-
preventable severe pneumonia and 32.7% of pneumonia death is caused by Streptococcus 
pneumoniae. 
It kills more than 1.6 million people including between 700,000 and 1 million children 
under five each year (Figure 2): According to the WHO, at least one child dies of 
pneumococcal disease every minute, making it the leading cause of childhood pneumonia 
deaths in the developing world and the number one vaccine-preventable cause of  
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death in children worldwide. In fact, more than 98% of deaths attributable to pneumococcal 
disease occur in developing countries (Table 2). Despite the considerable social, clinical and 
economic burdens, the WHO and UNICEF describe pneumonia as the “forgotten killer of 
children” (80). In addition it must be also taken into account that, compared with other 
diseases affecting the developing world, determining the incidence of pneumococcal disease is 
relatively difficult. This is due to factors including the difficulty of stringent laboratory testing 
and sample collection and the unavailability of quality surveillance data in developing 
countries. 
Figure 2: Causes of under-five child deaths in low-income countries. Source: WHO, World Health Statistics 
2012 
There is no simple method to obtain the samples for such testing without potentially harming 
patients, and testing the most commonly available bacterial samples still may miss up to 90% 
of cases. This lack of epidemiological evidence has likely contributed to a gross under-
appreciation of the economic, clinical and human burdens imposed by pneumococcal disease 
and hindered public health planning and decision-making in developing countries.  In absolute 
numbers, developing countries with large populations, such as India, Bangladesh and 
Indonesia, report the largest numbers of deaths by pneumococcal disease. An 
estimated826,000 child deaths by pneumococcal disease in 2000 occurred in Africa, with a 
further 187,000 in South-East Asia. 
- 10 countries in Asia and sub-Saharan Africa account for over 60% of pneumococcal 
ease deaths worldwide. 
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Region Incidence Total episodes (x106)
Total severe 
episodes (x106)
Total deaths 
(x103)
African region 0.27 36.4 4.17 540.6
American 
region
0.08 6.4 0.78 23.9
Eastern 
Mediterranean 
region
0.23 16.4 1.88 168.4
European 
region
0.03 1.6 0.41 18.1
Southeast
Asian region
0.26 47.4 5.44 433.8
Western Pacific 
region
0.11 12.2 1.43 61.9
World 0.19 120.4 14.11 1256.8
Table 2. Global and regional burden of pneumonia per year in children aged 0-4 years in 2010-2011, by WHO. 
- In Bangladesh, a “very conservative” estimate suggests that 50,000 children die 
annually by pneumococcus. 
- Among Indian children, pneumonia causes a quarter of all deaths. That is, 410,000 
children under five die of pneumonia each year and of these, between 123,000 and 164,000 
are estimated to die because of pneumococcal pneumonia. 
- The Aga Khan University estimated that in the Pakistani Province of Sindh, 
pneumococcal meningitis occurs at a rate of 11 per 100,000. Low detection rates and cases 
managed in hospitals not included in this study contribute to what is likely a six-fold 
underestimate. The actual rate could be as many as 66 cases of pneumococcal meningitis per 
100,000 infants.  
- Countries in Sub-Saharan Africa have the highest mortality rates from pneumococcal 
disease. Pneumonia causes 21% of deaths of children under five in these countries. 
According to the WHO, annual incidence of pneumococcal disease in Gambia and South Africa 
is 224 and 345 per 100,000 inhabitants respectively. In Kenya, it is estimated that 250,000 
children (of the approximately six million populations) will get a pneumococcal disease related 
illness.  
In developed countries, as many as 175,000 hospitalizations by pneumococcal pneumonia are 
estimated to occur annually in the United States (CDC. Invasive pneumococcal disease in 
young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 
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2007. MMWR 2010;59(No.9):253-7.). Pneumococci account for up to 36% of adult 
community-acquired pneumonia and 50% of hospital-acquired pneumonia. The case-fatality 
rate is 5%–7% and may be much higher among elderly persons.
More than 50,000 cases of pneumococcal bacteremia occur each year. Bacteremia occurs 
in about 25%–30% of patients with pneumococcal pneumonia. The overall case-fatality rate 
for bacteremia in this case is about 20% but may be as high as 60% among elderly 
patients. Patients with asplenia who develop bacteremia may experience a fulminant clinical 
course.  Pneumococci cause 13%–19% of all cases of bacterial meningitis in the United 
States. An estimated 3,000 to 6,000 cases of pneumococcal meningitis occur each year. 
One-fourth of patients with pneumococcal meningitis also have pneumonia. The 
clinical symptoms, cerebrospinal fluid (CSF) profile and neurologic complications are 
similar to other forms of purulent bacterial meningitis. The case-fatality rate of 
pneumococcal meningitis is about 30% but may be as high as 80% among elderly persons. 
Neurologic effects are common among survivors. Persons with a cochlear implant appear 
to be at increased risk of pneumococcal meningitis.
Europe has the lowest incidence of childhood pneumococcal disease in the world, 
504/100,000 children aged ≤5 years compared to a global average of 2,331/100,000 (AOM not 
included) (69). The majority of cases are pneumonia, which accounts for 92% of all 
pneumococcal episodes in Europe. Invasive diseases are less common, with a incidence of 
42/100,000 in European children aged ≤5 years in 2009. Cases of pneumococcal meningitis are 
relatively rare, with an incidence of 6/100,000, yet, there is a high associated case–fatality 
ratio of 38% (81). European mortality figures were comparatively low, with around 15,000 
estimated deaths in 2000; yet, pneumococcal disease clearly remains an important health 
concern. In the pre-PCV7 era, the incidence of AOM has been assessed in several countries in 
Europe (Czech Republic, Slovakia, Finland, and Switzerland) with varying results. The incidence 
of AOM in Czech Republic and Slovakian was 12,520 episodes per 100,000 person-years (82), 
which is lower than that of Switzerland (2500 per 100,000 children aged ≤23 months and 
18,000 per 100,000 children aged 24–59 months) (83) and that demonstrated in two 
prospective studies from Finland (1.2–1.4 episodes per person-year) (82, 84). In Germany, it 
was estimated that there were 277,000 cases of pneumococcal OM per year in children aged 
<5 years (85). In Spain, as same than in others European countries, even after introducing the 
first conjugate vaccine, no significant reduction in IPD rates have  been observed (Table 3). 
Nevertheless these data could be even better just by using routinely an efficient vaccine. 
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5. Pneumococcal Vaccines 
Due to large serotype diversity in pneumococcus, vaccines that induce antibody responses 
against multiple capsular antigens have had to be developed.  
5.1. Pneumococcal Polysaccharide Vaccine
Pneumococcal polysaccharide vaccine is composed of purified preparations of 
pneumococcal capsular polysaccharide. In 1983, a 23-valent polysaccharide vaccine 
(PPSV23) was licensed. PPSV23 contains polysaccharide antigens from 23 types of 
pneumococcal bacteria that caused 88% of bacteremic pneumococcal disease in that 
time. In addition, there was evidence of cross-protection for several other 
capsular types that account for an additional 8% of bacteremic cases.  
More than 80% of healthy adults who receive PPSV23 (Pneumovax 23, Merck) 
develop antibodies against the serotypes contained in the vaccine, usually within 2 to 3 
weeks after vaccination (86) in healthy adults. Older adults and persons with some 
chronic illnesses or immunodeficiency may not respond as well (87-89). PPV23 
activate B-cells but elicit T-cell independent immune response; because of this, in 
children younger than 2 years of age, antibody response to most serotypes is 
generally poor (86, 90). Elevated antibody levels persist for at least 5 years in 
healthy adults but decline more quickly in persons with certain underlying illnesses 
(CDC. ACIP Updated recommendations for prevention of IPD amoung adults using the 
PPV23. MMWR 2010;59:1102-6).
PPSV23 vaccine efficacy studies have resulted in various estimates of clinical 
effectiveness. Overall, the vaccine is 60%–70% effective in preventing invasive disease 
in healthy patients (91). The vaccine may be less effective in preventing pneumococcal 
infection in some groups, particularly those with significant underlying illnes (91). 
Although the vaccine may ineffective in some persons, especially those who do not have 
normal resistance to infection, it is still recommended for such persons because 
they are at high risk of developing severe disease. PPSV23 has not been 
demonstrated to provide protection against non  bacteremic  pneumococcal pneumonia. 
For this reason, providers should avoid referring to PPSV23 as “pneumonia vaccine” (93). 
Studies comparing patterns of pneumococcal carriage before and after PPSV23 
vaccination have not shown  clinically  significant  decreases in carrier rates  among vaccines. In 
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Relative risk
Country/serotype
Prevaccine 
(1999-2002)
Postmarketing 
(2005-2006)
(95% CI) p value
1.0 0.8 0.8 (0.6-1.3) 0.387
2.1 4.6 2.2 (1.8-2.7) <0.001
3.0 1.2 0.4 (0.2-0.7) <0.001
3.9 6.1 1.6 (1.2-2.1) 0.003
0.7 0.8 1.1 (0.7-1.6) 0.664
1.3 2.0 1.5 (1.2-2.0) 0.001
0.7 1.0 1.4 (1.0-1.9) 0.026
0.7 2.0 2.9 (2.3-3.6) <0.001
PCV types
Non-PCV types
PCV types
Non-PCV types
Incidence rate
Spain
Belgium
France
Engaland and Wales
PCV types
Non-PCV types
PCV types
Non-PCV types
Table 3. Incidence rate in the prevaccine and postmarketing of PCV7 era in four European countries. 
*PCV7, heptavalent pneumococcal conjugate vaccine; CI, confidence interval. Marketing indicates that the vaccine
was marketed and available for use in the country but not introduced in the vaccine Schedule free of charge. Vaccine 
coverage differed by country during this period, ranging from 33% to 48% in Spain, Belgium, and France but <1% in 
Engalnd and Wales. PCV7 types include serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.  
Incidence rates in cases per 100,000 children 5-14 years of age. Date for 1999-2002 are annual averages. Prevaccine 
period is 2001-2002 for France (data not available for previous years) (92). 
addition no change in the distribution of vaccine-type and non–vaccine-type organisms has
been observed as the result of vaccination (86, 90).  
5.2. Pneumococcal Conjugate Vaccine 
A first conjugate vaccine against pneumococcal disease was licensed in the United States in 
2000. In October 2000, the Advisory Committee on Immunization Practices recommended 
Pneumococcal conjugate vaccine 7-valent (PCV7) [Prevnar, Wyeth] for all children aged <2 
years and for older children at increased risk for IPD (Advisory Committee on Immunization 
Practices. Preventing pneumococcal disease among infants and young children. 
Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 
2000;49(No.RR-9)). This was a vaccine only contained polysaccharides from the seven more 
prevalent serotypes in developed countries, but not those more prevalent in developing 
countries. Newer vaccines that protect against an increased number of serotypes are now 
available and include a 10- and a 13-valent vaccine. On February 2010, a 13-valent 
pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., a subsidiary 
of Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of 
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invasive pneumococcal disease (IPD) (Licensure of a 13-Valent Pneumococcal 
Conjugate Vaccine (PCV13) and Recommendations for Use Among Children --- Advisory 
Committee on Immunization Practices (ACIP), 2010). They offer increased protection against 
those serotypes highly prevalent in children from developing countries. 
PCV7 include purified capsular polysaccharide of seven serotypes of S. pneumoniae (4, 9V, 14, 
19F, 23F, 18C, and 6B) conjugated to a nontoxic variant of diphtheria toxin known as CRM197. 
PCV13 contains the 7 PCV7 serotypes plus 1, 3, 5, 6A, 7F and 19A which are also conjugated to 
CRM197. A 0.5-mL PCV13 dose contains approximately 2.2 μg of polysaccharide from each of 12 
serotypes and approximately 4.4 μg of polysaccharide from serotype 6B; the total 
concentration of CRM197 is approximately 34 μg. In addition, a 10-valent was authorized in 
2009 only by the European Medicines Agency (EMEA) to vaccinate children aged between six 
week and five years. This vaccine differs from PCV13 in polysaccharides content (serotypes 3, 
6A and 19A are no included) and also the protein carrier (protein D from Haemophilus 
influenzae). 
In a large clinical trial, PCV7 was shown to reduce invasive disease incidence rates caused by 
vaccine serotypes by 97%, and also was effective against invasive disease caused by 
all serotypes with a 89% reduction in the total invasive pneumococcal disease burden in 
children who had received one or more doses of the pneumococcal conjugate (94, 95). 
Children who received PCV7 had 7% fewer episodes of AOM and underwent 20% fewer 
tympanostomy tube placements than did unvaccinated children. There is evidence that 
PCV7 reduces naso-pharyngeal carriage of pneumococcal serotypes included in the vaccine 
(96). 
PCV13 was licensed in the US based upon studies that compared the serologic response 
of children who received PCV13 to those who received PCV7. These studies showed that 
PCV13 induced levels of antibodies that were comparable to those induced by PCV7 and 
shown to be protective against invasive disease (97).
In Europe, 24 countries have recommended or implemented a routine infant 
pneumococcal vaccination program of which 17 (partly) reimburse vaccination for all infants 
rather than only for high-risk groups (Figure 3) (98).PCV7 was introduced in Spain in 2001, 
PCV10 in 2009 and PCV13 in 2010. Although they were temporarily included in the official 
immunization program in some regional areas (Madrid y Galicia and Navarra), neither 
of are currently being subsidized by the Spanish Health Service (99). In developing 
countries the vaccine is available thanks to the funding of Global Alliance for Vaccines and 
Immunisation (GAVI) alliance because they cannot afford the high cost of the vaccine. 
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Figure 3. Pneumococcal vaccination in European 
countries. In green represent those countries in which 
universal pneumococcal vaccination is free of charge, gray 
represents countries in which universal pneumococcal 
vaccination is only free of charge for children at increased 
risk of infection, and red represents those countries where 
vaccination is not available free of charge (Rozenbaum 
2011, The Journal of Infection) (101).  
6. Pneumococcal adaptation 
6.1. Mechanisms of adaptation
Due to the ability to undergo horizontal gene transfer, S. pneumoniae easily adapts 
to environmental changes (including antibiotic and vaccine pressure), which leads to 
substantial genetic heterogeneity as well as genomic plasticity (Figure 4). 
Figure 4. Evolution of naturally transformable Streptococcus pneumoniae. Source: Hsieh, et al., 2008 (100). 
Theoretically, the genotype should primarily correlate it behavior in antibiotic resistance and a 
vaccination program. Thus, serotype-related antibiotic resistance has also been studied with 
interest. Hsieh et al. (100) showed that different serotypes of S. pneumoniae possess different 
levels of genetic competence, which is the ability of a cell to take up extracellular DNA from its 
environment. Isolates belonging to serotypes 3 and 18C that were 100% sensitive to penicillin 
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were significantly less competent than isolates belonging to serotypes 6B, 14, 19F, 9V, and 
23F, which were frequently resistant to penicillin. Intriguingly, the capsule (cps) locus of S. 
pneumoniae is flanked by the pbp2x and pbp1a genes, which code for penicillin-binding 
proteins (PBPs) (101).  PBPs are enzymes involved in cell wall synthesis and are targets for β-
lactam antibiotics. Under the natural selection imposed by host immunity and antibiotics, the 
recombination events on mosaic PBP genes evolve to be penicillin resistant via acquiring PBP 
from other Streptococcus species (102). Moreover, Prudhomme et al., reported an induction of 
competence and genetic transformation by DNA-damaging agents and antibiotics in a naturally 
transformable bacterium (103), for which is required the type IV like pilus (104). This shows 
that the pneumococcus is able to vary their genes to adapt to the pressure by external agents 
(antibiotics or vaccines), which suggests that it could do the same for other drugs or vaccines 
that target molecules not essential for cell viability. In recent decades an increase of S. 
pneumoniae strains' resistance to beta-lactam antibiotics and other classes of antimicrobials 
has appeared and consequently the treatment has turned even more complicated. However, 
strategies for pneumococcal vaccines are actually based on serotype distribution. 
The second mechanism is the evolution to enhancer virulence via recombination. Serotype 6B 
causes more invasive diseases than serotype 6A. By using multilocus sequence typing, serotype 
6B clones evolved almost exclusively by recombination, whereas serotype 6A evolved by 
mutation (105). 
The third mechanism is capsular switching under a large-scale vaccination program (106). This 
phenomenon has occurred in resistant isolates of serotype 19A. In contrast to other non-
vaccine serotypes, the disturbing increase in resistant isolates of serotype 19A is only partially 
due to expansion of a pre-existing clone (sequence type (ST) 199) that was rare before the 
introduction of vaccination. Results of multilocus sequence analyses show that some 19A 
isolates collected in the post-PCV-7 implementation era are of different STs that were 
originally related to other serotypes (e.g. serotype 4) (92, 107-113). These isolates are called 
‘vaccine escape recombinants’ and are probably the result of recombination events. 
Brueggemann et al. (114) have identified at least three recombinational events that lead to 
serotype 19A strains with different STs escape to the vaccine. They assumed that there was a 
main event around 2003 when a fragment containing the capsular locus and two adjacent 
penicillin-binding proteins was transferred from a strain of ST199 and serotype 19A to a strain 
of ST695 and serotype 4. The resulting strain of ST695 and serotype 19A strain has been 
increased rapidly since 2003. Thus, capsular switching is another mechanism that contributes 
to the expansion of non-vaccine serotypes. 
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0.6.2. Clinical and ecological impact
The most common serotypes causing IPD can change rapidly and all of these adaptations 
are translated in variations in and ecological clinical manifestations.  In carriage, a 
significant increase in the prevalence of serotype 6C has been observed since PCV7 
introduction in the UK (115, 116). This is despite the presence of the 6B polysaccharide in 
PCV7, which does provide protection against 6A (117) but this cross-reactivity is not extended 
to 6C. Therefore the PCV7 elicits negligible or no immune protection against this serotype 
(118).  
On the other hand, serotypes not covered by the conjugate vaccine (NVS) have increased both 
in nasopharyngeal colonization and clinical illness (118). In fact, Muñoz-Almagro et al., 
2008, showed that since the introduction of PCV7 for children, there has been an emergence 
of IPD caused by invasive clones of non-PCV7 serotypes in Barcelona (Table 4) (119). 
Moreover, it has been demonstrated, by genetic analyses of pneumococcal isolates 
collected after the introduction of the vaccine, that the increases in most non-vaccine 
serotypes is not due, in most cases, to a de novo emergence of new pneumococcal clones 
but to an expansion of pre-existing clones of non-vaccine serotypes (120).  
Thus, before the introduction of PCV7, serotypes 19F, 6A, 6B and 23F, were prevalent in 
young children aged less than 5 years, while serotypes 3 and 23F were relatively 
common in adolescents and adults (19, 20, 121). After the introduction of PCV7, these were 
replaced by NVs including 19A, 6C, 11A, 15A and 15B/C (25, 26, 122). In USA, Spain and 
Portugal, serotype 6C pneumococci increased (123). In US, a shift in the prevalent 
serotypes circulating in the population and causing disease was observed ((124). 
However, in this country, the total number of invasive pneumococcal disease (IPD) cases 
in those over 5 years of age did not change significantly between 2005–2006 (5514 
cases) and 2007– 2008 (5496 cases).  IPD continues increasing in Barcelona, and the rate is 
higher than previously reported as a result of low sensitivity of bacterial culture. NVS were 
responsible for 91% of episodes and pneumonia was the main clinical presentation (125). 
These NVS have also been observed to cause an increased incidence of IPD, such as 7F in 
Portugal (126) and 19A and 22F in the US (127). In Scotland, IPD-causing serotypes changed 
considerably from 2005/2006 to 2009. In 2009, 7F was reported to be the most common 
IPD-causing serotype in the under 5 years, accounting for 12% of cases (128). 
In France, Spain, Belgium, England and Wales, increased invasive disease from NVTs increased, 
especially by serotypes 1, 7F and 19A (92). Importantly, a recent increased incidence of 
IPD caused by PCV7 NVS has been detected in all age groups, particularly involving serotypes 
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Variable
Nº(%) of 
episodes
Rate 
(episodes 
per 100,000)
Nº(%) of 
episodes
Rate 
(episodes 
per 100,000)
Change, % 
(95% CI)
P
IPD serotype
  All 29 32.4 67 51.3 58 0.037
  PCV7 24 (83) 26.8 21 (31) 16.1 -40 0.095
  Non-PCV7 5 (17) 5.6 46 (69) 35.2 531 <0.001
Clinical manifestation of IPD
  Meningitis 10 (35) 11.2 14 (21) 10.7 -4 1.00
  Pneumonia
Overall 3 (10) 3.4 17 (25) 13 289 0.021
With empyema 2 2.2 12 9.2 311 0.055
Without empyema 1 1.1 5 3.8 243 0.41
  Occult bacteremia and/or sepsis 13 (45) 14.5 28 (42) 21.4 48 0.26
Arthritis/appendicitis/endophthalmitis 3 (10) 3.4 8 (12) 6.1 83 0.54
Table 4. Rates of invasive pneumococcal disease among children during the prevaccine (1997-2001) and vaccine periods (2002- 
2006) in children aged <2 years in children living in the geographical area of Hospital Sant Joan de Deu (Barcelona, Spain) (Muñoz-
Almagro, 2008, Clinical infectious diseases: an official publication of the Infectious Diseases Society of America) 
7F, 19A and 22F (124). In fact, serotype 19A has become the most prominent serotype
worldwide, both clinical important and multidrug-resistant (non-susceptible to more than 
3 antibiotic classes) in the era of PCV7. In Spain, F. de Sevilla et al 2012, showed that this 
strain was the most important, just behind of serotype 1, in episodes number caused in 
an epidemiologic study of 300 episodes of IPD (129).
The post-PCV7 19A increase in the US was particularly associated with one 
multilocus sequence type, ST320, a clone that had high antibiotic resistance (130, 131). 
However, the increasing 19A clone in the UK is predominantly ST199 (127), instead of 
ST320, suggesting factors other than antibiotic resistance were involved in causing this 
increase. Vaccine inclusion of related serotypes within a serogroup was previously assumed 
to confer some level of crossprotection (132). However, serotype 19A IPD incidence has 
increased in the UK despite the fact that the related serotype 19F was included in the vaccine.  
In fact, serotype 19A pneumococcal AOM increased predominantly after the introduction 
of PCV7 (133, 134). Yildirim et al. (135) compared the incidence and serotype distribution of 
IPD among children younger than 18 years of age between the early (2001-2006) and late 
(2007- 2010) periods of the PCV7 era in the US. The overall IPD incidence rate was 7.5 
cases per 100,000 inhabitants, without a statistical difference between these two periods, 
although the proportion of bacteremic pneumonia among all IPD cases was almost three-
fold greater in 2009-2010 compared to the early period. IPD due to serotypes 19A and 7F 
increased during the late period of the PCV7 era, representing 41% and 20% of all IPD cases in 
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the same perior respectively. Changes in the distribution of serotypes may affect the clinical
presentation of IPD. 
Many studies showed that most pediatric empyema cases were mostly due to non-PCV7 
serotype 1, and this might have been related to selective PCV7 pressure (55, 99). According to 
the MLST of serotype 1 isolates, ST227, ST228, and ST304 were genotypes that circulated in 
pre-PCV7 period, while ST306 expansion was temporally associated to PCV7 introduction 
(136). Serotype 1 pneumococcal empyema was also common in adults aged between 18 and 
50 years.  
Serotype prevalence of pneumococcal meningitis in the US has undergone a significant shift 
since routine immunization with PCV7 commenced. Comparing data from 1998-1999 to 2004-
2005, there has been a significant reduction in pneumococcal meningitis among the PCV7 
serotypes, from 59 to 23% of cases (137).  
Non- PCV7 serotype disease has increased, from 28 to 65%, with a preponderance of the 
increase being attributed to serotypes 19A and 22F (138). Despite the observed serotype shift, 
the overall incidence of pneumococcal meningitis in the US has decreased by 30 % to 
0.79cases/100,000 (139). However, in Spain, Belgium and France, from the prevaccine period 
to 2005-2006, meningitis cases have increased significantly because of serotypes 19A and 7F; 
in England and Wales, it did not increase significantly. 
In hemolytic uremic syndrome, before the introduction of PCV7, serotype 14 was the most 
common, but a serotype shift was observed, with increasing cases of serotypes 1, 3, 7F, and 
19A, with serotype 3 being predominant (53, 139, 140).  
On the other hand, dramatic changes in serotype prevalence can occur over time. In addition, 
serotype distribution can fluctuate substantially in the absence of vaccination. For example, a 
highly significant increase in serotype 1 was observed within the UK prior to routine PCV7 
immunization, highlighting that other factors are also involved in pneumococcal serotype 
dynamics (128, 141).  
Now, a few years after introducing PVC13, the same patterns are observed. According to 
Active Bacterial Core from CDC data in 2008, a total of 61% of invasive pneumococcal disease 
cases among children younger than 5 years were attributable to the serotypes no included in 
PCV13, with serotype 19A accounting for 43% of cases; PCV7 serotypes caused less than 2% of 
cases (101). In USA, after the introduction of PCV13, invasive pneumococcal infections 
decreased among 8 children hospitals compared with the 3 years before the PCV13 use. 
However, slight increases in some non-PCV13 serotype isolates were noted in 2011 (142). 
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Moreover, serotype 22F (ST433 was the main clone) caused invasive pneumococcal disease in 
Gipuzkoa (Spain) (143). Due to the emerging of non PCV13 serotypes, some experts predict 
that the use of PCV13 will rapidly become irrelevant as the prevalence of serotypes included in 
this vaccine diminishes. Continued surveillance is necessary to determine the effectiveness of 
PCV13 including herd protection as well as any emerging invasive serotypes (15, 69, 120, 144-
146). 
Then, serotypes related to the VS have contributed to serotype replacement more than was 
perhaps first expected, potentially because they are in a prime position to fill the specific niche 
vacated by their counterpart in an environment under vaccine pressure, which produces the 
emergence of invasive pneumococcal disease caused by virulent clones of NVS. Although not 
the only cause, PCV7 first and PCV13 probably in the next years, play an important role in 
serotype replacement disease, which has reduced the effectiveness of PCV7 vaccination. 
Moreover, the cost-effectiveness ratios of vaccination with the current vaccines are not clear 
because the evidence on the efficiency and effectiveness of current vaccination programs is 
suboptimal and they may impose a significant economical burden on public health budget. To 
this regard, there is only limited information about economic evaluation (147, 148). In a cost-
effectiveness analysis (CEA) of PCV7 in Taiwan, Bin Chia Wu et al., (149) exploring the impact of 
herd 
 effect and direct and indirect cost of vaccination program, think that PCV7 vaccination could 
prevent 1281 cases of invasive pneumococcal diseases, 178,145 cases of all-cause hospitalized 
pneumonia, 69,962 cases of all-cause AOM, and 981 deaths over a 10-year time horizon in a 
vaccination program with an annual cost of NT$1,950.5 million, saving 15.4% in direct medical 
costs and 64.1% in indirect costs of NT$9,467 million. However, their conclusions are not clear 
and they suggest more pharmacoeconomic studies and a preventable treatment should show 
a very clear impact in cost-effectiveness analysis. Although assessment of the effect of PCV on 
carriage as well as invasive disease should be part of enhanced surveillance activities for PCVs, 
polysaccharide pneumococcal vaccine is a big business. Public Health Programs expend billions 
of dollars each year trying to improve the capsule-based pneumococcal vaccine when these 
have been the subject of a large number of studies and almost all conclude that a new cheaper 
serotype-independent vaccine is necessary due to plasticity and adaptation capacity of 
pneumococcus (150). 
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7. Discovering potential candidates for non-serotype dependent
vaccine 
In order to overcome the major disadvantages of current pneumococcal vaccines (151) (low 
number of coverage serotype-dependent in developing countries, serotype replacement, high 
cost of production and that genomic factors other than capsular determinants may modulate 
virulence (152) as well as reduce the natural machinery of pneumococcal adaptation, a new 
vaccine serotype-independent must be developed. Moreover, recent studies reveal that 
carriage is both immunising and a pre-requisite for mucosal and systemic disease (153). Then, 
carriage result in mucosal and systemic immunological responses that conferred protection 
against recolonization and invasive pneumococcal disease (69, 120, 144-146, 154). Because of 
this, newer vaccines must have the property of discriminate between colonization and disease 
states and not interfere with nasopharyngeal ecology (as occur in varicella (155). An effective 
vaccine with these features would be of great epidemiological value because to the direct 
effect on the vaccine target groups, it would be add the herd effect. This herd effect would 
result mainly in protection against infection in adults by reduction in reservoirs (children 
behave well in this disease) (15). A number of potentially more inexpensive, serotype-
independent candidate vaccines are being energetically pursued. For example, whole cell-
pneumococcal vaccine (WCV) has been used satisfactorily in animal models and Children’s 
Hospital Boston is developing an inactivated WCV for phase I clinical trials (156). However, 
from the viewpoint of vaccine manufacturers, although WCV are low cost to manufacture, they 
are disadvantageous because of antigenic complexity and the challenge of reproducibility. 
Now, researches are trying to define them biochemically in order to develop pneumococcal 
constructs with a similar bifunctional potential (150). Then, the best targets for this purpose 
are protein subunits, like single or multicomponent vaccine. The development of protein-based 
pneumococcal vaccines has been pursed for decades with some promising results. Although 
cytoplasmic proteins have been tested as vaccine candidates with positive results (157, 158), 
surface proteins are the best potential drug targets and candidates for vaccine, since they play 
a critical role in the interaction between cells and their environment (159, 160) they are the 
best potential drug targets and candidates for vaccines, as they are molecules with the highest 
probabilities to be recognized by the elements of the immune system (161, 162). In fact, a 
traditional view has been that antibodies to pneumococcal antigens other than the capsular 
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polysaccharide do not confer immunity effectively because of hindering by the capsule; thus, 
the different serotypes are, in effect, independent pathogens regarding immunity (163). More 
recent work, however, has challenged this view. Nasopharyngeal colonization is a prerequisite 
of pneumococcal infection and this is a complex process in which differing host cell receptors 
are engaged by pneumococcal components other than the capsular polysaccharide (164, 165). 
When isolated from the bloodstream, pneumococci are highly capsulated; when isolated from 
the nasopharynx, subcapsular structures, such as the cell wall teichoic acid, are more exposed 
and indeed, needs to be surface-expressed for interaction with receptors on mucosal cells 
(166, 167). Thus, the ideal new vaccine candidate(s) must be present on the cell surface, highly 
expressed during infection in all stages of the disease, highly conserved within all serotypes 
(168), essential in viability, capable to elicit CD4+ T cell-dependent response (69-171) and 
prevent pneumococcal disease but no colonization (154). A large number of looked for these 
candidates, several proteins have been tested as immunogenic and some of them in a survival 
or colonization assay (Appendix III).  To date, 12 proteins or fragments of these have been 
evaluated in different phases of clinical trials (reviewed in Darrieux et al., 2013 (172) in a single 
or multicomponent protein-based vaccines (173-178). As a multicomponent protein-based 
vaccine, effect can be additive or even synergistic when more than one specificity is used 
together (176, 179) and, in addition to enhance, may reduce the possibility that pneumococcus 
would readily evolve to evade immunity induced by vaccination. Chimeric protein-based 
pneumococcal vaccines, fusions of pneumococcal proteins to other protein or to 
polysaccharides, have been proposed in many studies with stimulating results (180-182). Some 
protein vaccines have been tested in humans (183). They studied the kinetics of antibody 
responses to three highly conserved and immunogenic PSPs (pneumococcal histidine triad D 
(PhtD, Spr0907 in reference strain database R6), pneumococcal choline-binding protein A 
(PcpA, Spr1945), and serine proteinase precursor A (PrtA, Spr0561) in 106 children. Another 
study of pneumococcal proteins as vaccine was carried out with PhtD, pneumolysin (Ply, 
Spr1739) toxoid (dPly) and NTHi Protein D (PD), in adults. Two doses of this protein vaccine 
induced humoral immunity and antigen-specific CD4+ T-cell responses after each dose (184). 
However, anti-PSP antibody concentrations failed to increase in the convalescent sera of 30 
from 61 (49.2%) bacteraemic children. However, this work did not measure cellular response, 
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which has been shown to be an early contributor in the natural immunity against 
pneumococcus (183, 184). For this reason, new protein vaccine candidates must be found. 
8. Non-serotype dependent protein vaccine candidates previously
tested 
PspA 
Pneumococcal surface protein A (Spr0121) is a choline-binding protein; it inhibits otherwise 
spontaneous classical complement activation on the pneumococcal surface (185, 186) and 
inhibits killing by the bactericidal peptides of lactoferrin (187, 188). 
Pneumolysin (Ply) 
Ply is a cholesterol-dependent pore forming cytolysin expressed by virtually all pneumococcal 
strains (189). It promotes pneumococcal evasion by inhibiting the respiratory burst and, 
consequently, the bactericidal activity of leukocytes (reviewed in (Paton, 1996) (189)). It also 
induces complement depletion during infection (190) and causes injury to the pulmonary 
endothelial and alveolar cells, as well as the expression of pro-inflammatory cytokines 
(reviewed in Marriot et al 2008 (191)). It has been shown that Ply recognition by TLR-4 
activates innate immune responses to pneumococcal infection, since TLR4-/- mice were more 
susceptible to pneumococcal infection than wild type mice (192). Furthermore, Ply is able to 
induce TLR-4- independent activation of the NLRP3 inflammasome contributing to host 
protection against pneumococcal pneumonia (193). 
Neuraminidases 
Streptococcus pneumoniae expresses three types of sialidases; NanA (Spr1536) is necessary 
for successful colonization of the mucosa, while NanB (Spr1531) contributes to pneumococcal 
survival in the blood (194); and NanC, that could contribute to NanA and NanB in pathologies 
such as necrotizing neumonia and hemolytic syndrome (195, 196). These proteins exert their 
function by cleaving terminal sialic acid residues from glycoconjugates (reviewed by King et al., 
2006 (197)). 
PspC 
PspC (also known as CbpA, SpsA, PbcA or Hic, Spr1995) is a polymorphic surface-exposed 
protein with a structural organization similar to PspA, including a coiled-coil portion, a proline-
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rich region and a choline-binding domain (198). PspC binds to secretory IgA and the inhibitory 
complement regulator factor H (FH). While binding to FH is important to inhibit C3 deposition 
on the bacterial surface, interaction with secretory IgA appears to mediate pneumococcal 
translocation from the nasopharynx to sterile sites such as the lungs or the bloodstream (199, 
200). PspC displays high sequence variability, being classified into 11 clades (201). These 
differences could reflect on the extent of protection induced by immunization with PspC. 
PcpA 
Pneumococcal choline-binding protein A (PcpA, Spr1945) is a surface protein expressed in 
more than 90% of the pneumococcal isolates tested (202) and regulated by manganese 
concentrations. It is attached to the bacterial surface through a C-terminal choline-binding 
domain, while the N-terminal portion contains several leucine-rich repeats (LRR) (203). The 
structural organization of the LRR motifs provides a scaffold for protein-protein interactions 
suggesting a possible role for PcpA in adhesion (204). PcpA is expressed during invasive disease 
(in the lungs and blood), but not in the nasal mucosa, where Mn2+ concentrations are high. 
PsaA 
Pneumococcal surface antigen A (PsaA, Spr1494) is a conserved lipoprotein present in all 
pneumococcal strains that plays several important roles in pneumococcal virulence, such as 
manganese transport (205), resistance to oxidative stress (206) and bacterial adhesion (207). 
PppA 
Pneumococcal protective protein A (PppA, Spr1430) was isolated during a search for low 
molecular weight proteins in PBS washes of Streptococcus pneumoniae that could bind to 
nasopharyngeal mucin; PppA was the major component in that protein mixture. 
Immunoelectron microscopy studies suggested it could be surface exposed, while sequence 
analysis demonstrated that PppA is conserved among clinical isolates of various serotypes 
(208). 
PhT 
The PhT family of proteins was selected from the S. pneumoniae genome database (209) based 
on the presence of hydrophobic leader sequences, characteristic of cell surface proteins (209, 
210) and includes four members: PhtA (Spr1061), PhtB, PhtD (Spr0907) and PhtE (Spr0908), 
which have highly conserved sequences. Although the function of these proteins has not been 
completely elucidated, they have been shown to inhibit complement deposition on the 
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bacterial surface (211) and to bind zinc (212). The low concentrations of Zn2+ at the mucosal 
sites suggest a possible role for PhT proteins during colonization (213). This data was further 
supported by a recent study showing that purified Fab antibody fragments specific to PhtD and 
PhtE are able to reduce pneumococcal adhesion to human airway epithelial cells (214). 
PotD 
PotD (Spr1243) is a member of the polyamine transport operon, which consists of four 
members, potABCD (215). It is a surface-associated, polyamine-binding protein, mediating 
polyamine intake by the bacterial cell (216). Signature tagged mutagenesis studies have 
suggested a role for PotD in pneumococcal virulence (217). This result was confirmed by 
evaluation of PotD negative mutant pneumococci, which displayed reduced virulence in 
mouse models of sepsis and pneumonia. 
StkP and PcsB 
Serine/threonine protein kinase (StkP, Spr1577) and Protein required for cell wall separation of 
group B streptococcus (PcsB, Spr2021) are two conserved proteins identified by the 
ANTIGENome strategy, in which a pneumococcal peptide library was screened using sera from 
infected or convalescent patients (218). After a series of in vitro tests and animal studies, StkP 
and PcsB were shown to be crossprotective in models of sepsis and pneumonia (218, 221).
Sequence analysis revealed that these proteins are highly conserved among pneumococcal 
strains (218). StkP has been shown to act as a global regulator of gene expression in S. 
pneumoniae, including oxidative stress response, iron uptake, DNA repair, pyrimidine 
biosynthesis and cell wall metabolism (219). This functional diversity, together with a surface 
location (218, 220), suggests that StkP is an interesting candidate to be included in future 
pneumococcal vaccines. PcsB is a hydrolase involved in cell wall separation, which is also 
accessible to antibodies (221). 
Pili proteins 
The pneumococcal pilus was first characterized in the serotype 4 TIGR4 strain (222) and is 
composed of three structural proteins named RrgA (Sp_0462), RrgB (Sp_0463) and RrgC 
(Sp_0464) (222, 223). RrgB forms the backbone of the pilus structure, while RrgA and RrgC are 
accessory proteins located on the external and internal ends, respectively (223, 224). RrgA is 
an adhesin involved in biofilm formation. RrgB occurs in three forms, and a hybrid protein 
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including a fusion protein with all three variants has been shown to be protective against 
systemic challenge with different piliated pneumococcal strains (225).  
PiuA and PiaA 
PiuA (Spr1687) and PiaA (Spr0934) are two components of the iron uptake system that have 
been identified as possible lipoproteins located in pneumococcal membrane (226) and are 
required for full virulence in animal models of pneumococcal infection (227). PCR analysis has 
demonstrated that both genes are present in all pneumococci tested (226) and show high 
sequence similarities to surface iron receptors from other organisms. 
9. Strategies for discovering protein vaccine candidates
Several strategies have been developed for this purpose in the last years, from classical 
procedures before publication of the pneumococcus genome in 2001 (215) to in silico 
screening based on the presence of signal peptides (such as SPase I and II), transmembrane 
helices, choline-binding domains, type IV pre-pillin signal sequences, sortase motifs (LPXTG) or 
the search for homologues of known virulence proteins (228). However, around one third of 
the genes of any genome code for surface proteins (comprising secreted proteins, membrane 
proteins lipoproteins and covalently cell wall-attached proteins, in the case of bacteria) (162). 
For this reason, other approaches have been carried out, as immunoproteomic assays (229), 
targeting either the membrane fraction (157, 230, 231) or studying the cell wall-attached 
proteins (232). Moreover, when a “first generation proteomics” strategy is used (i.e. 
separation of proteins by 2-DE and identification by MALDI-TOF MS), membrane proteins, 
whose nature is normally hydrophobic, are underrepresented as they usually precipitate under 
standard IEF conditions (233, 234) and because of their low copy number. In addition, topology 
characterization of surface-exposed epitopes becomes impossible. Because of this, these 
approaches were avoided and protocols preferentially based on “second-generation 
proteomics” were used: surfomic analysis and membrane-vesicles production. These allow the 
identification of a higher proportion of this type of proteins, compared to gel-based 
approaches.  
The first approach consists of “shaving” intact living cells with proteases, after which the 
generated peptides (the “surfome” or “surfaceome”) are recovered and analyzed by 
LC/MS/MS. Although this approach has been applied to several kind of biological systems 
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(Appendix I: Olaya-Abril et al., Journal of proteomics 2013 Surfomics: shaving live organism 
for a fast proteomic identification of surface proteins, (235)), the highest success has 
been reached in bacteria, and particularly in Gram-positive organisms, as the rigid cell wall 
makes them more resistant to osmotic lysis than other species. This approach was first 
optimized and applied to the pathogen Streptococcus pyogenes (236), showing also the 
usefulness for the discovery of new protective antigens. However, due to autolysis 
occurring naturally in pneumococcus (237, 238), an optimization of the protocol was 
carried out (Chapter 1: Optimization of proteomics surface protein identification in 
Streptococcus pneumoniae (239). Once, the optimized protocol was applied to a set of 
clinical isolates in order to describe the “pan-surfome” of pneumococcus (Chapter 2: 
Identification of Potential New Protein Vaccine Candidates through Pan-Surfomic Analysis of 
Pneumococcal Clinical Isolates from Adults (240); and Chapter 3: Olaya-Abril et al., Pan-
Surfomic analysis of pediatric clinical isolates for protein vaccine and diagnostic 
candidates discovering), which presented a low evolutionary relationship (Appendix 
III). “Pan-surfome” was used to develop a serological test to improve etiological diagnostic 
yield of pneumococcal pneumonia in clinical ground and epidemiological studies to evaluate 
natural immunity to pneumococcal carriage in children, as well as vaccine efficacy and 
effectiveness (241). From Chapter II, a joint database with all available 
pneumococcal complete protein databases from UniprotKB was used in order to identify 
all possible proteins and not miss any by the fact that a particular protein was not included 
in a particular database or by the intrinsic variability of a protein between different 
strains. For example, the reference, acapsulated and avirulent strain R6 possesses 1,813 
proteins while other capsulated and virulent as TIGR4 or AP200, 2,105 and 2,216 
respectively. Then, if only the reference strain R6 is used for all analyses, exclusive proteins 
from TIGR4 or AP200 never will be identified. On the other hand, strains chosen for the analysis 
cover the whole range of genomic variability of Streptococcus pneumoniae (Figure 5). The 
second approach (Chapter IV: Olaya-Abril et al., J Proteomics (accepted), “Characterization of 
protective extracellular vesicles produced by Streptococcus pneumoniae” and V: Streptococcus
pneumoniae extracellular vesicles are toxic to J774 macrophages and modulate host immune
response) is based in membrane external vesicles (EV) production and characterization from the 
reference strain R6 and another four virulent strains from serotypes 1, 6B, 8 and 23F. MVs are 
distinct from membranous blebs produced during cell lysis as they are produced as a regulated, 
selective secretion event (242-245). The EV secretion mechanism functions to disseminate 
virulence factors including toxins and degradative enzymes into the extracellular milieu. Once 
released, EV have been demonstrated  to  function offensively  as a   virulence factor  delivery 
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mechanism, as well as  defensively, to aid in the colonization of a host and the survival of an 
organism in a hostile environment. EV are produced by many pathogenic microorganisms but 
very little is known about  their  production  by  Gram-positive  bacteria,  as well  as their  
biogenesis  and  release 
Figure 5. Streptococcus pneumoniae dendrogram based on genomic BLAST. Underlined protein databases used in our 
proteomic approaches 
mechanisms. In Gram-positive organisms, EV carry toxins in Bacillus anthracis (246) and 
Staphylococcus aureus (247, 248);  fuse with host cells, inducing their death (247, 248); 
induce a proinflammatory response in vitro and in vivo in Mycobacterium spp. (249) 
and are even able to induce a protective immune response against infection (246).  
In total, 40 clinical isolates (corresponding to 29 different ST) plus reference strains R6 
and TIGR4 have been analyzed by surfomic approach and four strains of serotype 1, 6B, 8 
and 23F were used for membrane-derived vesicles characterization. 
Immunoreactivity of 95 pneumococcal recombinant proteins was tested by different 
techniques and survival assays, using a serotype 8, with 7 fragment of pneumococcal 
recombinant proteins plus serotype 8 membrane-derived vesicles was carried out. We used 
as model of surveillance a serotype 8 strain because is not included in the vaccine and, 
according to the expert, is a serotype with invasive capacity and could produce shoots that 
tend to affect older children and adults (250).
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
67 
10. References 
1. Bratcher PE, et al. (2011) Evolution of the capsular gene locus of Streptococcus
pneumoniae serogroup 6. Microbiology 157(Pt 1):189-198.
2. Calix JJ, Dagan R, Pelton SI, Porat N, & Nahm MH (2012) Differential occurrence of
Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive
pneumococcal disease isolates reflects a unique model of pathogen microevolution.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of
America 54(6):794-799.
3. Calix JJ, et al. (2012) Biochemical, genetic, and serological characterization of two
capsule subtypes among Streptococcus pneumoniae Serotype 20 strains: discovery of
a new pneumococcal serotype. The Journal of biological chemistry 287(33):27885-
27894. 
4. Henrichsen J (1995) Six newly recognized types of Streptococcus pneumoniae. J Clin
Microbiol 33(10):2759-2762.
5. Jin P, et al. (2009) First report of putative Streptococcus pneumoniae serotype 6D
among nasopharyngeal isolates from Fijian children. J Infect Dis 200(9):1375-1380.
6. Muller A, Hinrichs W, Wolf WM, & Saenger W (1994) Crystal structure of calcium-free
proteinase K at 1.5-A resolution. The Journal of biological chemistry 269(37):23108-
23111. 
7. Park IH, et al. (2008) Differential effects of pneumococcal vaccines against serotypes
6A and 6C. J Infect Dis 198(12):1818-1822.
8. Park IH, Park S, Hollingshead SK, & Nahm MH (2007) Genetic basis for the new
pneumococcal serotype, 6C. Infect Immun 75(9):4482-4489.
9. Song JH, Dagan R, Klugman KP, & Fritzell B (2012) The relationship between
pneumococcal serotypes and antibiotic resistance. Vaccine 30(17):2728-2737.
10. Yother J (2011) Capsules of Streptococcus pneumoniae and other bacteria: paradigms
for polysaccharide biosynthesis and regulation. Annual review of microbiology 65:563-
581. 
11. Benson CE & Sweeney CR (1984) Isolation of Streptococcus pneumoniae type 3 from
equine species. J Clin Microbiol 20(6):1028-1030.
12. van der Linden M, Al-Lahham A, Nicklas W, & Reinert RR (2009) Molecular
characterization of pneumococcal isolates from pets and laboratory animals. PLoS One
4(12):e8286.
13. Denapaite D & Hakenbeck R (2011) A new variant of the capsule 3 cluster occurs in
Streptococcus pneumoniae from deceased wild chimpanzees. PLoS One 6(9):e25119.
14. Garcia-Rodriguez JA & Fresnadillo Martinez MJ (2002) Dynamics of nasopharyngeal
colonization by potential respiratory pathogens. The Journal of antimicrobial
chemotherapy 50 Suppl S2:59-73.
15. Bogaert D, De Groot R, & Hermans PW (2004) Streptococcus pneumoniae colonisation:
the key to pneumococcal disease. Lancet Infect Dis 4(3):144-154.
16. Gray BM, Converse GM, 3rd, & Dillon HC, Jr. (1980) Epidemiologic studies of
Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the
first 24 months of life. J Infect Dis 142(6):923-933.
17. Brugger SD, Frey P, Aebi S, Hinds J, & Muhlemann K (2010) Multiple colonization with
S. pneumoniae before and after introduction of the seven-valent conjugated
pneumococcal polysaccharide vaccine. PLoS One 5(7):e11638.
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
68 
18. Turner P, et al. (2011) Improved detection of nasopharyngeal cocolonization by
multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping
by microarray. J Clin Microbiol 49(5):1784-1789.
19. Abdullahi O, Nyiro J, Lewa P, Slack M, & Scott JA (2008) The descriptive epidemiology
of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in
children and adults in Kilifi district, Kenya. Pediatr Infect Dis J 27(1):59-64.
20. Adetifa IM, et al. (2012) Pre-vaccination nasopharyngeal pneumococcal carriage in a
Nigerian population: epidemiology and population biology. PLoS One 7(1):e30548.
21. Scott JR, et al. (2012) Impact of more than a decade of pneumococcal conjugate
vaccine use on carriage and invasive potential in Native American communities. J Infect
Dis 205(2):280-288.
22. Song JY, Nahm MH, & Moseley MA (2013) Clinical implications of pneumococcal
serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J
Korean Med Sci 28(1):4-15.
23. Hill PC, et al. (2006) Nasopharyngeal carriage of Streptococcus pneumoniae in
Gambian villagers. Clinical infectious diseases : an official publication of the Infectious
Diseases Society of America 43(6):673-679.
24. Mackenzie GA, Leach AJ, Carapetis JR, Fisher J, & Morris PS (2010) Epidemiology of
nasopharyngeal carriage of respiratory bacterial pathogens in children and adults:
cross-sectional surveys in a population with high rates of pneumococcal disease. BMC
Infect Dis 10:304.
25. Kim KH, et al. (2011) Nasopharyngeal pneumococcal carriage of children attending day
care centers in Korea: comparison between children immunized with 7-valent
pneumococcal conjugate vaccine and non-immunized. J Korean Med Sci 26(2):184-190.
26. Kronenberg A, Zucs P, Droz S, & Muhlemann K (2006) Distribution and invasiveness of
Streptococcus pneumoniae serotypes in Switzerland, a country with low antibiotic
selection pressure, from 2001 to 2004. J Clin Microbiol 44(6):2032-2038.
27. Smith T, et al. (1993) Acquisition and invasiveness of different serotypes of
Streptococcus pneumoniae in young children. Epidemiology and infection 111(1):27-
39.
28. Ritchie ND, Mitchell TJ, & Evans TJ (2012) What is different about serotype 1
pneumococci? Future microbiology 7(1):33-46.
29. Sleeman KL, et al. (2006) Capsular serotype-specific attack rates and duration of
carriage of Streptococcus pneumoniae in a population of children. J Infect Dis
194(5):682-688.
30. Hostetter MK (1986) Serotypic variations among virulent pneumococci in deposition
and degradation of covalently bound C3b: implications for phagocytosis and antibody
production. J Infect Dis 153(4):682-693.
31. Nelson AL, et al. (2007) Capsule enhances pneumococcal colonization by limiting
mucus-mediated clearance. Infect Immun 75(1):83-90.
32. Wartha F, et al. (2007) Capsule and D-alanylated lipoteichoic acids protect
Streptococcus pneumoniae against neutrophil extracellular traps. Cellular microbiology
9(5):1162-1171.
33. Rodgers GL, Arguedas A, Cohen R, & Dagan R (2009) Global serotype distribution
among Streptococcus pneumoniae isolates causing otitis media in children: potential
implications for pneumococcal conjugate vaccines. Vaccine 27(29):3802-3810.
34. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, & Dagan R (2006) Site-specific disease
potential of individual Streptococcus pneumoniae serotypes in pediatric invasive
disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 25(7):602-607.
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
69 
35. Briles DE, Crain MJ, Gray BM, Forman C, & Yother J (1992) Strong association between
capsular type and virulence for mice among human isolates of Streptococcus
pneumoniae. Infect Immun 60(1):111-116.
36. Hausdorff WP, Feikin DR, & Klugman KP (2005) Epidemiological differences among
pneumococcal serotypes. Lancet Infect Dis 5(2):83-93.
37. Brueggemann AB, et al. (2003) Clonal relationships between invasive and carriage
Streptococcus pneumoniae and serotype- and clone-specific differences in invasive
disease potential. J Infect Dis 187(9):1424-1432.
38. Sa-Leao R, et al. (2011) Analysis of invasiveness of pneumococcal serotypes and clones
circulating in Portugal before widespread use of conjugate vaccines reveals
heterogeneous behavior of clones expressing the same serotype. J Clin Microbiol
49(4):1369-1375.
39. Hanage WP, et al. (2005) Invasiveness of serotypes and clones of Streptococcus
pneumoniae among children in Finland. Infect Immun 73(1):431-435.
40. Yildirim I, et al. (2010) Serotype specific invasive capacity and persistent reduction in
invasive pneumococcal disease. Vaccine 29(2):283-288.
41. Jansen AG, et al. (2009) Invasive pneumococcal disease among adults: associations
among serotypes, disease characteristics, and outcome. Clinical infectious diseases : an
official publication of the Infectious Diseases Society of America 49(2):e23-29.
42. Rodriguez MA, et al. (2011) Invasive pneumococcal disease: association between
serotype, clinical presentation and lethality. Vaccine 29(34):5740-5746.
43. Weinberger DM, et al. (2010) Association of serotype with risk of death due to
pneumococcal pneumonia: a meta-analysis. Clinical infectious diseases : an official
publication of the Infectious Diseases Society of America 51(6):692-699.
44. Niederman MS (2004) Review of treatment guidelines for community-acquired
pneumonia. The American journal of medicine 117 Suppl 3A:51S-57S.
45. Brandenburg JA, et al. (2000) Clinical presentation, processes and outcomes of care for
patients with pneumococcal pneumonia. Journal of general internal medicine
15(9):638-646.
46. Burman LA, et al. (1991) Diagnosis of pneumonia by cultures, bacterial and viral
antigen detection tests, and serology with special reference to antibodies against
pneumococcal antigens. J Infect Dis 163(5):1087-1093.
47. Cilloniz C, et al. (2012) Pulmonary complications of pneumococcal community-
acquired pneumonia: incidence, predictors, and outcomes. Clin Microbiol Infect
18(11):1134-1142.
48. Briles DE, et al. (2003) Immunizations with pneumococcal surface protein A and
pneumolysin are protective against pneumonia in a murine model of pulmonary
infection with Streptococcus pneumoniae. J Infect Dis 188(3):339-348.
49. Gentile A, et al. (2012) Epidemiology of community-acquired pneumonia in children of
Latin America and the Caribbean: a systematic review and meta-analysis. International
journal of infectious diseases : IJID : official publication of the International Society for
Infectious Diseases 16(1):e5-15.
50. Aliberti S & Kaye KS (2013) The changing microbiologic epidemiology of community-
acquired pneumonia. Postgraduate medicine 125(6):31-42.
51. Sousa D, et al. (2013) Community-acquired pneumonia in immunocompromised older
patients: incidence, causative organisms and outcome. Clin Microbiol Infect 19(2):187-
192. 
52. Pande A, et al. (2012) The incidence of necrotizing changes in adults with
pneumococcal pneumonia. Clinical infectious diseases : an official publication of the
Infectious Diseases Society of America 54(1):10-16.
Ph.D. Thesis – Alfonso Olaya Abril         Introduction 
 
70 
 
53. Bender JM, et al. (2008) Pneumococcal necrotizing pneumonia in Utah: does serotype 
matter? Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America 46(9):1346-1352. 
54. Yangco BG & Deresinski SC (1980) Necrotizing or cavitating pneumonia due to 
Streptococcus Pneumoniae: report of four cases and review of the literature. Medicine 
59(6):449-457. 
55. Byington CL, et al. (2006) Impact of the pneumococcal conjugate vaccine on 
pneumococcal parapneumonic empyema. Pediatr Infect Dis J 25(3):250-254. 
56. Eastham KM, et al. (2004) Clinical features, aetiology and outcome of empyema in 
children in the north east of England. Thorax 59(6):522-525. 
57. Obando I, et al. (2006) Molecular typing of pneumococci causing parapneumonic 
empyema in Spanish children using multilocus sequence typing directly on pleural fluid 
samples. Pediatr Infect Dis J 25(10):962-963. 
58. Weil-Olivier C, et al. (2005) [Multicenter pediatric retrospective study on pneumonia 
with empyema in France]. Archives de pediatrie : organe officiel de la Societe francaise 
de pediatrie 12(6):823-826. 
59. Buckingham SC, King MD, & Miller ML (2003) Incidence and etiologies of complicated 
parapneumonic effusions in children, 1996 to 2001. Pediatr Infect Dis J 22(6):499-504. 
60. Gupta R & Crowley S (2006) Increasing paediatric empyema admissions. Thorax 
61(2):179-180. 
61. Langley JM, et al. (2008) Empyema associated with community-acquired pneumonia: a 
Pediatric Investigator's Collaborative Network on Infections in Canada (PICNIC) study. 
BMC Infect Dis 8:129. 
62. Lee JH, Kim SH, Lee J, Choi EH, & Lee HJ (2012) Diagnosis of pneumococcal empyema 
using immunochromatographic test on pleural fluid and serotype distribution in 
Korean children. Diagn Microbiol Infect Dis 72(2):119-124. 
63. Yu J, Salamon D, Marcon M, & Nahm MH (2011) Pneumococcal serotypes causing 
pneumonia with pleural effusion in pediatric patients. J Clin Microbiol 49(2):534-538. 
64. Burgos J, Falco V, & Pahissa A (2013) The increasing incidence of empyema. Curr Opin 
Pulm Med 19(4):350-356. 
65. Schultz KD, et al. (2004) The changing face of pleural empyemas in children: 
epidemiology and management. Pediatrics 113(6):1735-1740. 
66. Saez-Llorens X & McCracken GH, Jr. (2003) Bacterial meningitis in children. Lancet 
361(9375):2139-2148. 
67. Ginsberg L (2004) Difficult and recurrent meningitis. Journal of neurology, 
neurosurgery, and psychiatry 75 Suppl 1:i16-21. 
68. Tunkel AR, et al. (2004) Practice guidelines for the management of bacterial 
meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America 39(9):1267-1284. 
69. O'Brien KL, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in 
children younger than 5 years: global estimates. Lancet 374(9693):893-902. 
70. Kisakye A, et al. (2009) Surveillance for Streptococcus pneumoniae meningitis in 
children aged <5 years: implications for immunization in Uganda. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America 48 Suppl 
2:S153-161. 
71. Gessner BD, Mueller JE, & Yaro S (2010) African meningitis belt pneumococcal disease 
epidemiology indicates a need for an effective serotype 1 containing vaccine, including 
for older children and adults. BMC Infect Dis 10:22. 
72. Brueggemann AB & Spratt BG (2003) Geographic distribution and clonal diversity of 
Streptococcus pneumoniae serotype 1 isolates. J Clin Microbiol 41(11):4966-4970. 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
71 
73. Hemsley C & Eykyn SJ (1998) Pneumococcal peritonitis in previously healthy adults:
case report and review. Clinical infectious diseases : an official publication of the
Infectious Diseases Society of America 27(2):376-379.
74. Sirotnak AP, Eppes SC, & Klein JD (1996) Tuboovarian abscess and peritonitis caused by
Streptococcus pneumoniae serotype 1 in young girls. Clinical infectious diseases : an
official publication of the Infectious Diseases Society of America 22(6):993-996.
75. Cabrera GR, et al. (1998) Hemolytic uremic syndrome associated with invasive
Streptococcus pneumoniae infection. Pediatrics 101(4 Pt 1):699-703.
76. Kaplan SL, et al. (1998) Three-year multicenter surveillance of systemic pneumococcal
infections in children. Pediatrics 102(3 Pt 1):538-545.
77. Huang YH, et al. (2006) Hemolytic uremic syndrome associated with pneumococcal
pneumonia in Taiwan. European journal of pediatrics 165(5):332-335.
78. von Vigier RO, Fossali E, Crosazzo L, & Bianchetti MG (2005) Positive Coombs test in
postpneumococcal hemolytic-uremic syndrome. Pediatr Infect Dis J 24(11):1028-1029.
79. Bhutta ZA & Das JK (2013) Global burden of childhood diarrhea and pneumonia: what
can and should be done? Pediatrics 131(4):634-636.
80. Wardlaw T, Salama P, Johansson EW, & Mason E (2006) Pneumonia: the leading killer
of children. Lancet 368(9541):1048-1050.
81. Tzanakaki G & Mastrantonio P (2007) Aetiology of bacterial meningitis and resistance
to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int J
Antimicrob Agents 29(6):621-629.
82. Eskola J, et al. (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis
media. The New England journal of medicine 344(6):403-409.
83. Ess SM, Schaad UB, Gervaix A, Pinosch S, & Szucs TD (2003) Cost-effectiveness of a
pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine
21(23):3273-3281.
84. Kilpi T, Herva E, Kaijalainen T, Syrjanen R, & Takala AK (2001) Bacteriology of acute
otitis media in a cohort of Finnish children followed for the first two years of life.
Pediatr Infect Dis J 20(7):654-662.
85. Ziebold C, von Kries R, Siedler A, & Schmitt HJ (2000) Epidemiology of pneumococcal
disease in children in Germany. Acta paediatrica 89(435):17-21.
86. Herva E, et al. (1980) The effect of polyvalent pneumococcal polysaccharide vaccine on
nasopharyngeal and nasal carriage of Streptococcus pneumoniae. Scandinavian journal
of infectious diseases 12(2):97-100.
87. Lee H, Nahm MH, & Kim KH (2010) The effect of age on the response to the
pneumococcal polysaccharide vaccine. BMC Infect Dis 10:60.
88. Musher DM, Luchi MJ, Watson DA, Hamilton R, & Baughn RE (1990) Pneumococcal
polysaccharide vaccine in young adults and older bronchitics: determination of IgG
responses by ELISA and the effect of adsorption of serum with non-type-specific cell
wall polysaccharide. J Infect Dis 161(4):728-735.
89. Romero-Steiner S, et al. (1999) Reduction in functional antibody activity against
Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with
decreased IgG antibody avidity. Clinical infectious diseases : an official publication of
the Infectious Diseases Society of America 29(2):281-288.
90. Overturf GD (2000) American Academy of Pediatrics. Committee on Infectious
Diseases. Technical report: prevention of pneumococcal infections, including the use
of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis.
Pediatrics 106(2 Pt 1):367-376.
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
72 
91. Gaillat J (2009) Should patients with chronic obstructive pulmonary disease be
vaccinated against pneumococcal diseases? Expert review of respiratory medicine
3(6):585-596.
92. Hanquet G, et al. (2010) Pneumococcal serotypes in children in 4 European countries.
Emerg Infect Dis 16(9):1428-1439.
93. Melegaro A & Edmunds WJ (2004) The 23-valent pneumococcal polysaccharide
vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in
England and Wales. European journal of epidemiology 19(4):365-375.
94. Black S, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal
conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study
Center Group. Pediatr Infect Dis J 19(3):187-195.
95. Whitney CG, Goldblatt D, & O'Brien KL (2014) Dosing schedules for pneumococcal
conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J 33 Suppl
2:S172-181.
96. Pilishvili T, et al. (2010) Sustained reductions in invasive pneumococcal disease in the
era of conjugate vaccine. J Infect Dis 201(1):32-41.
97. Robinson KA, et al. (2001) Epidemiology of invasive Streptococcus pneumoniae
infections in the United States, 1995-1998: Opportunities for prevention in the
conjugate vaccine era. JAMA 285(13):1729-1735.
98. Rozenbaum MH, Boersma C, Postma MJ, & Hak E (2011) Observed differences in
invasive pneumococcal disease epidemiology after routine infant vaccination. Expert
Rev Vaccines 10(2):187-199.
99. Munoz-Almagro C, et al. (2011) Serotypes and clones causing invasive pneumococcal
disease before the use of new conjugate vaccines in Catalonia, Spain. The Journal of
infection 63(2):151-162.
100. Hsieh YC, Lee WS, Shao PL, Chang LY, & Huang LM (2008) The transforming
Streptococcus pneumoniae in the 21st century. Chang Gung Med J 31(2):117-124.
101. Trzcinski K, Thompson CM, & Lipsitch M (2004) Single-step capsular transformation
and acquisition of penicillin resistance in Streptococcus pneumoniae. J Bacteriol
186(11):3447-3452.
102. Dowson CG, et al. (1989) Horizontal transfer of penicillin-binding protein genes in
penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci U
S A 86(22):8842-8846.
103. Prudhomme M, Attaiech L, Sanchez G, Martin B, & Claverys JP (2006) Antibiotic stress
induces genetic transformability in the human pathogen Streptococcus pneumoniae.
Science 313(5783):89-92.
104. Laurenceau R, et al. (2013) A type IV pilus mediates DNA binding during natural
transformation in Streptococcus pneumoniae. PLoS Pathog 9(6):e1003473.
105. Robinson DA, Briles DE, Crain MJ, & Hollingshead SK (2002) Evolution and virulence of
serogroup 6 pneumococci on a global scale. J Bacteriol 184(22):6367-6375.
106. Kaplan SL, et al. (2004) Decrease of invasive pneumococcal infections in children
among 8 children's hospitals in the United States after the introduction of the 7-valent
pneumococcal conjugate vaccine. Pediatrics 113(3 Pt 1):443-449.
107. Ghaffar F, et al. (2004) Effect of the 7-valent pneumococcal conjugate vaccine on
nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of
America 39(7):930-938.
108. Gonzalez BE, et al. (2006) Streptococcus pneumoniae serogroups 15 and 33: an
increasing cause of pneumococcal infections in children in the United States after the
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
73 
introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J 
25(4):301-305. 
109. Ho PL, Chiu SS, Ang I, & Lau YL (2011) Serotypes and antimicrobial susceptibilities of 
invasive Streptococcus pneumoniae before and after introduction of 7-valent 
pneumococcal conjugate vaccine, Hong Kong, 1995-2009. Vaccine 29(17):3270-3275. 
110. Hsu KK, Shea KM, Stevenson AE, Pelton SI, & Massachusetts Department of Public H 
(2010) Changing serotypes causing childhood invasive pneumococcal disease: 
Massachusetts, 2001-2007. Pediatr Infect Dis J 29(4):289-293. 
111. Kaplan SL, et al. (2010) Serotype 19A Is the most common serotype causing invasive 
pneumococcal infections in children. Pediatrics 125(3):429-436. 
112. Pai R, et al. (2005) Postvaccine genetic structure of Streptococcus pneumoniae 
serotype 19A from children in the United States. J Infect Dis 192(11):1988-1995. 
113. Singleton RJ, et al. (2007) Invasive pneumococcal disease caused by nonvaccine 
serotypes among alaska native children with high levels of 7-valent pneumococcal 
conjugate vaccine coverage. JAMA 297(16):1784-1792. 
114. Brueggemann AB, Pai R, Crook DW, & Beall B (2007) Vaccine escape recombinants 
emerge after pneumococcal vaccination in the United States. PLoS Pathog 3(11):e168. 
115. Green MC, et al. (2011) Increase in prevalence of Streptococcus pneumoniae serotype 
6C at Eight Children's Hospitals in the United States from 1993 to 2009. J Clin Microbiol 
49(6):2097-2101. 
116. Rolo D, et al. (2011) Trends of invasive serotype 6C pneumococci in Spain: emergence 
of a new lineage. The Journal of antimicrobial chemotherapy 66(8):1712-1718. 
117. Nunes S, Valente C, Sa-Leao R, & de Lencastre H (2009) Temporal trends and molecular 
epidemiology of recently described serotype 6C of Streptococcus pneumoniae. J Clin 
Microbiol 47(2):472-474. 
118. McEllistrem MC, Adams J, Mason EO, & Wald ER (2003) Epidemiology of acute otitis 
media caused by Streptococcus pneumoniae before and after licensure of the 7-valent 
pneumococcal protein conjugate vaccine. J Infect Dis 188(11):1679-1684. 
119. Munoz-Almagro C, et al. (2008) Emergence of invasive pneumococcal disease caused 
by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America 
46(2):174-182. 
120. Weinberger DM, Malley R, & Lipsitch M (2011) Serotype replacement in disease after 
pneumococcal vaccination. Lancet 378(9807):1962-1973. 
121. Beall B, et al. (2013) Proteomic Biomarkers Associated with Streptococcus agalactiae 
Invasive Genogroups. PLoS One 8(1):e54393. 
122. Cho EY, et al. (2012) Changes in serotype distribution and antibiotic resistance of 
nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after 
optional use of the 7-valent conjugate vaccine. J Korean Med Sci 27(7):716-722. 
123. Spratt BG & Greenwood BM (2000) Prevention of pneumococcal disease by 
vaccination: does serotype replacement matter? Lancet 356(9237):1210-1211. 
124. Hicks LA, et al. (2007) Incidence of pneumococcal disease due to non-pneumococcal 
conjugate vaccine (PCV7) serotypes in the United States during the era of widespread 
PCV7 vaccination, 1998-2004. J Infect Dis 196(9):1346-1354. 
125. Munoz-Almagro C, et al. (2011) DNA bacterial load in children and adolescents with 
pneumococcal pneumonia and empyema. European journal of clinical microbiology & 
infectious diseases : official publication of the European Society of Clinical Microbiology  
30(3):327-335. 
126. Sa-Leao R, et al. (2009) Changes in pneumococcal serotypes and antibiotypes carried 
by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
74 
widespread use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol 
Infect 15(11):1002-1007. 
127. Pichon B, Bennett HV, Efstratiou A, Slack MP, & George RC (2009) Genetic 
characteristics of pneumococcal disease in elderly patients before introducing the 
pneumococcal conjugate vaccine. Epidemiology and infection 137(7):1049-1056. 
128. Jefferies JM, et al. (2010) Temporal analysis of invasive pneumococcal clones from 
Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of 
pneumococcal conjugate vaccine. J Clin Microbiol 48(1):87-96. 
129. de Sevilla MF, et al. (2012) Clinical presentation of invasive pneumococcal disease in 
Spain in the era of heptavalent conjugate vaccine. Pediatr Infect Dis J 31(2):124-128. 
130. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, & Porat N (2009) Introduction and 
proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones 
that cause acute otitis media in an unvaccinated population. J Infect Dis 199(6):776-
785. 
131. Pillai DR, et al. (2009) Genome-wide dissection of globally emergent multi-drug 
resistant serotype 19A Streptococcus pneumoniae. BMC genomics 10:642. 
132. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, & Siber GR (2000) The contribution of 
specific pneumococcal serogroups to different disease manifestations: implications for 
conjugate vaccine formulation and use, part II. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 30(1):122-140. 
133. Casey JR, Adlowitz DG, & Pichichero ME (2010) New patterns in the otopathogens 
causing acute otitis media six to eight years after introduction of pneumococcal 
conjugate vaccine. Pediatr Infect Dis J 29(4):304-309. 
134. Mahjoub-Messai F, Doit C, Mariani-Kurkdjian P, Francois M, & Bingen E (2008) 
[Epidemiology of acute otitis media caused by Streptococcus pneumoniae: emergence 
of serotype 19A]. Archives de pediatrie : organe officiel de la Societe francaise de 
pediatrie 15(11):1713-1716. 
135. Yildirim I, Stevenson A, Hsu KK, & Pelton SI (2012) Evolving picture of invasive 
pneumococcal disease in massachusetts children: a comparison of disease in 2007-
2009 with earlier periods. Pediatr Infect Dis J 31(10):1016-1021. 
136. Obando I, et al. (2008) Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 
14(9):1390-1397. 
137. Hsu HE, et al. (2009) Effect of pneumococcal conjugate vaccine on pneumococcal 
meningitis. The New England journal of medicine 360(3):244-256. 
138. Hanage WP, et al. (2007) Diversity and antibiotic resistance among nonvaccine 
serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent 
conjugate vaccine era. J Infect Dis 195(3):347-352. 
139. Waters AM, et al. (2007) Hemolytic uremic syndrome associated with invasive 
pneumococcal disease: the United kingdom experience. The Journal of pediatrics 
151(2):140-144. 
140. Merieau E, Lanotte P, Chantreuil J, & Cantagrel S (2008) [Streptococcus pneumoniae 
19A-induced hemolytic-uremic syndrome: a new pathology?]. Archives de pediatrie : 
organe officiel de la Societe francaise de pediatrie 15(12):1825-1827. 
141. Kirkham LA, et al. (2006) Identification of invasive serotype 1 pneumococcal isolates 
that express nonhemolytic pneumolysin. J Clin Microbiol 44(1):151-159. 
142. Kaplan SL, et al. (2013) Early trends for invasive pneumococcal infections in children 
after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect 
Dis J 32(3):203-207. 
143. Alonso M, Marimon JM, Ercibengoa M, Perez-Yarza EG, & Perez-Trallero E (2013) 
Dynamics of Streptococcus pneumoniae serotypes causing acute otitis media isolated 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
75 
from children with spontaneous middle-ear drainage over a 12-year period (1999-
2010) in a region of northern Spain. PLoS One 8(1):e54333. 
144. Nurhonen M, Cheng AC, & Auranen K (2013) Pneumococcal transmission and disease 
in silico: a microsimulation model of the indirect effects of vaccination. PLoS One 
8(2):e56079. 
145. Pletz MW, Maus U, Hohlfeld JM, Lode H, & Welte T (2008) [Pneumococcal vaccination: 
conjugated vaccine induces herd immunity and reduces antibiotic resistance]. 
Deutsche medizinische Wochenschrift 133(8):358-362. 
146. Rose M & Zielen S (2009) Impact of infant immunization programs with pneumococcal 
conjugate vaccine in Europe. Expert Rev Vaccines 8(10):1351-1364. 
147. Cortés I, Pérez-Camarero S, del Llano J, Peña LM, & Hidalgo-Vega Á (2013) Systematic 
review of economic evaluation analyses of available vaccines in Spain from 1990 to 
2012. Vaccine 31(35):3473-3484. 
148. García-Altés A (2013) Systematic review of economic evaluation studies: Are 
vaccination programs efficient in Spain? Vaccine 31(13):1656-1665. 
149. Wu DB, Rinaldi F, Huang YC, Chang JA, & Chang CJ (2013) Economic evaluation of 
universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness 
analysis. Journal of the Formosan Medical Association = Taiwan yi zhi 112(3):151-160. 
150. Malley R & Anderson PW (2012) Serotype-independent pneumococcal experimental 
vaccines that induce cellular as well as humoral immunity. Proc Natl Acad Sci U S A 
109(10):3623-3627. 
151. Pittet LF & Posfay-Barbe KM (2012) Pneumococcal vaccines for children: a global public 
health priority. Clin Microbiol Infect 18 Suppl 5:25-36. 
152. Thomas JC, et al. (2011) Streptococcus pneumoniae clonal complex 199: genetic 
diversity and tissue-specific virulence. PLoS One 6(4):e18649. 
153. Wright AK, et al. (2013) Experimental human pneumococcal carriage augments IL-17A-
dependent T-cell defence of the lung. PLoS Pathog 9(3):e1003274. 
154. Ferreira DM, et al. (2013) Controlled Human Infection and Rechallenge 
withStreptococcus pneumoniaeReveals the Protective Efficacy of Carriage in Healthy 
Adults. American Journal of Respiratory and Critical Care Medicine 187(8):855-864. 
155. Carrillo-Santisteve P & Lopalco PL (2014) Varicella vaccination: a laboured take-off. Clin 
Microbiol Infect. 
156. Webster J, et al. (2011) An evaluation of emerging vaccines for childhood 
pneumococcal pneumonia. BMC Public Health 11 Suppl 3:S26. 
157. Ling E, et al. (2004) Glycolytic enzymes associated with the cell surface of 
Streptococcus pneumoniae are antigenic in humans and elicit protective immune 
responses in the mouse. Clin Exp Immunol 138(2):290-298. 
158. Portnoi M, Ling E, Feldman G, Dagan R, & Mizrachi-Nebenzahl Y (2006) The vaccine 
potential of Streptococcus pneumoniae surface lectin- and non-lectin proteins. Vaccine 
24(11):1868-1873. 
159. Cordwell SJ (2006) Technologies for bacterial surface proteomics. Curr Opin Microbiol 
9(3):320-329. 
160. Navarre WW & Schneewind O (1999) Surface proteins of gram-positive bacteria and 
mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev 
63(1):174-229. 
161. Grandi G (2006) Genomics and proteomics in reverse vaccines. Methods Biochem Anal 
49:379-393. 
162. Zagursky RJ & Anderson AS (2008) Application of genomics in bacterial vaccine 
discovery: a decade in review. Curr Opin Pharmacol 8(5):632-638. 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
76 
163. Bynoe MS, Viret C, Flavell RA, & Janeway CA, Jr. (2005) T cells from epicutaneously 
immunized mice are prone to T cell receptor revision. Proc Natl Acad Sci U S A 
102(8):2898-2903. 
164. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, & Tuomanen EI (1995) 
Streptococcus pneumoniae anchor to activated human cells by the receptor for 
platelet-activating factor. Nature 377(6548):435-438. 
165. Weiser JN (2010) The pneumococcus: why a commensal misbehaves. Journal of 
molecular medicine 88(2):97-102. 
166. Weiser JN, Austrian R, Sreenivasan PK, & Masure HR (1994) Phase variation in 
pneumococcal opacity: relationship between colonial morphology and nasopharyngeal 
colonization. Infect Immun 62(6):2582-2589. 
167. Weiser JN, Markiewicz Z, Tuomanen EI, & Wani JH (1996) Relationship between phase 
variation in colony morphology, intrastrain variation in cell wall physiology, and 
nasopharyngeal colonization by Streptococcus pneumoniae. Infect Immun 64(6):2240-
2245. 
168. Grandi G (2001) Antibacterial vaccine design using genomics and proteomics. Trends in 
biotechnology 19(5):181-188. 
169. Lipsitch M, et al. (2005) Are anticapsular antibodies the primary mechanism of 
protection against invasive pneumococcal disease? PLoS Med 2(1):e15. 
170. Malley R, et al. (2005) CD4+ T cells mediate antibody-independent acquired immunity 
to pneumococcal colonization. Proc Natl Acad Sci U S A 102(13):4848-4853. 
171. McCool TL & Weiser JN (2004) Limited role of antibody in clearance of Streptococcus 
pneumoniae in a murine model of colonization. Infect Immun 72(10):5807-5813. 
172. Darrieux M, Goulart C, Briles D, & Leite LC (2013) Current status and perspectives on 
protein-based pneumococcal vaccines. Crit Rev Microbiol. 
173. Bologa M, et al. (2012) Safety and immunogenicity of pneumococcal protein vaccine 
candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA–
pneumococcal histidine triad protein D vaccine. Vaccine 30(52):7461-7468. 
174. Cao J, et al. (2007) Enhanced protection against pneumococcal infection elicited by 
immunization with the combination of PspA, PspC, and ClpP. Vaccine 25(27):4996-
5005. 
175. Denoël P, et al. (2011) A protein-based pneumococcal vaccine protects rhesus 
macaques from pneumonia after experimental infection with Streptococcus 
pneumoniae. Vaccine 29(33):5495-5501. 
176. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, & Paton JC (2000) Immunization of 
mice with combinations of pneumococcal virulence proteins elicits enhanced 
protection against challenge with Streptococcus pneumoniae. Infect Immun 
68(5):3028-3033. 
177. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, & Paton JC (2007) Development of a 
vaccine against invasive pneumococcal disease based on combinations of virulence 
proteins of Streptococcus pneumoniae. Infect Immun 75(1):350-357. 
178. Ogunniyi AD, Woodrow MC, Poolman JT, & Paton JC (2001) Protection against 
Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. 
Infect Immun 69(10):5997-6003. 
179. Briles DE, et al. (2000) Intranasal immunization of mice with a mixture of the 
pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal 
carriage of Streptococcus pneumoniae. Infect Immun 68(2):796-800. 
180. Darrieux M, et al. (2007) Fusion proteins containing family 1 and family 2 PspA 
fragments elicit protection against Streptococcus pneumoniae that correlates with 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
77 
antibody-mediated enhancement of complement deposition. Infect Immun 
75(12):5930-5938. 
181. Goulart C, et al. (2013) Characterization of protective immune responses induced by 
pneumococcal surface protein A in fusion with pneumolysin derivatives. PLoS One 
8(3):e59605. 
182. Nguyen CT, Kim SY, Kim MS, Lee SE, & Rhee JH (2011) Intranasal immunization with 
recombinant PspA fused with a flagellin enhances cross-protective immunity against 
Streptococcus pneumoniae infection in mice. Vaccine 29(34):5731-5739. 
183. Hagerman A, et al. (2012) Failure to elicit seroresponses to pneumococcal surface 
proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, 
and serine proteinase precursor A) in children with pneumococcal bacteraemia. Clin 
Microbiol Infect 18(8):756-762. 
184. Berglund J, et al. (2013) Safety, Immunogenicity, and Antibody Persistence following 
an Investigational Streptococcus pneumoniae and Haemophilus influenzae Triple-
Protein Vaccine in a Phase 1 Randomized Controlled Study in Healthy Adults. Clinical 
and Vaccine Immunology 21(1):56-65. 
185. Mukerji R, et al. (2012) Pneumococcal surface protein A inhibits complement 
deposition on the pneumococcal surface by competing with the binding of C-reactive 
protein to cell-surface phosphocholine. J Immunol 189(11):5327-5335. 
186. Ren B, Li J, Genschmer K, Hollingshead SK, & Briles DE (2012) The absence of PspA or 
presence of antibody to PspA facilitates the complement-dependent phagocytosis of 
pneumococci in vitro. Clin Vaccine Immunol 19(10):1574-1582. 
187. Mirza S, et al. (2011) Serine protease PrtA from Streptococcus pneumoniae plays a role 
in the killing of S. pneumoniae by apolactoferrin. Infect Immun 79(6):2440-2450. 
188. Shaper M, Hollingshead SK, Benjamin WH, Jr., & Briles DE (2004) PspA protects 
Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA 
enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun 
72(9):5031-5040. 
189. Paton JC (1996) The contribution of pneumolysin to the pathogenicity of Streptococcus 
pneumoniae. Trends Microbiol 4(3):103-106. 
190. Alcantara RB, Preheim LC, & Gentry-Nielsen MJ (2001) Pneumolysin-induced 
complement depletion during experimental pneumococcal bacteremia. Infect Immun 
69(6):3569-3575. 
191. Marriott HM, Mitchell TJ, & Dockrell DH (2008) Pneumolysin: a double-edged sword 
during the host-pathogen interaction. Current molecular medicine 8(6):497-509. 
192. Malley R, et al. (2003) Recognition of pneumolysin by Toll-like receptor 4 confers 
resistance to pneumococcal infection. Proc Natl Acad Sci U S A 100(4):1966-1971. 
193. Witzenrath M, et al. (2011) The NLRP3 inflammasome is differentially activated by 
pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J 
Immunol 187(1):434-440. 
194. Manco S, et al. (2006) Pneumococcal neuraminidases A and B both have essential roles 
during infection of the respiratory tract and sepsis. Infect Immun 74(7):4014-4020. 
195. Janapatla RP, et al. (2013) Necrotizing pneumonia caused by nanC-carrying serotypes 
is associated with pneumococcal haemolytic uraemic syndrome in children. Clin 
Microbiol Infect 19(5):480-486. 
196. Xu G, et al. (2011) Three Streptococcus pneumoniae sialidases: three different 
products. Journal of the American Chemical Society 133(6):1718-1721. 
197. King SJ, Hippe KR, & Weiser JN (2006) Deglycosylation of human glycoconjugates by 
the sequential activities of exoglycosidases expressed by Streptococcus pneumoniae. 
Mol Microbiol 59(3):961-974. 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
78 
198. Brooks-Walter A, Briles DE, & Hollingshead SK (1999) The pspC gene of Streptococcus 
pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive 
antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun 
67(12):6533-6542. 
199. Dave S, Brooks-Walter A, Pangburn MK, & McDaniel LS (2001) PspC, a pneumococcal 
surface protein, binds human factor H. Infect Immun 69(5):3435-3437. 
200. Dave S, Carmicle S, Hammerschmidt S, Pangburn MK, & McDaniel LS (2004) Dual roles 
of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory 
IgA and factor H. J Immunol 173(1):471-477. 
201. Iannelli F, Oggioni MR, & Pozzi G (2002) Allelic variation in the highly polymorphic 
locus pspC of Streptococcus pneumoniae. Gene 284(1-2):63-71. 
202. Selva L, et al. (2012) Prevalence and clonal distribution of pcpA, psrP and Pilus-1 
among pediatric isolates of Streptococcus pneumoniae. PLoS One 7(7):e41587. 
203. Sanchez-Beato AR, Lopez R, & Garcia JL (1998) Molecular characterization of PcpA: a 
novel choline-binding protein of Streptococcus pneumoniae. FEMS microbiology letters 
164(1):207-214. 
204. Seepersaud R, et al. (2005) Characterization of a novel leucine-rich repeat protein 
antigen from group B streptococci that elicits protective immunity. Infect Immun 
73(3):1671-1683. 
205. Dintilhac A, Alloing G, Granadel C, & Claverys JP (1997) Competence and virulence of 
Streptococcus pneumoniae: Adc and PsaA mutants exhibit a requirement for Zn and 
Mn resulting from inactivation of putative ABC metal permeases. Mol Microbiol 
25(4):727-739. 
206. Tseng HJ, McEwan AG, Paton JC, & Jennings MP (2002) Virulence of Streptococcus 
pneumoniae: PsaA mutants are hypersensitive to oxidative stress. Infect Immun 
70(3):1635-1639. 
207. Berry AM & Paton JC (1996) Sequence heterogeneity of PsaA, a 37-kilodalton putative 
adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun 
64(12):5255-5262. 
208. Green BA, et al. (2005) PppA, a surface-exposed protein of Streptococcus pneumoniae, 
elicits cross-reactive antibodies that reduce colonization in a murine intranasal 
immunization and challenge model. Infect Immun 73(2):981-989. 
209. Adamou JE, et al. (2001) Identification and characterization of a novel family of 
pneumococcal proteins that are protective against sepsis. Infect Immun 69(2):949-958. 
210. Hamel J, et al. (2004) Prevention of pneumococcal disease in mice immunized with 
conserved surface-accessible proteins. Infect Immun 72(5):2659-2670. 
211. Ogunniyi AD, et al. (2009) Pneumococcal histidine triad proteins are regulated by the 
Zn2+-dependent repressor AdcR and inhibit complement deposition through the 
recruitment of complement factor H. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology 23(3):731-738. 
212. Rioux S, et al. (2011) Transcriptional regulation, occurrence and putative role of the 
Pht family of Streptococcus pneumoniae. Microbiology 157(Pt 2):336-348. 
213. Godfroid F, Hermand P, Verlant V, Denoel P, & Poolman JT (2011) Preclinical 
evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine 
antigens. Infect Immun 79(1):238-245. 
214. Khan MN & Pichichero ME (2012) Vaccine candidates PhtD and PhtE of Streptococcus 
pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine 
30(18):2900-2907. 
215. Hoskins J, et al. (2001) Genome of the bacterium Streptococcus pneumoniae strain R6. 
J Bacteriol 183(19):5709-5717. 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
79 
216. Ware D, Watt J, & Swiatlo E (2005) Utilization of putrescine by Streptococcus 
pneumoniae during growth in choline-limited medium. Journal of microbiology 
43(5):398-405. 
217. Polissi A, et al. (1998) Large-scale identification of virulence genes from Streptococcus 
pneumoniae. Infect Immun 66(12):5620-5629. 
218. Giefing C, et al. (2008) Discovery of a novel class of highly conserved vaccine antigens 
using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. 
Journal of Experimental Medicine 205(1):117-131. 
219. Saskova L, Novakova L, Basler M, & Branny P (2007) Eukaryotic-type serine/threonine 
protein kinase StkP is a global regulator of gene expression in Streptococcus 
pneumoniae. J Bacteriol 189(11):4168-4179. 
220. Giefing C, Jelencsics KE, Gelbmann D, Senn BM, & Nagy E (2010) The pneumococcal 
eukaryotic-type serine/threonine protein kinase StkP co-localizes with the cell division 
apparatus and interacts with FtsZ in vitro. Microbiology 156(Pt 6):1697-1707. 
221. Mills MF, Marquart ME, & McDaniel LS (2007) Localization of PcsB of Streptococcus 
pneumoniae and its differential expression in response to stress. J Bacteriol 
189(12):4544-4546. 
222. Barocchi MA, et al. (2006) A pneumococcal pilus influences virulence and host 
inflammatory responses. Proc Natl Acad Sci U S A 103(8):2857-2862. 
223. Hilleringmann M, et al. (2009) Molecular architecture of Streptococcus pneumoniae 
TIGR4 pili. EMBO J 28(24):3921-3930. 
224. Hilleringmann M, et al. (2008) Pneumococcal pili are composed of protofilaments 
exposing adhesive clusters of Rrg A. PLoS Pathog 4(3):e1000026. 
225. Wizemann TM, et al. (2001) Use of a whole genome approach to identify vaccine 
molecules affording protection against Streptococcus pneumoniae infection. Infect 
Immun 69(3):1593-1598. 
226. Brown JS, Ogunniyi AD, Woodrow MC, Holden DW, & Paton JC (2001) Immunization 
with components of two iron uptake ABC transporters protects mice against systemic 
Streptococcus pneumoniae infection. Infect Immun 69(11):6702-6706. 
227. Brown JS, Gilliland SM, & Holden DW (2001) A Streptococcus pneumoniae 
pathogenicity island encoding an ABC transporter involved in iron uptake and 
virulence. Mol Microbiol 40(3):572-585. 
228. Zagursky RJ, Olmsted SB, Russell DP, & Wooters JL (2003) Bioinformatics: how it is 
being used to identify bacterial vaccine candidates. Expert Rev Vaccines 2(3):417-436. 
229. Choi CW, et al. (2010) Analysis of cytoplasmic membrane proteome of Streptococcus 
pneumoniae by shotgun proteomic approach. Journal of microbiology 48(6):872-876. 
230. Soualhine H, et al. (2005) A proteomic analysis of penicillin resistance in Streptococcus 
pneumoniae reveals a novel role for PstS, a subunit of the phosphate ABC transporter. 
Mol Microbiol 58(5):1430-1440. 
231. Sun X, et al. (2011) Proteomic analysis of membrane proteins from Streptococcus 
pneumoniae with multiple separation methods plus high accuracy mass spectrometry. 
Omics : a journal of integrative biology 15(10):683-694. 
232. Morsczeck C, et al. (2008) Streptococcus pneumoniae: proteomics of surface proteins 
for vaccine development. Clin Microbiol Infect 14(1):74-81. 
233. Rabilloud T (2009) Membrane proteins and proteomics: love is possible, but so 
difficult. Electrophoresis 30 Suppl 1:S174-180. 
234. Rabilloud T, Chevallet M, Luche S, & Lelong C (2010) Two-dimensional gel 
electrophoresis in proteomics: Past, present and future. J Proteomics 73(11):2064-
2077. 
Ph.D. Thesis – Alfonso Olaya Abril  Introduction 
80 
235. Olaya-Abril A, Jimenez-Munguia I, Gomez-Gascon L, & Rodriguez-Ortega MJ (2013) 
Surfomics: Shaving live organisms for a fast proteomic identification of surface 
proteins. J Proteomics. 
236. Rodriguez-Ortega MJ, et al. (2006) Characterization and identification of vaccine 
candidate proteins through analysis of the group A Streptococcus surface proteome. 
Nat Biotechnol 24(2):191-197. 
237. Claverys JP & Havarstein LS (2007) Cannibalism and fratricide: mechanisms and raisons 
d'etre. Nat Rev Microbiol 5(3):219-229. 
238. Claverys JP, Martin B, & Havarstein LS (2007) Competence-induced fratricide in 
streptococci. Mol Microbiol 64(6):1423-1433. 
239. Olaya-Abril A, Gomez-Gascon L, Jimenez-Munguia I, Obando I, & Rodriguez-Ortega MJ 
(2012) Another turn of the screw in shaving Gram-positive bacteria: Optimization of 
proteomics surface protein identification in Streptococcus pneumoniae. J Proteomics 
75(12):3733-3746. 
240. Olaya-Abril A, Jimenez-Munguia I, Gomez-Gascon L, Obando I, & Rodriguez-Ortega MJ 
(2013) Identification of potential new protein vaccine candidates through pan-
surfomic analysis of pneumococcal clinical isolates from adults. PLoS One 8(7):e70365. 
241. Vernet G, et al. (2011) Laboratory-based diagnosis of pneumococcal pneumonia: state 
of the art and unmet needs. Clin Microbiol Infect 17 Suppl 3:1-13. 
242. Ferrari G, et al. (2006) Outer membrane vesicles from group B Neisseria meningitidis 
delta gna33 mutant: proteomic and immunological comparison with detergent-derived 
outer membrane vesicles. Proteomics 6(6):1856-1866. 
243. McBroom AJ & Kuehn MJ (2007) Release of outer membrane vesicles by Gram-
negative bacteria is a novel envelope stress response. Mol Microbiol 63(2):545-558. 
244. Mug-Opstelten D & Witholt B (1978) Preferential release of new outer membrane 
fragments by exponentially growing Escherichia coli. Biochim Biophys Acta 508(2):287-
295. 
245. Zhou M, Boekhorst J, Francke C, & Siezen RJ (2008) LocateP: genome-scale subcellular-
location predictor for bacterial proteins. BMC Bioinformatics 9:173. 
246. Rivera J, et al. (2010) Bacillus anthracis produces membrane-derived vesicles 
containing biologically active toxins. Proc Natl Acad Sci U S A 107(44):19002-19007. 
247. Gurung M, et al. (2011) Staphylococcus aureus produces membrane-derived vesicles 
that induce host cell death. PLoS One 6(11):e27958. 
248. Thay B, Wai SN, & Oscarsson J (2013) Staphylococcus aureus alpha-toxin-dependent 
induction of host cell death by membrane-derived vesicles. PLoS One 8(1):e54661. 
249. Prados-Rosales R, et al. (2011) Mycobacteria release active membrane vesicles that 
modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest 
121(4):1471-1483. 
250. Sanz JC, et al. (2011) Multidrug-resistant pneumococci (serotype 8) causing invasive 
disease in HIV+ patients. Clin Microbiol Infect 17(7):1094-1098. 


83
PH.D. THESIS – ALFONSO OLAYA ABRIL - 2014 
Objectives 

Ph.D. Thesis – Alfonso Olaya Abril Objectives
85
The overall objective of the thesis was the identification of proteins and structures derived 
from the surface of Streptococcus pneumoniae for vaccine and diagnostic purposes. For this 
purpose, the following specific objectives were considered: 
1. Optimization of proteomics surface protein identification in Streptococcus 
pneumoniae.
2. Identification of potential new protein vaccine candidates through pan-
surfomic analysis of pneumococcal clinical isolates from adults and children.
3. Serological profile analysis and development of a fast, sensitive and robust 
diagnostic biomarker tool against pneumococcal infection.
4. Identification and characterization of membrane-derived vesicles in 
Streptococcus pneumoniae.
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Bacterial surface proteins are of outmost importance as they play critical roles in the interaction 
between cells and their environment. In addition, they can be targets of either vaccines or 
antibodies. Proteomic analysis through “shaving” live cells with proteases has become a 
successful approach for a fast and reliable identification of surface proteins. However, this 
protocol has not been able to reach the goal of excluding cytoplasmic contamination, as cell 
lysis is an inherent process during culture and experimental manipulation. In this work, we 
carried out the optimization of the “shaving” strategy for the Gram-positive human pathogen 
Streptococcus pneumoniae, a bacterium highly susceptible to autolysis, and set up the conditions 
for maximizing the identification of surface proteins containing sorting or exporting signals, 
and for minimizing cytoplasmic contamination. We also demonstrate that cell lysis is an 
inherent process during culture and experimental manipulation, and that a low level of lysis is 
enough to contaminate a “surfome” preparation with peptides derived from cytoplasmic 
proteins. When the optimized conditions were applied to several clinical isolates, we found the 
majority of the proteins described to induce protection against pneumococcal infection. In 
addition, we found other proteins whose protection capacity has not been yet tested. In 
addition, we show the utility of this approach for providing antigens that can be used in 
serological tests for the diagnosis of pneumococcal disease. 
© 2012 Elsevier B.V. All rights reserved. 
1. Introduction 
Bacterial surface proteins play a critical role in the interaction 
between cells and their environment [1,2]. They constitute a 
diverse group of molecules with important functions, are 
potential drug targets and candidates for vaccines, as they are 
molecules with the highest probability to be recognized by the 
elements of the immune system [3,4]. The availability of 
sequenced and annotated genomes of many pathogenic micro- 
organisms makes the selection of surface-exposed proteins 
possible through bioinformatic algorithms. However, around 
one third of the genes of any genome code for surface proteins 
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1874-3919/$ – see front matter © 2012 Elsevier B.V. All rights reserved. 
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(comprising secreted proteins, membrane proteins, lipoproteins 
and covalently cell wall-attached proteins, in the case of bacteria) 
[5], so that the number of potential candidates is huge. In addi- 
tion, in silico prediction algorithms do not inform about whether, 
when and to what extent a protein is expressed. Therefore, 
experimental strategies are required to identify which proteins 
are expressed on the cell surface and what are their domains 
exposed and available to the immune system (e.g. antibodies) 
[6]. 
Proteomics offers excellent technological platforms and 
strategies for the identification of large numbers of proteins in 
biological samples. Nevertheless, the proteomic characteriza- 
tion of bacterial surface proteins (including those anchored to 
the plasma membrane) can be a challenging task because of the 
difficulty in obtaining samples with almost no contamination of 
proteins from other compartments. Moreover, when a “first- 
generation proteomics” strategy is used (i.e. separation of 
proteins by 2-DE and identification by MALDI-TOF MS), mem- 
brane proteins, whose nature are normally hydrophobic, are 
underrepresented as they usually precipitate under standard 
IEF conditions [7,8] and because of their low copy number. In 
addition, topology characterization of surface-exposed epitopes 
becomes impossible. 
Alternative protocols based on “second-generation proteo- 
mics” allow the identification of a higher proportion this type of 
proteins, compared to gel-based approaches. A successful 
strategy for a fast and reliable identification of microbial surface 
proteins consists of “shaving” intact living cells with proteases, 
after which the generated peptides (the “surfome” or “surfa- 
ceome”) are recovered and analyzed by LC/MS/MS. Although 
this approach can be applied theoretically to any kind of 
biological systems, the highest success has been reached in 
bacteria, and particularly in Gram-positive organisms, as the 
rigid cell wall makes them more resistant to osmotic lysis than 
Gram-negative species. This approach was first optimized and 
applied to the pathogen Streptococcus pyogenes [9], showing also 
the usefulness for the discovery of new protective antigens. 
However, when applied to other bacteria, this protocol has not 
been able to reach the goal of eliminating cytoplasmic contam- 
ination [10–13]. Although it has been proposed that some 
cytoplasmic proteins might be present on the bacterial surface 
as possessing moonlighting functions [14], the most plausible 
explanation is that their presence derives mainly from cell lysis— 
even when this is a small percentage within the total cell 
population. Lysis during culture and/or experimental phase to 
get the “surfome” fraction appears to be inherent in these 
biological systems. Some species are especially susceptible to 
autolysis, as is the case of Streptococcus pneumoniae—also known 
as pneumococcus. This bacterium contains dedicated systems 
to kill and  lyse a subset of its population  during infection, 
which increases adhesion and virulence of surviving cells [15,16]. 
In this work, we have optimized the “shaving” of pneumococcal 
cells and demonstrate that cell lysis is both intrinsic and due 
to experimental manipulation. Also, we show that the 
“pansurfome” of a collection of clinical isolates can provide, in 
addition to vaccine candidates, antigens that could be used to 
develop serological tests to improve etiological diagnostic yield of 
pneumococcal pneumonia in clinical ground and epidemiologi- 
cal studies and to evaluate natural immunity to pneumococcal 
carriage in children [17]. 
2. Materials and methods 
2.1. Bacterial strains and growth 
S. pneumoniae strain R6 was grown until mid-exponential 
phase at 37 °C in Todd-Hewitt broth (THB) or in a chemically-
defined medium (CDM) as described [18], supplemented 
with either 5 μ g/ml choline (CDM + C) or 20 μ g/ml 
ethanol-amine (CDM + EA) as source of aminoalcohol [19]. 
Clinical isolates were collected from  Spanish  human 
patients, either children (strain 57H, serotype 18C; strain 
6H, sero- type 23F) or adults (strain 5337, serotype 7F; 
strain 5284, serotype 9V), and grown in CDM + EA at 37 
°C until mid-exponential phase. 
2.2. Human sera 
All human sera were obtained from infant patients admitted 
to Hospital Universitario Infantil Virgen del Rocío (HUIVR) at 
Seville (Spain). Sera were drawn either from patients with a 
diagnosis of pneumococcal infection, determined by isolation 
of the microorganism from a sterile site (blood or pleural fluid) 
according to standardized protocols or from control children 
with non-pneumococcal infectious diseases. All sera were 
obtained within ten days of hospital admission. Written 
informed consent was obtained from parents or legal guardians 
of participating children and the Hospital Ethic Committee 
approved the study. We tested three sera from pneumococcus- 
infected patients, corresponding to two cases of empyema and 
one of pneumonia in children of 59, 62 and 39 months old 
respectively, and two control sera, corresponding to infection by 
H1N1 influenza virus and Staphylococcus aureus in children of 149 
and 72 months old, respectively. 
2.3. Surface tryptic digestion of live cells 
Bacteria from 100 ml of culture were harvested by centrifugation 
at 3500 ×g for 10 min at 4 °C, and washed twice with PBS. Cells 
were resuspended in one-hundredth volume of PBS containing 
30%  sucrose  (pH  7.4)  as  trypsin  incubation  buffer.  Tryptic 
digestions were  carried out  with 5 μ g  trypsin (Promega) for 
different times at 37 °C. The digestion mixtures were centrifuged 
at  3500 ×g  for  10 min  at  4 °C,  and  the  supernatants  (the 
“surfomes” containing the peptides) were filtered using 0.22-μ m 
pore-size filters (Milipore). Surfomes were re-digested with 2 μ g 
trypsin overnight at 37 °C with top–down agitation. Before 
analysis, salts were removed using Oasis HLB extraction 
cartridges (Waters). Peptides were eluted with increasing con- 
centrations of acetonitrile/0.1% formic acid, according to manu- 
facturer's instructions. Peptide fractions were concentrated with 
a vacuum concentrator (Eppendorf), and kept at −20 °C until 
further analysis. 
2.4. Protein separation by SDS-PAGE 
30-μ l aliquots of tryptic digestion mixtures were separated 
by 12% SDS-PAGE and stained with Silver Stain Plus Kit 
(BioRad) according to the manufacturer's instructions. Gels 
were scanned in a GS-800 densitometer (BioRad). 
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2.5. Dot blot analysis 
Antibody-based detection of proteins was performed by dot blot. 
Briefly, 1 μ g of pneumococcus recombinant proteins Spr2021, 
Spr1707, Spr1382, Spr1918, Spr0075, Spr0247 (produced as GST-tag 
recombinant fragments using the pSpark® vector, Canvax 
Biotech, Córdoba, Spain, and expressed in Escherichia coli BL21. 
See Supplementary Dataset ( SDS) 1 for further details), 1 μ g of Lys9 
(His- tag recombinant protein of S. cerevisiae expressed in E. coli 
BL21 with pET/100 TOPO cloning system, Invitrogen, according 
to the manufacturer's instructions) and 15 μ g of total protein 
extract of pneumococcus were transferred to a nitrocellulose 
membrane and air-dried. Non-specific sites were blocked by 
incubation with 5% non-fat milk in T-TBS for 45 min. After 
two washes with T-TBS, a second 1 h incubation of the 
membrane with patient 
sera, diluted 1:100 in 3% non-fat milk in T-TBS, was carried out. As 
secondary antibodies we used rabbit anti-human IgG or rabbit 
anti-human IgM conjugated to horseradish peroxidase (Sigma), 
diluted 1:10,000 or 1:5000 in TBS, respectively. Following 1 h 
incubation, the membrane was washed three times with TBS and 
developed with ECL Plus Western Blotting Detection System (GE 
Healthcare) according to the manufacturer's instructions. 
2.6. LC/MS/MS analysis 
All analyses were performed with a Surveyor HPLC System in 
tandem with an LTQ-Orbitrap mass spectrometer (Thermo 
Fisher Scientific, San Jose, USA) equipped with nanoelectros- 
pray ionization interface (nESI). The separation column was 
150 mm × 0.150 mm ProteoPep2 C18 (New Objective, USA) at a 
postsplit flow rate of 1 μ l/min. For trapping of the digest 
a 5 mm × 0.3 mm precolumn Zorbax 300 SB-C18 (Agilent 
Tech- nologies, Germany) was used. One fourth of the total 
sample volume, corresponding to 5 μ l, was trapped at a 
flow rate of 10 μ l/min for 10 min and 5% acetonitrile/0.1% 
formic acid. After that, the trapping column was switched 
on-line with the separation column and the gradient was 
started. Peptides were eluted with a 60-min gradient of 5–40% 
of acetonitrile/0.1% formic acid solution at a 250 nl/min flow 
rate. All separations were performed using a gradient of 5–
40% solvent B for 60 min. MS data (Full Scan) were acquired in 
the positive ion mode over the 400–1500 m/z range. MS/MS 
data were acquired in depen- dent scan mode, selecting 
automatically the five most intense ions for fragmentation, 
with dynamic exclusion set to on. In all cases, a nESI spray 
voltage of 1.9 kV was used. 
2.7. Database searching and protein identification 
Tandem mass spectra were extracted using Thermo Proteo- 
meDiscoverer 1.0 (Thermo Fisher Scientific). Charge state 
deconvolution and deisotoping were not performed. All MS/ 
MS samples were analyzed using Sequest (Thermo Fisher 
Scientific, version v.27), applying the following search param- 
eters: peptide tolerance, 10 ppm; tolerance for fragment ions, 
0.8 Da; b- and y-ion series; oxidation of methionine and 
deamidation of asparagine and glutamine were considered 
as variable modifications; maximum trypsin missed cleavage 
sites: 3. The raw data were searched against a non-redundant 
local database containing the concatenated forward and 
reverse sequence proteins derived from the complete genome 
sequence of S. pneumoniae strain R6 (RefSeq NC_003098.1 
downloaded from ftp://ftp.ncbi.nih.gov/genomes/Bacteria/ 
Streptococcus_pneumoniae_R6, NCBInr version 20090707). 
Peptide identifications were accepted if they exceeded the 
filter parameter Xcorr score vs charge state with SequestNode 
Probability Score (+1 = 1.5, +2 = 2.0, +3 = 2.25, +4 = 2.5). With these 
search and filter parameters, no false-positive hits were obtained. 
For proteins identified from only one peptide, fragmentations 
were checked manually. 
2.8. Bioinformatic analysis of protein sequences 
Computational predictions of subcellular localization were 
carried out using the web-based algorithm LocateP (http:// 
www.cmbi.ru.nl/locatep-db/cgi-bin/locatepdb.py) [20]. Feature- 
based algorithms were also used to contrast LocateP predictions: 
TMHMM 2.0 (http://www.cbs.dtu.dk/services/TMHMM-2.0) [21] 
for searching transmembrane helices; SignalP 3.0 (http://www. 
cbs.dtu.dk/services/SignalP) [22] for type-I signal peptides: those 
proteins containing only a cleavable type-I signal peptide as fea- 
ured sequence were classed as secreted; LipoP (http://www.cbs. 
dtu.dk/services/LipoP) [23] for identifying type-II signal peptides, 
which are characteristic of lipoproteins. Topological represen- 
tations of membrane proteins were performed with the web- 
based TOPO2 software (http://www.sacs.ucsf.edu/TOPO2/). 
2.9. Flow cytometry analysis 
For analysis of bacterial viability, culture aliquots (50 μ l) 
were washed once with 0.85% NaCl stained with 
LIVE/DEAD Bac- Light Bacterial Viability kit (Invitrogen) 
containing SYTO-9 and propidium iodide dyes, according 
to the manufacturer's instructions. Bacteria were then 
washed once and resus- pended with 0.85% NaCl until 
analysis in a FACSCalibur flow cytometer (Becton 
Dickinson). Data were analyzed with FlowJo software (Tree 
Star, Inc., USA). 
2.10. Fluorescence microscopy 
Aliquots of bacteria (50 l) stained with LIVE/DEAD BacLight 
Bacterial Viability kit (see above) were visualized in a fluores- 
cence microscope fitted with a Plan-Fluor ×60 oil immersion 
objective. Specifically, cells were epi-illuminated at 480 and 
540 nm to assess cell viability in each chosen field. It took 10 
fields per condition and display. Image acquisition was con- 
trolled using METAFLUOR PC software (Universal Imaging Corp., 
West Chester, PA, USA) and fluorescence emissions were 
captured using a digital camera running in 1-bit mode. Before 
fluorescence monitoring, a bright-field image of the regions of 
interest was captured for reference purposes. Images were 
analyzed with Image. 
3. Results 
3.1. Optimization of “shaving” protocol 
3.1.1. Effect of culture medium 
In a first attempt to carry out the “shaving” protocol in 
pneumococcus, we applied the widely used conditions of mild 
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trypsin digestion (bacteria cultured in complex liquid growth 
medium; isotonic buffer consisting of PBS/30% sucrose, pH 7.4; 
5 μ g trypsin/cells coming from 100 ml culture; 30 min at 37 
°C) [24,25]. All the optimization work was done with S. 
pneumoniae R6, a reference strain whose genome is fully 
sequenced and annotated. Bacteria were harvested at mid-
exponential phase, in order to minimize cell lysis. That 
condition corresponded to an OD600 of 0.25 (Fig. 1A). The result 
of the “surfome” analysis by LC/MS/MS is shown in Fig. 1B: out 
of a total of 253 identified proteins, the vast majority, 209, were 
predicted as cytoplasmic (83%). 
Then, we cultured pneumococcus in a chemically-defined 
medium (CDM), in which this bacterium has been described to 
grow with a lower lysis rate than in enriched media [26]. We 
used two different CDM formulations: CDM supplemented with 
choline (CDM + C) and CDM with ethanolamine (CDM + EA). In 
these two media, growth rates were lower than in THB (Fig. 
1A). The mid-exponential phases in the different two CDM 
media corresponded to OD600 of 0.6 and 0.5 respectively. 
Bacteria were harvested at approximately OD600 = 0.25 (to have 
an equivalent number of cells as in THB), to carry out the 
identification of generated peptides after trypsin digestion. As 
shown in Fig. 1B, cytoplasmic contamination was found, with 
the percentages of cytoplasmic proteins 81% and 61%, 
corresponding to CDM + C and CDM + EA respectively. These 
differences were even higher when identified peptides were 
considered, with a proportion of those corresponding to 
cytoplasmic proteins of 85%, 75% and 57% (THB, CDM + C and 
CDM + EA, respectively;  Table S1). The  absolute  numbers of 
identified surface proteins in both CDM- based cultures were 
14 and  32, respectively (Table S1  and SDS2). Therefore, CDM 
+ EA was the culture medium chosen for further “shaving” 
procedure, as it was that in which surface protein identification 
was maximized. 
To understand cell viability before and after trypsin digestion, 
we performed both flow cytometry and fluorescence microscopy 
analyses. In the three culture media tested, survival rates varied 
between 98.2% and 99.6% (Fig. 1C). After centrifuging bacteria 
and resuspending them in trypsin incubation buffer (time 0), 
survival rates did not change compared to those measured in 
the cultures (ranging between 98% and 99.4%). However, when 
cells were trypsin-digested, a decrease in survival rates was 
observed in THB (around 4%), while in the CDM-based media 
it was around 1%. 
3.1.2. Effect of trypsin incubation time 
After choosing CDM + EA as the culture medium for surface 
protein identification in pneumococcus using the “shaving” 
approach, we studied the effect of trypsin digestion time. 
Independent cultures and trypsin digestion time conditions 
were performed to evaluate first the surface protein 
identification in a time-course experiment (Table 1 and SDS3). 
For each time point, we carried out its corresponding control. 
Control trypsin digestion at time 0 resulted in 11 identified 
proteins, of which 10 were cytoplasmic. After 5 min trypsin 
treatment, 11 surface proteins were identified, corre- sponding 
to 33% of identified proteins. Digestion at 15 min did not result in
Fig. 1 – Optimization of culture medium conditions for “shaving” pneumococcal cells. A) Growth curves of pneumococcus in THB (♦), CDM 
+ C (● ) and CDM + EA (▲ ). B) Proteins identified in the three tested media: predicted surface proteins (light gray) and predicted 
cytoplasmic proteins (dark gray). C) Cell viability in the corresponding culture medium (“Culture”), immediately after resuspending 
in trypsin incubation buffer (“0 min”) and after 30 min trypsin digestion (“30 min”). Pictures show fluorescence microscopy images 
of samples stained to distinguish between live (green) and dead cells (red). Numbers below pictures show values (average ± SD, n = 
3) of viability measurement by flow cytometry. 
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Table 1 – Effect of trypsin incubation time on protein identification after “shaving” pneumococcal cells cultured in CDM + EA 
followed by LC/MS/MS analysis.
Trypsin digestion time (min)
Protein category a 0 5 − b 5+ b 15 − 15 + 30 − 30 + 60 − 60 +
Lipoprotein 1 (9) c 0 (0) 1 (3) 0 (0) 0 (0) 1 (5.9) 4 (4.7) 1 (1.2) 4 (3.9) 
Cell wall 0 (0) 1 (2.9) 0 (0) 1 (4) 2 (5) 0 (0) 6 (7) 0 (0) 3 (2.8) 
Secretory 0 (0) 1 (2.9) 0 (0) 0 (0) 2 (5) 0 (0) 4 (4.7) 0 (0) 2 (2) 
Membrane (1 TMD) 0 (0) 2 (5.7) 5 (15.2) 3 (12) 3 (7.5) 0 (0) 9 (10.4) 0 (0) 3 (2.8) 
Membrane (> 1 TMD) 0 (0) 1 (2.9) 5 (15.2) 3 (12) 1 (2.5) 0 (0) 7 (8.2) 4 (4.8) 11 (10.8) 
Surface proteins 1 (9) 5 (14.3) 11 (33.3) 7 (28) 8 (20) 1 (5.9) 30 (35) 5 (6) 23 (22.5) 
Cytoplasmic proteins 10 (91) 30 (85.7) 22 (66.7) 18 (72) 32 (80) 16 (94.1) 56 (65) 79 (94) 79 (77.5) 
Total 11 (100) 35 (100) 33 (100) 25 (100) 40 (100) 17 (100) 86 (100) 84 (100) 102 (100)
a  Protein categories were established according to LocateP subcellular predictions: lipoproteins were those predicted as lipid-anchored 
proteins; cell wall proteins, as those having an LPXTG motif; secretory proteins, as those possessing an SP1-type signal peptide; membrane 
proteins with one transmembrane domain (TMD), as those possessing either a C- or an N-terminally anchored transmembrane region; 
membrane proteins with more than one transmembrane domain, those predicted as multi-transmembrane proteins; “surface proteins” means 
the sum of the five previous categories; and cytoplasmic proteins, those without any exporting or sorting signal, and predicted as intracellular 
proteins. 
b   “−” indicates no enzyme in the incubation buffer (control), and further digestion of the supernatant after removing cells; “+” indicates trypsin 
digestion. 
c   In brackets are the percentage for every protein category figure referred to its total.
an increase in identified surface proteins (only 8, representing 
20% of total proteins found at this time, 40). However, after 30 
min digestion, the absolute number of identified surface 
proteins augmented to 30, which represented 35% of total 
found proteins at this time, 86. Finally, bacterial exposure to 
trypsin during 60 min resulted in an increase in cytoplasmic 
proteins that were identified (79, representing a 78% of total 
found proteins), with a decrease in  identified surface proteins 
compared to 30 min “shaving”. An increase in cytoplasmic 
protein identification was observed in the controls as the 
incubation time in the buffer augmented, thus indicating that 
cells lost stability spontaneously. Again, when identified 
peptides were considered, the lowest percentage of those 
corresponding to cytoplasmic proteins corresponded to 30 min 
digestion (50%; Table S2). To obtain mathematically the time in 
which the tryptic digestion is optimal (in terms of minimal 
cytoplasmic contamination and maximal surface protein 
identification), we represented the percentages of found surface 
proteins vs time. The curve was adjusted to a quadratic 
equation, and the maximum was obtained at 33.6 min (Fig. S1). 
Survival of cells during the time-course trypsin digestion 
was monitored by flow cytometry analysis, to evaluate the rate 
of cells that die either by trypsin treatment or by spontaneous 
autolysis in the incubation buffer (Fig. 2). At time 0, 99.7% of 
cells remaining after centrifuging and washing from the 
CDM + EA culture were alive. After 5 min, no significant 
variation of live cells was observed, either with trypsin or its 
respective non- enzyme control. At times 15 and 30 min, a 
very slight decrease of survival was observed when compared 
to time 0, either when bacteria were trypsin-treated (98.6% and 
98.4% respectively) or in their respective non-tryptic controls 
(99.2% of live cells at 15 min and 98.6% at 30 min), thus 
indicating that cells did not lyse significantly at these short 
times either by the effect of trypsin digestion or by losing 
stability in the incubation buffer. However, when we 
incubated bacteria  for  a  longer  time (60 min), the rate of 
cell death significantly increased, both in 
the case of trypsin digestion (82.3% of live cells) and its non- 
enzyme control (88.2%), which indicates that loss of viability 
of bacteria has at least a double component: time in which 
cells are left in the buffer and, to a lesser extent, protease 
treatment. 
In addition, we monitored the efficiency of trypsin digestion 
over time, in order to determine whether the conditions of the 
study were enough to remove the exposed domains of surface 
proteins. Equal-volume aliquots of time-course trypsin- 
generated surfomes, together with their corresponding controls, 
were separated by SDS-PAGE (Fig. 3). Protein bands were 
observed in all the samples, with very faint intensities at time 0 
and at the negative controls (no “shaved” bacteria) at times 5 
and 15 min. The band pattern obtained was qualitatively 
different when samples from “shaved” bacteria were compared 
to their controls, thus indicating that trypsin removed large 
pieces of surface-associated proteins. However, we cannot 
exclude that some of the bands could come from cytoplasmic 
proteins that are present in the samples, released during 
manipulation and/or incubation. At 30 and 60 min, more bands 
and with greater intensities were observed than at shorter times 
in the negative controls, thus being  in agreement with the 
observation of higher cell death rates as the incubation time 
increases (Fig. 2). Interestingly, still large pieces of protein were 
obtained at these longer times, indicating that the “shaving” 
approach is a compromise between the efficiency of protease- 
generated peptides and avoidance of cell lysis that might 
contaminate a “surfome” analysis with cytoplasmic proteins. 
An important proportion of identified surface proteins 
corresponded to transmembrane proteins, i.e., proteins with at 
least one transmembrane domain. For most of them, peptides 
found by LC/MS/MS analysis corresponded to domains 
theoretically localized on the extracellular side (Fig.4). 
However, a small fraction of proteins, 2 out of 11, were not in 
agreement for the expected localization of identified peptides, 
as we found these in regions that, according to transmembrane 
prediction algorithms (TMHMM),  should be on the cytoplasmic 
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Fig. 2 – Effect of trypsin incubation time on cell survival. Representative flow cytometry dot plots showing the gating for analysis of dead 
(in every chart, left polygon) and live cells (right polygon). “0” chart indicates control at time 0 trypsin digestion. Non-enzyme controls at 
different minutes of trypsin treatment are in the above row (5 −, 15 −, 30 −, 60 −) and digested samples are shown in the row below (5+, 15
+, 30+, 60 +). Numbers below each chart indicate values (average ± SD, n = 3 ) for live cells. 
side of the cell. 
In total, we identified 49 surface proteins in the strain R6 by 
the “shaving” approach, after integrating analyses of both 
culture medium and trypsin time optimizations, carried out 
under optimal conditions: 30 min trypsin digestion after 
culturing bacteria in CDM + EA (Table 3). Similar to that 
obtained in other organisms [9–11], the identified proteins 
represented only a fraction of the total of predicted proteins 
from the genome for each of the different subcellular 
localizations (Table 2), the highest percentages being for cell-
wall proteins and lipoproteins (as they are the most exposed 
and expressed ones on the surface), and the lowest one for 
transmembrane proteins, as they are generally less expressed  
and are less accessible if they do not have enough  
Fig. 1.3 – Efficiency of trypsin removal of surface-exposed 
protein domains. Silver-stained SDS-PAGE of “surfome” 
fractions at different digestion times, in minutes (“−” indicates 
no enzyme; “+” indicates trypsin treatment). 
large domains to reach the bacterial surface. 
3.2. Application of optimized conditions to a collection of 
clinical isolates 
To explore the validity of the “shaving” approach in pneumo- 
coccus in field clinical isolates causing virulent invasive 
diseases, we carried out the “surfome” analysis of other four 
strains: two isolated from children and two isolated from 
adults. A total of 114 surface proteins were identified in the set 
of the four clinical isolates plus the reference strain R6 (Table 3 
and SDS4). Of these, 12 (10.5%) were present in the 5 analyzed 
strains; two others were present in the four clinical isolates, but 
not in R6; and 20 (17.5%) proteins were identified in 3 out of 4 
clinical isolates. These numbers indicate that around 30% of the 
identified proteins were present in at least 60% of the five 
analyzed strains, or in at least 75% of the four clinical isolates. 
These proteins corresponded to 6 cell-wall anchored proteins, 10 
lipoproteins, 6 secreted proteins, 6 proteins with one TMD and 6 
multi-transmembrane proteins. The analysis included most of 
the proteins that so far have been demonstrated to induce 
protection against pneumococcal infection (Table S3). 
3.3. Utility of “shaving” approach for the discovery of 
diagnostic biomarkers in serological assays 
To evaluate the utility of this approach to provide candidate 
proteins for early detection of pneumococcal infection by 
serological tests, we selected six proteins among those most 
frequently found in the clinical isolates, and produced GST- 
fusion recombinant fragments. These proteins corresponded to 
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Fig. 4 – Topology representation of identified membrane proteins. LocateP-predicted membrane proteins were topologically 
represented according to TMHMM algorithm, with extracellular domains above the membrane (represented as an orange strip), and 
predicted cytoplasmic domains below the membrane. Peptides experimentally identified by LC/MS/MS analysis are highlighted in 
red. 
two cell-wall anchored proteins, three lipoproteins and one 
secreted protein. All the proteins were found in the four clinical 
isolates plus the strain R6, except lipoprotein Spr1918, which 
was not found in 1 out of 4 clinical isolates (strain 5337, serotype 
7F). We performed dot blots to detect antibodies against these 
proteins in sera from convalescent children that had been 
infected by pneumococcus (Fig. 5). As controls, we used two 
sera from two patients infected by S. aureus and influenza 
virus, respectively. We measured both IgM and IgG 
responses, as a means of detecting primary or secondary 
antibody response to pneumococcal infection. Positive IgG 
responses were obtained for all the proteins in the three patient 
sera (except for Spr1707 in serum 3). A positive response was 
also obtained for the 6 tested proteins in the control serum 4, 
and for two proteins (Spr0247 and Spr2021) in serum 5. As 
expected, weaker responses were obtained for primary IgM 
antibodies, with a positive reaction against protein Spr2021 in 
sera 1, 3 and 5 (one of the controls), and for Spr1382 in serum 3. 
In addition, we obtained positive reaction against whole cell 
extract in sera 1, 3 and, in a lower extent, control serum 5, 
thus indicating that sera contain IgM antibodies against 
pneumococcal antigens. These overall re- sults would 
indicate two main issues: i) a positive reaction can be obtained 
in patients due to colonization but without disease 
development; and ii) the utility of IgM detection will depend on 
taking sera in earlier phases of disease. 
4. Discussion 
Gel-free based proteomics is most widely used for the identifi- 
cation of membrane and surface-associated proteins of any 
biological system, as this approach overcomes the limitations of 
classical gel-based first generation proteomic strategies [27]. In 
Gram-positive bacteria, shaving surface-exposed proteins with 
Table  2 – Summary of identified surface proteins in Streptococcus pneumoniae R6 after optimization of the “shaving” protocol.
Protein category a # identified proteins # predicted proteins in Identified/predicted (%)
S. Pneumoniae R6 genome
Lipoprotein 8 39 20.5
Cell wall 8 11 72.7
Secretory 7 32 21.9
Membrane 14 107 13.1
(1 TMD)
Membrane 12 368 3.3
(> 1 TMD)
a  Protein categories were established according to LocateP subcellular predictions: lipoproteins were those predicted as lipid-anchored
proteins; cell wall proteins, as those having an LPXTG motif; secretory proteins, as those possessing an SP1-type signal peptide; membrane
proteins with one transmembrane domain (TMD), as those possessing either a C- or an N-terminally anchored transmembrane region;
membrane proteins with more than one transmembrane domain, those predicted as multi-transmembrane proteins; “surface proteins” means
the sum of the five previous categories; and cytoplasmic proteins, those without any exporting or sorting signal, and predicted as intracellular
proteins.
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proteases has been shown to be a valuable tool for identifying 
quickly a set of some tens of proteins (the “surfome”) whose 
most frequent application is the discovery of vaccine candidates 
[9,11,28,29] or virulence factors [30]. However, numerous studies 
have shown that cytoplasmic contamination, even at a relative- 
ly  low  degree,  is  unavoidable.  Although  some  cytoplasmic 
Table 3 – Surface proteins identified by “shaving” pneumococcal cells cultured in CDM + EA, followed by LC/MS/MS analysis, in 
four clinical isolates and in the reference strain R6.
Locus Function annotation Protein categorya R6 6H 57H 5284 5335
spr0008 hypothetical protein spr0008 Membrane (1 TMD) x
spr0012 cell division protein FtsH Membrane (> 1 TMD) x x x x
spr0044 competence factor transport protein ComB Membrane (1 TMD) x
spr0057 beta-N-acetylhexosaminidase Secretory x x x x
spr0071 Trk transporter NAD+ binding protein - K+ transport Membrane (1 TMD) x
spr0075b cell wall surface anchor family protein Cell wall x x x x x
spr0086 hypothetical protein spr0086 Membrane (> 1 TMD) x x x x
spr0087 hypothetical protein spr0087 Membrane (1 TMD) x x
spr0096 LysM domain protein Secretory x
spr0108 hypothetical protein spr0108 Secretory x x
spr0113 hypothetical protein spr0113 Membrane (> 1 TMD) x
spr0121 surface protein pspA precursor Membrane (1 TMD) x x x
spr0136 glycosyl transferase family protein Membrane (1 TMD) x
spr0146 ABC transporter substrate-binding protein - amino acid transport Lipoprotein x x x
spr0174 hypothetical protein spr0174 Lipoprotein x
spr0242 determinant for enhanced expression of pheromone Membrane (> 1 TMD) x
spr0247 alkaline amylopullulanase Cell wall x x x x x
spr0259 phosphotransferase system, m-annose specific EIID Membrane (> 1 TMD) x
spr0286 hyaluronate lyase precursor (hyaluronidase/hyase) Cell wall x x
spr0304 penicillin-binding protein 2X Membrane (1 TMD) x x x
spr0327 ABC transporter substrate-binding protein - oligopeptide transport Lipoprotein x x x
spr0328 cell wall surface anchor family protein Cell wall x x x x
spr0329 penicillin-binding protein 1A Membrane (1 TMD) x x
spr0334 hypothetical protein spr0334 Membrane (1 TMD) x x x x x
spr0337 cholin-ebinding protein F Membrane (1 TMD) x
spr0440 endo-beta-N-acetylglucosaminidase, putative Cellwall x x x
spr0467 hypothetical protein spr0467 Membrane (1 TMD) x
spr0468 hypothetical protein spr0468 Membrane (> 1 TMD) x
spr0483 hypothetical protein spr0483 Membrane (> 1 TMD) x
spr0516 polynucleotide phosphorylase/polyadenylase Membrane (1 TMD) x x
spr0526 peptide ABC transporter permease Membrane (> 1 TMD) x
spr0554 hypothetical protein spr0554 Lipoprotein x
spr0561 cell wall-associated serine proteinase precursor PrtA Cell wall x x x x x
spr0565 beta-galactosidase precursor Cell wall x x x x
spr0569 hypothetical protein spr0569 Membrane (1 TMD) x x
spr0581 Zinc metalloprotease Membrane (> 1 TMD) x x x x x
spr0583 pneumococcal surface protein, putative Lipoprotein x x
spr0641 P-type ATPase-copper transporter Membrane (> 1 TMD) x
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Table 3 (continued)
Locus Function annotation Protein categorya R6 6H 57H 5284 5335
spr0667 cell division ABC transporter, permease protein FtsX Membran(e> 1 TMD) x
spr0668 PTS system, IIABC components Membrane (> 1 TMD) x x
spr0679 peptidyl-prolyl cis-trans isomerase, cyclophilin-type Lipoprotein x x
spr0693 hypothetical protein spr0693 Membrane (1 TMD) x x x x
spr0716 septation ring formation regulator EzrA Membrane (1 TMD) x
spr0698 hypothetical protein spr0698 Membrane (> 1 TMD) x
spr0747 hypothetical protein spr0747 Lipoprotein x x
spr0760 hypothetical protein spr0760 Membrane (> T1MD) x
spr0770 hypothetical protein spr0770 Membrane (> 1 TMD) x
spr0776 D-alanyl-D-alanine carboxypeptidase Secretory x
spr0780 PTS system, fructose specific IIABC components Membrane (> 1 TMD) x
spr0781 SpoE family protein Membrane (> 1 TMD) x
spr0794 x-proly-ldipeptidyl aminopeptidase Membrane (1 TMD) x
spr0799 hypothetical protein spr0799 Lipoprotein x x
spr0813 ABC transporter membrane-spanning permease - unknown substrate Membrane (> 1 TMD) x
spr0867 endo-beta-N-acetylglucosaminidase Secretory x
spr0884 foldase protein PrsA Lipoprotein x x x x
spr0901 hypothetical protein spr0901 Membrane (> 1 TMD) x
spr0906 adhesion lipoprotein Lipoprotein x x x
spr0907 pneumococcal histidine triad protein D precursor Membrane (1 TMD) x x x x
spr0908 pneumococcal histidine triad protein E precursor Secretory x x x x
spr0931 hypothetical protein spr0931 Secretory x x x x x
spr0934 iron-compound ABC transporter, iron compound-binding protein Lipoprotein x x x
spr1042 immunoglobulin A1 protease Membrane (> 1 TMD) x x x x x
spr1060 histidine motif-containing protein Membrane (1 TMD) x x x
spr1061 pneumococcal histidine triad protein A precursor Lipoprotein x x x
spr1098 sortase Membrane (1 TMD) x x
spr1106 sensory box sensor histidine kinase Membrane (1 TMD) x
spr1120 amino acid ABC transporter permease/amino acid-binding protein Membrane (> 1 TMD) x x x x
spr1178 hypothetical protein spr1178 Secretory x
spr1221 hypothetical protein spr1221 Membrane (> 1 TMD) x x x
spr1226 hypothetical protein spr1226 Membrane (1 TMD) x
spr1251 amino acid ABC transporter amino acid-binding protein Lipoprotein x x x x
spr1269 prolipoprotein diacylglyceryl transferase Membrane (> 1 TMD) x
spr1364 F0F1 ATP synthase subunit B Membrane (1 TMD) x
spr1370 hypothetical protein spr1370 Membrane (1 TMD) x x x x x
spr1382 ABC transporter substrate-binding protein - oligopeptide transport Lipoprotein x x x x
spr1403 hypothetical protein spr1403 Membrane (> 1 TMD) x x x x x
spr1407 hypothetical protein spr1407 Membrane (> 1 TMD) x x
spr1418 hypothetical protein spr1418 Membrane (1 TMD) x
spr1431 1,4-beta-N-acetylmuramidase Secretory x x
spr1465 hypothetical protein spr1465 Membrane (> 1 TMD) x
(continued on next page)
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Table 3 (continued)
Locus Function annotation Protein categorya R6 6H 57H 5284 5335
spr1483 hypothetical protein spr1483 Membrane (> 1 TMD)   x x
spr1494 ABC transporter substrate-binding protein - manganese transport. Lipoprotein    x
spr1496 hypothetical protein spr1496 Membrane (> 1 TMD)     x
spr1525 sugar ABC transporter, permease protein Membrane (> 1 TMD)   x
spr1527 sugar ABC transporter, sugar-binding protein Lipoprotein x    x
spr1531 sialidase B precursor (neuraminidase B) Membrane (1 TMD)   x x
spr1536 sialidase A precursor (neuraminidase A) Cell wall  x x x
spr1561 hypothetical protein spr1561 Membrane (> 1 TMD)   x
spr1645 ABC transporter substrate-binding protein Lipoprotein   x
spr1652 cell wall surface anchor family protein Cell wall x  x
spr1656 ABC transporter permease/ATP-binding protein Membrane (> 1 TMD)    x
spr1677 ABC transporter membrane-spanning permease - choline transporter Membrane (> 1 TMD)  x
spr1706 oligopeptide ABC transporter, permease protein AmiC Membrane (> 1 TMD)  x
spr1707 ABC transporter substrate-binding protein - oligopeptide transport Lipoprotein x x x x x
spr1759 transcriptional regulator Secretory   x
spr1771 subtilisin-like serine protease Cell wall x    x
spr1772 hypothetical protein spr1772 Membrane (> 1 TMD)    x
spr1779 DNA-entry nuclease Membrane (1 TMD) x
spr1782 hypothetical protein spr1782 Membrane (1 TMD)   x
spr1806 cell wall surface anchor family protein Cell wall     x
spr1815 sensor histidine kinase, putative Membrane (> 1 TMD)     x
spr1823 penicillin-binding protein 2A Membrane (1 TMD) x  x
spr1862 competence protein CglC Membrane (1 TMD)     x
spr1875 hypothetical protein spr1875 Secretory x x x x
spr1903 UTP-glucose-1-phosphate uridylyltransferase Secretory x x  x
spr1918 maltose/maltodextrin ABC transporter, maltose/maltodextrin-binding prot ein   Lipoprotein x x x x
spr1945 choline binding protein PcpA Membrane (1 TMD)    x
spr1962 hypothetical protein spr1962 Membrane (1 TMD) x
spr1975 zinc ABC transporter zinc-binding protein Lipoprotein  x x
spr1995 choline binding protein A Secretory x  x x x
spr2010 DHH subfamily 1 protein Membrane (> 1 TMD)   x
spr2021 general stress protein GSP-781 Secretory x x x x x
spr2042 putative sensor histidine kinase ComD Membrane (> 1 TMD)     x
spr2045 serine protease Membrane (1 TMD) x x x x x
aProtein categories were established according to LocateP subcellular predictions: lipoproteins were those predicted as lipid-anchored proteins;
cell wall proteins, as those having an LPXTG motif; secretory proteins, as those possessing an SP1-type signal peptide; membrane proteins with
one transmembrane domain (TMD), as those possessing either a C- or an N-terminally anchored transmembrane region; membrane proteins
with more than one transmembrane domain, those predicted as multi-transmembrane proteins; “surface proteins” means the sum of the five
previous categories; and cytoplasmic proteins, those without any exporting or sorting signal, and predicted as intracellular proteins.
bHighlighted in gray are the proteins that were selected for dot blot analysis (see Fig. 5).
proteins can be naturally present on the bacterial surface 
because of moonlighting functions [31], extensive presence of 
cytoplasmic components indicates cell lysis occurrence. As a 
zero-rate lysis is impossible in most culture conditions, it must 
be assumed that this phenomenon, and therefore the derived 
cytoplasmic contamination of “surfome” fractions, is inherent to 
this approach. It has been estimated that less than 2% of cell 
death is enough to contaminate a “shaving” experiment with 
cytoplasmic proteins [24]. Although the “shaving” strategy has 
already been applied to a wide variety of microorganisms, it had 
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Fig. 5 – Dot blot analysis of surface proteins against human sera. Detection of both IgG (left) and IgM (right) was carried out. NC: 
negative control corresponding to His-tag recombinant protein Lys9 from Saccharomyces cerevisiae; TE: total protein extract from 
Streptococcus pneumoniae. 
not yet been used in the human pathogen S. pneumoniae. In this 
bacterium, proteomic identification of surface proteins had been 
carried out employing other strategies, such as mutanolysin- 
extracted cell wall proteins followed by gel separation and 
MALDI-TOF analysis, with a limited success [32]. Here we have 
optimized the experimental conditions for maximizing the 
identification of surface proteins (minimizing cytoplasmic pro- 
teins identification) in pneumococcus, which has a tendency to 
autolyse [33,34]. Release of intracellular virulence factors in order 
to favor the chances of infection of surviving cells has been 
proposed as an explanation for this phenomenon [15,16]. 
First, we checked for pneumococcus those conditions 
already established as standard in other Gram-positive micro- 
organisms: short protease digestion time in a PBS/sucrose- 
based buffer, in bacteria cultured in a complex medium until 
mid-exponential phase (in order to minimize cell death and to 
maximize surface protein expression) [35]. After obtaining a 
high percentage of identified cytoplasmic proteins and pep- 
tides, we decided to test chemically-defined media, in which 
pneumococcus has been described to grow with very minor 
lysis rates, especially when the naturally occurring aminoalco- 
hol choline is replaced by ethanolamine [26]. However, although 
the proportion of live cells was very high in the three tested 
media, the greatest decrease in survival after 30-min digestion 
was observed for THB-cultured bacteria, which could explain 
the higher rates of cytoplasmic proteins identified. As we 
obtained the best results in CDM + EA, both in terms of number 
and percentage of surface proteins and peptides compared to 
the total, we chose this culture medium for further optimization 
of the protocol. 
Then, we tested the effect of trypsin incubation time both on 
survival and surface protein identification.  During the first 
30 min, survival rates decreased around 1%, either in the 
absence or in the presence of trypsin. However, 30 min later, 
survival rate of controls dropped significantly around 10% (from 
98.6% to 88.2%), and even more (around 16%, from 98.4% to 
82.3%) in trypsin-treated cells, thus suggesting that protease 
digestion can contribute to destabilize cell integrity. This can 
explain the highest number of cytoplasmic proteins and their 
corresponding peptides identified after 1 h incubation. Very 
similar results have been obtained in S. aureus, in which cell lysis 
begins after 30 min of trypsin addition [12]. As stated before, the 
choice of the best conditions for a “shaving” experiment is a 
compromise in which two factors must be balanced: to 
maximize the identification of surface proteins (at least 20, in 
order to have chances of identifying common interesting 
antigens when analyzing several strains of the same species) 
and to minimize the inherent lysis occurrence (especially high 
in pneumococcus and in S. aureus; low in other species like 
S. pyogenes and S. Streptococcus agalactiae) that leads to a certain 
degree of cytoplasmic contamination. In this work, we have 
shown that optimal conditions can be calculated mathemati- 
cally by adjusting the curve to a second-grade equation, and that 
the calculated optimal time (33.6 min) is very close to that tested 
experimentally (30 min). Nevertheless, the conditions employed 
in such “shaving” experiments (buffer, pH, time) are not those 
ideal for the highest enzymatic activity of trypsin, as the aim is, 
above all, seeking the maximal stability of cells. As a conse- 
quence, the protease does not totally digest its substrates, and 
large pieces of proteins can be observed in the peptide-containing 
supernatants of shaved cells. This has also been observed in 
other “shaving” experiments in Gram-positive bacteria [10,12,13]. 
However, we can affirm that these conditions allow the 
identification of a significant proportion of the,  in principle, 
most exposed surface proteins, mainly cell wall proteins contain- 
ing the LPXTG anchoring motif and lipoproteins [36]. 
In our study, most cell-wall anchored proteins predicted 
from the R6 genome (8 out of 11, 73%) were identified, as well 
as 21% of predicted lipoproteins and 22% of predicted secreted 
proteins.  This  has  also  been  observed  in  S.  pyogenes  [9], 
S. agalactiae [11] and Enterococcus faecalis [10]. In these cited 
works, the proteins identified in higher percentages compared 
to their predicted numbers from the respective genomes were 
those expected to be most exposed and abundant, i.e., cell 
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wall proteins and lipoproteins. Moreover, Rodríguez-Ortega et 
al. [9] have demonstrated through FACS analysis that most of 
the identified proteins are accessible to the antibodies, which 
means that the strategy allows the selection of candidates with 
the highest chances to raise an immune response and 
consequently to induce protection against infection. In the 
present work, we have identified 22 out of the 27 predicted 
surface proteins so far  demonstrated to induce protection 
[37–39]. One of these, PcsB (Spr2021), whose protective capacity 
has been demonstrated by Giefing et al. [40], is actually being 
developed as a promising vaccine candidate by Intercell. 
Proteins with some TMD were identified in lower percentages 
compared to  their predicted figures from the genome. This  is 
expected as these proteins are more embedded in the bacterial 
surface  and  are  therefore  less  exposed  and  less  accessible  to 
proteases   [13,41].   For   those   whose   topology   prediction   by 
subcellular   localization   algorithms   was   in   agreement   with 
proteomics data (i.e., peptides identified in domains theoretical- 
ly  in  the  extracellular  side  of  the  membrane),  the  minimum 
distance from the membrane was 30 amino acids or more, which 
is   thus   calculated   to   cross   the   average   thickness   of   the 
peptidoglycan  cell  wall  [2,13].  However,  some  discrepancies 
between experimental proteomics data and predicted topologies 
were observed, as for 2 out of 11 represented proteins (Fig. 4), 
identified  peptides  fell  into  theoretically  cytoplasmic  domains. 
This  has  been  also  observed  in  other  studies  [9,12,30]  and 
although  it  could  be  because  of  residual  lysis,  in  most  cases 
such discrepancies are most probably due to errors in prediction 
algorithms, as demonstrated  by Rodríguez-Ortega  et al.  [9].  A  
clear example in the present work is protein Spr2045, for which 
LocateP predicts a unique TMD, with the N-term located in the 
cytoplasm; however, TMHMM prediction for that protein shows 
the  opposite  topology,  while  PSORT  and  SignalP  predict  a 
completely extracellular localization without any TMD. 
The identification of new pneumococcal surface proteins 
has renewed the interest in the serological diagnosis of infection 
[17,42,43]. Some epidemiological studies based on a reduced set 
of proteins have shown unclear patterns of antibody responses 
when applied to heterogeneous cohorts of patients [42,44,45]. A 
complementary application of the “shaving” strategy that we 
show in this study is the discovery of antigens that can be used 
in serological tests to diagnose pneumococcal infection. How- 
ever, serological tests in epidemiological studies have the 
drawback of potential detection of antibodies induced by non- 
symptomatic colonization and the difficulty in obtaining acute 
sera from patients (especially with children), in order to 
determine IgM responses [43]. We tested antibody responses 
against six proteins, five of which have been demonstrated to 
induce protection, plus one whose protective activity has not 
been tested (Spr0247). An IgG positive pattern was observed not 
only in the three patient sera, but also in the two controls. 
Positive responses in control patients could be due either to 
pneumococcal non-symptomatic carriage or homology with 
proteins from other pathogens that have caused disease in the 
tested patients. The poor IgM response can be explained 
because the sera were taken in the convalescent phase, 
therefore the IgM levels would be much lower than during the 
acute phase of the infection. Nevertheless, this strategy can be 
very useful for proposing a wide array of protein antigens to be 
applied  in serological  studies after carefully  designing  and 
selecting the cohort of patients, in terms of serum sampling 
(acute and convalescent phase), age, development of disease, 
etc. Further studies are needed, and we will apply the strategy in 
the near future for the development of a Luminex-based assay 
using a panel of identified surface proteins from a collection of 
clinical isolates. 
5. Conclusion 
Surface protein identification of bacteria through “shaving” 
approach has been already demonstrated extensively to be a 
fast and reliable  means for  selecting vaccine candidates. In 
some organisms, the drawback of the overwhelming presence of 
cytoplasmic contamination can render the interpretation of 
results more difficult. This is especially true if the aim is to 
include in the pipeline of vaccine testing some proteins for 
which surface prediction is not clear, after contrasting bioinfor- 
matics and experimental analyses. Identification of cytoplasmic 
proteins can be minimized by an optimization of the culture and 
digestion protocol, which must be done specifically for each 
organism. The “shaving” strategy can also be the experimental 
basis to select proteins to be used for the development of new 
diagnostic tools of pneumococcal infection in clinical studies. 
Comparing different strains of a certain species is a necessary 
step to define the set of surface proteins (the common 
“pansurfome”) that have biological relevance for a purpose, 
like the selection of ideal vaccine candidates or those that can be 
included in serologically-based diagnostic tests—i.e., proteins 
highly expressed, abundant and widely distributed. 
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6. Supplementary dataset (SDS) 
Table S1. Effect of culture medium on protein and peptide identification after “shaving” pneumococcal cells 
followed by LC/MS/MS analysis. 
Proteins 
Protein category (a)/Culture 
medium THB CDM+C CDM+EA 
# % # % # % 
Lipoprotein 3 1.2 1 1.4 6 7.2 
Cell Wall 4 1.6 3 4.2 5 6.0 
Secretory 6 2.4 3 4.2 4 4.8 
1 TMD 7 2.8 2 2.8 9 10.8 
>1 TMD 24 9.5 5 6.9 8 9.6 
Cytosolic 209 82.6 58 80.6 51 61.4 
Peptides 
Protein category/Culture medium THB CDM+C CDM+EA 
# % # % # % 
Lipoprotein 7 0.5 1 0.4 20 7.9 
Cell Wall 44 3.1 4 1.4 17 6.7 
Secretory 29 2.1 37 13.1 22 8.7 
1 TMD 34 2.4 14 5.0 24 9.5 
>1 TMD 90 6.4 14 5.0 26 10.3 
Cytosolic 1204 85.5 212 75.2 144 56.9 
(a) Protein categories were established according to LocateP subcellular predictions: lipoproteins were those predicted as lipid-anchored 
proteins; cell wall proteins, as those having an LPXTG motif; secretory proteins, as those possessing an SP1-type signal peptide; 
membrane proteins with one transmembrane domain (TMD), as those possessing either a C- or an N-terminally anchored 
transmembrane region;  membrane proteins with more than one transmembrane domain, those predicted as multi-
transmembrane proteins; “surface proteins” means the sum of the five previous categories; and cytoplasmic proteins, those 
without any exporting or sorting signal, and predicted as intracellular proteins. 
Table S2. Effect of trypsin incubation time on protein and peptide identification after “shaving” 
pneumococcal cells cultured in CDM + EA followed by LC/MS/MS analysis. 
Protein category (a)/trypsin 
incubation time 
PROTEINS 
T0 T5- (b) T5+ T15- T15+ T30- T30+ T60- T60+ 
# % # % # % # % # % # % # % # % # % 
Lipoprotein 1 9.1 0 0 1 3.0 0 0 0 0 1 5.9 4 4.7 1 4.2 4 3.9 
Cell Wall 0 0.0 1 2.9 0 0.0 1 4 2 5 0 0.0 6 7.0 0 0.0 3 2.9 
Secretory 0 0.0 1 2.9 0 0.0 0 0 2 5 0 0.0 4 4.7 0 0.0 2 2.0 
1 TMD 0 0.0 2 5.7 5 15.2 3 12 3 7.5 0 0.0 9 10.5 0 0.0 3 2.9 
>1 TMD 0 0.0 1 2.9 5 15.2 3 12 1 2.5 0 0.0 7 8.1 4 16.7 11 10.8 
Cytosolic 10 90.9 30 85.7 22 66.7 18 72 32 80 16 94.1 56 65.1 79 79.2 79 77.5 
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Protein category (a)/trypsin 
incubation time 
PEPTIDES 
T0 T5- T5+ T15- T15+ T30- T30+ T60- T60+ 
# % # % # % # % # % # % # % # % # % 
Lipoprotein 20 44.4 0 0 1 0.6 0 0 0 0 5 6.8 11 2.7 2 2.1 20 3.4 
Cell Wall 0 0.0 5 4.9 0 0.0 3 3.7 10 4.9 0 0.0 20 4.8 0 0.0 16 2.7 
Secretory 0 0.0 4 3.9 0 0.0 0 0 9 4.4 0 0.0 12 2.9 0 0.0 16 2.7 
1 TMD 0 0.0 14 13.7 22 12.6 9 11.1 15 7.3 0 0.0 76 18.4 0 0.0 13 2.2 
>1 TMD 0 0.0 1 1 35 20.1 19 23.5 1 0.5 0 0.0 85 20.6 7 7.2 51 8.6 
Cytosolic 25 55.6 78 76.5 116 66.7 50 61.7 170 82.9 68 93.2 209 50.6 88 90.7 477 80.4 
(a) Protein categories were established according to LocateP subcellular predictions: lipoproteins were those predicted as lipid-anchored 
proteins; cell wall proteins, as those having an LPXTG motif; secretory proteins, as those possessing an SP1-type signal peptide; 
membrane proteins with one transmembrane domain (TMD), as those possessing either a C- or an N-terminally anchored 
transmembrane region;  membrane proteins with more than one transmembrane domain, those predicted as multi-transmembrane 
proteins; “surface proteins” means the sum of the five previous categories; and cytoplasmic proteins, those without any exporting or 
sorting signal, and predicted as intracellular proteins. 
(b)  “-” indicates no enzyme in the incubation buffer (control), and further digestion of the supernatant after removing cells; “+” indicates 
trypsin digestion. 
Table S3. proteins that so far have been demonstrated to induce protection against pneumococcal infection 
Protein family Antigen Locus Found in # strains in our study 
Choline-binding proteins 
PspA spr0121 3/5 
CbpA (PspC) spr1995 4/5 
PcpA spr1945 1/5 
LytA spr1754 0/5 
LytB spr0867 1/5 
Toxins Pneumolysin spr1739 3/5 
Sortase and sortase-dependent 
proteins 
SrtA spr1098 2/5 
RrgA/B/C Gene(s) absent in R6 genome 
NanA spr1536 3/5 
PrtA spr2045 5/5 
ABC transporter proteins 
PiaA spr0934 3/5 
PsaA spr1494 1/5 
PotD spr1243 0/5 
SP2108 spr1918 4/5 
SP0148 spr0146 3/5 
Enzymatic proteins 
ClpP spr0656 0/5 
StkP spr1577 0/5 
FBA spr0530 5/5 
GAPDH spr1825 5/5 
Enolase spr1036 5/5 
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Trigger factor spr0362 5/5 
ldh spr1100 5/5 
Pyruvate kinase spr0797 4/5 
Phosphoglycerate kinase spr0441 4/5 
6PGD spr0335 4/5 
Histidine triad proteins 
PhtA spr1061 3/5 
PhtB spr1060 3/5 
PhtD spr0907 4/5 
PhtE spr0908 4/5 
Others 
PcsB spr2021 5/5 
PppA spr1430 2/5 
PpmA (PrsA) spr0884 4/5 
SlrA spr0679 2/5 
AmiA spr1707 5/5 
AliB spr1382 4/5 
AliA spr0327 3/5 
PfbB spr0075 5/5 
PsrP sp_1772 Gene(s) absent in R6 genome 
Figure S1. Percent of identified surface proteins were represented vs time. The curve was adjusted to a second-
grade equation. 
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Abstract 
Purified polysaccharide and conjugate vaccines are widely used for preventing infections in adults and in children against 
the Gram-positive bacterium Streptococcus pneumoniae, a pathogen responsible for high morbidity and mortality rates, 
especially in developing countries. However, these polysaccharide-based vaccines have some important limitations, such as 
being serotype-dependent, being subjected to losing efficacy because of serotype replacement and high manufacturing 
complexity and cost. It is expected that protein-based vaccines will overcome these issues by conferring a broad coverage 
independent of serotype and lowering production costs. In this study, we have applied the ‘‘shaving’’ proteomic approach, 
consisting of the LC/MS/MS analysis of peptides generated by protease treatment of live cells, to a collection of 16 
pneumococcal clinical isolates from adults, representing the most prevalent strains circulating in Spain during the last years. 
The set of unique proteins identified in all the isolates, called ‘‘pan-surfome’’, consisted of 254 proteins, which included most 
of the protective protein antigens reported so far. In search of new candidates with vaccine potential, we identified 32 that 
were present in at least 50% of the clinical isolates analyzed. We selected four of them (Spr0012, Spr0328, Spr0561 and 
SP670_2141), whose protection capacity has not yet been tested, for assaying immunogenicity in human sera. All of them 
induced the production of IgM antibodies in infected patients, thus indicating that they could enter the pipeline for vaccine 
studies. The pan-surfomic approach shows its utility in the discovery of new proteins that can elicit protection against 
infectious microorganisms. 
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1. Introduction 
Streptococcus pneumoniae is a Gram-positive bacterium that can be 
found as a commensal in the human respiratory tract and that, 
under appropriate conditions, is pathogenic, being able to cause 
high morbidity and mortality [1]. This microorganism is a leading 
cause of mucosal diseases such as otitis media, sinusitis and 
pneumonia and is a prominent pathogen in invasive diseases 
including bacteremia, meningitis, and sepsis [2]. Pneumococcal 
disease disproportionally affects young children and the elderly 
although it may occur in all age groups and with higher frequency 
among patients with co-morbid conditions. It has been estimated 
that approximately 800,000 children die each year due to 
pneumococcal disease and .90% of these deaths occur in 
developing countries [3]. Burden of disease due to pneumococcal 
diseases, generally related to pneumonia, is also high among adults 
in developed countries with around 25,000 deaths per year in the 
United  States  in  adults  over  50  years  of  age  and  significant 
mortality and long-term effects on quality of life in European 
countries  [4,5]. 
Prevention of pneumococcal disease by immunization has long 
been considered a major goal that could help to reduce the burden 
of pneumococcal diseases and to control antimicrobial resistance 
rates [6,7]. Two types of pneumococcal vaccines are available in 
the market, both based on the capsule polysaccharide: pneumo- 
coccal purified polysaccharide vaccine and conjugate vaccines, in 
which polysaccharides are conjugated to a protein carrier capable 
of recruiting CD4+  T-cells, increasing immunogenicity in young
children [8]. The first type is mainly used in adults, covering 23 
capsule serotypes (Pneumovax 23V) that represent about 80% of 
the most prevalent pneumococcal disease-causing ones in children 
and adults in the USA [9]. A pneumococcal conjugate vaccine 
covering 7 serotypes (PCV7) was initially licensed for exclusive use 
in children, and new vaccines with broader serotype coverage 
(10V and 13V) were later developed. The 13-valent pneumococcal 
conjugate vaccine (PCV13) has been approved for prevention of 
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invasive disease (FDA and EMEA) and pneumonia (FDA) caused 
by PCV13 serotypes among adults aged 50 years and older, and 
was recently recommended for adults aged $19 years with 
immunocompromising conditions in the United States by ACIP 
[10]. 
Although it seems that Pneumovax-23 protects effectively 
against invasive pneumococcal disease (IPD) in healthy adults, its 
efficacy in high-risk groups and against other outcomes (pneumo- 
nia, mortality) is less clear [1]. In addition, and together with 
conjugate vaccines, they present some important limitations [11]: 
i) coverage is serotype-dependent, not covering the majority of the
93 capsule serotypes described so far; ii) coverage is designed on 
the basis of the most prevalent serotypes identified in developed 
countries and  may be  less effective in  developing countries;  iii) 
vaccine effectiveness may decrease in the long term due to non- 
vaccine serotype replacement [12]; iv) high manufacturing 
complexity and cost make these  vaccines  less accessible to 
developing countries; and v) genomic factors other than capsular 
determinants may modulate virulence, and therefore it has been 
suggested that a vaccine based on genetic factors other than 
serotype may be necessary especially for otitis media and 
nonbacteremic pneumonia [13]. Protein-based vaccines theoret- 
ically offer advantages over those based on the capsule polysac- 
charides, by allowing them to overcome the previously cited 
problems: targeting conserved antigens in a serotype-independent 
way, covering a broader pneumococcal biotype population, and 
lowering cost of production [14]. Here, surface proteins are ideal 
as they have the highest chance of raising an effective immune 
response. So far, numerous pneumococcal proteins have shown 
protection against infection in animal models, but most of them 
are still in clinical trials. Proteomics provides excellent platforms 
and strategies to identify in a fast and reliable way the set  of 
proteins expressed on the surface of pathogenic microorganisms. 
To this regard, the ‘‘shaving’’ approach –consisting of treating live 
cells with proteases, followed by LC/MS/MS analysis of the 
generated peptides– has become a highly valuable tool when 
searching for protein vaccine candidates [15,16]. In this study, we 
have screened a collection of pneumococcal clinical isolates from 
adults by defining its ‘‘pan-surfome’’, (i.e. the whole set of 
expressed surface proteins), in order to identify which proteins that 
have not been tested so far in animal models for protection against 
infection could enter the vaccine pipeline in future studies. 
2. Materials and Methods 
2.1. Ethics Statement for Human Sera Sampling and Use 
This research was performed according to the principles 
expressed in the Declaration of Helsinki. All human sera were 
obtained from patients .8 years old admitted to Hospital 
Universitario Infantil Virgen del Rocı´o (HUIVR) in Seville, 
Spain. Sera were drawn either from patients with a diagnosis of 
pneumococcal infection, determined by isolation of the microor- 
ganism from a sterile site (blood or pleural fluid) according to 
standardised protocols or from healthy control children aged .8 
years old. All sera from patients were obtained within ten days of 
hospital admission. Written informed consent was obtained from 
parents or legal guardians of participating children and the 
Hospital Universitario Virgen del Rocı´o Ethic Committee 
approved the study (code no. 010470, certificate no. 14/2010), 
for sera to be used within the project in which this work was 
designed. 
2.2. Bacterial Strains and Growth 
The 16 S. pneumoniae strains used in this study isolated from adult 
patients corresponded to 9 different capsule serotypes (Table 1). 
All the strains were maintained at 280uC, plated on Columbia 
blood agar base containing 6% (v/v) sheep blood and grown in a 
chemically-defined medium (CDM) [17]  supplemented  with 
20 mg/ml ethanolamine (CDM+EA) as source of 
aminoalcohol, at 37°C and 5% CO2 until OD600 of 0.25 (mid-
exponential phase) was reached. 
2.3. Molecular Genotyping 
MLST was performed using standard methodology [18]. In 
brief, internal fragments of 7 housekeeping genes (aroE, gdh, gki, 
recP, spi, xpt and ddl) were amplified by polymerase chain reaction 
and sequenced on each strand. Conventional primers were used, 
whose sequences are available at the MLST database (http:// 
www.mlst.net). Alleles were assigned by comparing the sequence at 
each locus to all known alleles at that locus, and the combination 
of 7 alleles determined the sequence type (ST). Allele and ST 
designations were made using the MLST website, hosted at 
Imperial College London, and funded by the Wellcome Trust. 
2.4. ‘‘Shaving’’ of Live Pneumococcal Cells with Trypsin 
Generation and recovery of tryptic peptides from ‘‘shaved’’ cells 
was carried out as described in [19] without modifications. Briefly, 
100 ml of cultures were centrifuged at 3,5006g for 10 min at 4uC, 
and the pelleted bacteria washed twice with PBS. Cells were 
resuspended in one-hundredth volume of PBS/30%  sucrose 
(pH 7.4). Tryptic digestions were performed with 5 mg trypsin 
(Promega) for 30 min at 37uC. The digestion mixtures were 
centrifuged at 3,5006g for 10 min at 4uC, and the supernatants 
(the ‘‘surfomes’’ containing the peptides) were filtered using 0.22- 
mm pore-size filters (Milipore). Surfomes were re-digested with 
2 mg trypsin overnight at 37uC with top-down agitation. Salts were 
removed prior to analysis, using Oasis HLB extraction cartridges 
(Waters). Peptides were eluted with increasing concentrations of 
acetonitrile/0.1% formic acid, according to manufacturer’s 
instructions. Peptide fractions were concentrated with a vacuum 
concentrator (Eppendorf), and kept at -20°C until further 
analysis. 
2.5. LC/MS/MS Analysis 
All analyses were performed with a Surveyor HPLC System in 
tandem with an LTQ-Orbitrap mass spectrometer (Thermo Fisher 
Scientific, S a n  J o s e , U S A ) e q u i p p e d  w i t h  
n a n o e l e c t r o s p r a y  ionization interface (nESI), as 
described [19]. The separation column was 150 mm60.150 mm 
ProteoPep2 C18 (New Objec- tive, USA) at a postsplit flow rate 
of 1 ml/min. For trapping of the digest a 5 mm60.3 mm 
precolumn Zorbax 300 SB-C18 (AgilentTechnologies, 
Germany) was used. One fourth of the total sample volume, i.e. 5 
ml, was trapped at a flow rate of 10 ml/min for 10 minutes and 
5% acetonitrile/0.1% formic acid. After that, the trapping 
column was switched on-line with the separation column and the 
gradient was started. Peptides were eluted with a 60-min 
gradient of 5–40% of acetonitrile/0.1% formic acid solution at a 
250 nl/min flow rate. All separations were performed using a 
gradient of 5–40% solvent B for 60 minutes. MS data (Full Scan) 
were acquired in the positive ion mode over the 400–1,500 m/z 
range. MS/MS data were acquired in dependent scan mode, 
selecting automatically the five most intense ions for fragmenta- 
tion, with dynamic exclusion set to on. In all cases, a nESI spray 
voltage of 1.9 kV was used. 
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2.6. Protein Identification by Database Searching 
Tandem mass spectra were extracted using Thermo Proteome- 
Discoverer 1.0 (Thermo Fisher Scientific). Charge state deconvo- 
lution and deisotoping were not performed. All MS/MS samples 
were analyzed using Sequest (Thermo Fisher Scientific, version 
v.27), applying the following search parameters: peptide tolerance, 
10 ppm; tolerance for fragment ions, 0.8 Da; b- and y-ion series; 
oxidation of methionine and deamidation of asparagine and 
glutamine were considered as variable modifications; maximum 
trypsin missed cleavage sites, 3. The raw data were searched 
against an in-house joint database containing the protein 
sequences from all the sequenced and annotated S. pneumoniae 
strains available at the NCBI ftp site. Peptide identifications were 
accepted if they exceeded the filter parameter Xcorr score vs 
charge   state   with   SequestNode   Probability   Score   (+1 = 1.5, 
+2 = 2.0, +3 = 2.25, +4 = 2.5). With these search and filter 
parameters, no false-positive hits were obtained. For proteins 
identified from only one peptide, fragmentations were checked 
manually. Strain R6 was used as reference for providing the 
accession numbers of the identified proteins; whenever a protein 
belonging to another strain was found, homology with a 
corresponding protein of strain R6 was given by using protein- 
BLAST. If homology with R6 or TIGR4 proteins was not 
observed, then the protein accession numbers of the other strains 
were used. 
Table 1. Sequence types (STs) and serotypes among 16 
Streptococcus pneumoniae invasive isolates recovered from 
adult patients. 
2.7. Bioinformatic Prediction of Protein Subcellular 
Localization 
Primary predictions of subcellular localization were assigned by 
using the web-based algorithm LocateP (http://www.cmbi.ru.nl/ 
locatep-db/cgi-bin/locatepdb.py). They were contrasted by sev- 
eral feature-based algorithms: TMHMM 2.0 (http://www.cbs.dtu. 
dk/services/TMHMM-2.0) for searching transmembrane helices; 
SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP) for type-I 
signal peptides: those proteins containing only a cleavable type-I 
signal peptide as featured sequence were classed as secreted; LipoP 
(http://www.cbs.dtu.dk/services/LipoP) for identifying type-II 
signal peptides, which are characteristic of lipoproteins. Topolog- 
ical representations of membrane proteins were performed with 
the web-based TOPO2 software (http://www.sacs.ucsf.edu/ 
TOPO2/). GO annotations were retrieved from the UniProt 
Knowledgebase  (http://www.uniprot.org/). 
2.8. Western Blot Analysis 
Immunoreactivity of pneumococcal proteins was performed by 
Western blotting. 2 mg of pneumococcal recombinant proteins 
Spr0328 and Spr0561, 5 mg of pneumococcal recombinant 
proteins Spr0012, Spr0121, and SP670_2141 (produced as 
GST-tag recombinant fragments using the pSpark® vector, 
Canvax Biotech, Co´rdoba, Spain, and expressed in E. coli BL21. 
See Dataset S1 for further details), 1 mg trypsin (Promega) as 
negative control, and 1 mg of total protein extract of pneumococ- 
cus as positive control were separated by 12% SDS-PAGE gels 
and transferred to nitrocellulose membranes (Life Sciences). Non- 
specific sites were blocked by incubation with 5% non-fat milk in 
T-TBS for 1 h. After two washes with T-TBS, a second 1-h 
incubation of the membranes with patient sera, diluted 1:100 in T- 
TBS for IgG detection and 1:1,000 for IgM detection, was carried 
out. Interference of IgG antibodies in IgM detection was avoided 
using  GullSORB  TM  (Meridian  Bioscience,  Inc.),  according  to 
manufacturers’  instructions.  Secondary  antibodies  consisted  of 
rabbit anti-human IgG or rabbit anti-human IgM conjugated to 
Isolate ST 
Allelic profile 
(MLST)* Serotype PMEN clone** 
horseradish peroxidase (Sigma), diluted 1:5,000 or 1:2,500 in TBS, 
respectively, for 1 h. Then, the membranes were washed three 
1 2480 12,8,4,5,18,58,18 9V 
2 191 8,9,2,1,6,1,17 7F Netherlands 7F-39 
times with TBS and developed with ECL Plus Western Blotting 
Dectection System (GE Healthcare) according to the manufactur- 
er’s instructions. 
3 191 8,9,2,1,6,1,17 7F Netherlands7F-39 
4 162 7,11,10,1,6,8,14 14 SLV-Spain9V-3*** 
5 228 12,8,1,5,17,4,20 1 
6 433 1,1,4,1,18,58,17 19A 
7 306 12,8,13,5,16,4,20 1 Sweden1-28 
8 289 16,12,9,1,41,33,33 5 Colombia5-19 
9 7340 2,5,36,12,17,21,271   8 
10 1201 1,5,1,12,17,3,8 19A 
11 156 7,11,10,1,6,8,1 14 Spain9V-3 
12 180 7,15,2,10,6,1,22 3 Netherlands3-31 
13 53 2,5,1,11, 16,3,14 8 
14 557 7,11,10,1, 6,58,1 9V SLV-Spain9V-3*** 
15 1223 16,12,9,1,6,33,33 5 SLV-Colombia5-19*** 
16 989 12,5,89,8,6,112,14 12F 
3. Results and Discussion
We analyzed  16  clinical isolates collected  from  adult patients 
with invasive pneumococcal disease (IPD). Nine different serotypes 
were identified. These serotypes included the five most prevalent 
ones found in IPD among older people in Spain during the most 
recent years (19A, 3, 7F, 14 and 1), serotypes 9V and 19F that had 
been circulating significantly in this population in pre- and post- 
PCV7 periods, as well as serotypes 8 and 12F that were generally 
restricted to adults and with epidemic potential [20,21]. We 
genotyped all clinical isolates by MLST, because genetic diversity 
of pneumococcal surface proteins depends on non-capsular 
genomic background. Fifteen clonal types were found including 
several major global clones recognized by the Pneumococcal 
Molecular   Epidemiology   Network   (PMEN)   (http://www.sph. 
emory.edu/PMEN) and genetically related genotypes as shown 
*Allelic profiles for each gene in multilocus sequence typing (MLST) are
presented in the following order: aroE, gdh, gki, recP,spi, xpt and ddl.
**PMEN clones are global clones recognized by pneumococcal molecular 
epidemiology network.
***SLV = single locus variant (i.e. differs at only one MLST locus and thus is a
closely-related genotype).
doi:10.1371/journal.pone.0070365.t001
in Table 1. The most relevant among them were: ST156 (Spain9V- 3), 
one of the most successful clones worldwide that has been 
especially responsible for the expansion of serotype 14 in IPD in 
various countries during recent years [22]; ST306 (Sweden1-28), a 
highly circulating genotype associated with the increase in the 
incidence of pleural empyema in children and adults in the last 
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Figure 1. Pan-surfomic analysis of pneumococcal adult clinical isolates. A) Yield of surface protein identification after trypsin treatment 
in each of the 16 analyzed isolates. B) Subcellular localization of the predicted surface proteins, according to LocateP (TMD: transmembrane domain). 
C) Gene Ontology annotations of the biological functions of the identified surface proteins. Numbers in panels B and C represent the proteins
belonging to each category. 
doi:10.1371/journal.pone.0070365.g001 
decade [23,24]; ST289 (Colombia5-19), a highly relevant genotype 
identified in IPD both in developing and developed countries and 
associated with major local geographical outbreaks [25,26]; ST180 
(Netherlands3-31), most commonly found clonal type in serotype 3 
that is associated to increased risk of mortality in pneumococcal 
pneumonia [27,28]; and finally, ST191 (Netherlands7F-39), the 
dominant clonal type associated to the emerging serotype 7F 
during the post-PCV7 period [29]. 
Interaction between cells and their environment is critically 
mediated by surface proteins. In the case of pathogenic bacteria, 
these molecules are often virulence factors or responsible for 
pathogenesis. Since they also interact with the immune system, 
many of them are highly immunogenic and are thus ideal targets 
for novel vaccine discovery and development [30]. Protein-based 
vaccines composed of a unique antigen or a combination of them 
in a single formulation, may overcome the challenges remaining 
with polysaccharide-based vaccines, such as serotype replacement 
and high cost, thus making prophylaxis more affordable for 
resource-limited populations [11]. 
To this regard, proteomics has been revealed as the best means 
for high-throughput screening of large amounts of proteins for any 
biological purpose, and in particular for defining the set of surface- 
expressed proteins on a given organism. Several proteomic 
analyses have been carried out on the pneumococcus, targeting 
either the membrane fraction [31–33] or the cell wall-attached 
proteins [34,35], but these biochemical fractionation-based 
methods have several limitations: they are relatively slow, 
membrane proteins are not always well resolved in polyacrylamide 
gels and topology information is lost [19,36]. The ‘‘shaving’’ 
approach has become a powerful way to identify the set of surface 
proteins expressed on a given organism (the ‘‘surfome’’), most of 
which are normally highly immunogenic as shown by different 
immunochemical techniques [15,16,37], and provides new candi- 
dates that elicit protective activity against infection [38]. We have 
previously set up this strategy in the pneumococcus [19], showing 
that the procedure enables to define the ‘‘pan-surfome’’ of a 
collection of clinical isolates, in order to select common proteins to 
all or most strains [37,39]. 
We applied the optimized ‘‘shaving’’ protocol for pneumococ- 
cus to the collection of adult clinical isolates, growing cells in a 
chemically-defined medium with ethanolamine (CDM+EA) and 
digesting them with trypsin for 30 min at 37uC. As already 
described by our group [19], we have compared the efficiency of 
the ‘‘shaving’’ procedure in different culture media. In the 
complex Todd-Hewitt broth, 44 surface proteins were identified 
at the described trypsin digestion conditions, compared to 32 
found in CDM+EA; however, a higher percentage of cytoplasmic 
proteins was found in THB than in CDM+EA (83% vs 61%). 
Moreover, these differences were even higher when considering 
identified  peptides  (in  THB, only  15%  corresponded  to  surface 
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Table 2. Identification of protective protein antigens against Streptococcus pneumoniae infection already described in literature. 
Protein family Antigen Locus Location References Found in # strains
Choline-binding proteins PspA spr0121 1TMD [53] 14/16
CbpA (PspC) spr1995 Secreted [41] 16/16
PcpA spr1945 Secreted [45] 5/16
LytA spr1754 Cytoplasmic [47] 3/16
LytB spr0867 .1TMD [52] 7/16
Toxins Ply spr1739 Cytoplasmic [40] 6/16
Sortase and sortase- 
dependent proteins
SrtA spr1098 1TMD [44] 4/16
RrgA SP_0462 Cell Wall [43] 0/16
RrgB SP_0463 Cell Wall [43] 0/16
RrgC SP_0464 Cell Wall [43] 0/16
NanA spr1536 Cell Wall [48] 13/16
SphtrA spr2045 1TMD [52] 11/16
ABC transporter proteins PiaA (ABC-SBP) spr0934 Lipoprotein [46] 2/16
PiuA (fecE) spr1686 Cytoplasmic [46] 2/16
PsaA spr1494 .1TMD [51] 2/16
PotD spr1243 1TMD [50] 1/16
sp0148 (ABC-SBP) spr0146 Lipoprotein [49] 5/16
Enzymatic proteins ClpP spr0656 Cytoplasmic [42] 1/16
StkP spr1577 1TMD [54] 1/16
FBA spr0530 Cytoplasmic [34] 13/16
gapA spr1825 Cytoplasmic [34] 16/16
eno spr1036 Cytoplasmic [56] 16/16
tig spr0362 Cytoplasmic [56] 9/16
ldh spr1100 Cytoplasmic [56] 11/16
pykF spr0797 Cytoplasmic [56] 15/16
pgk spr0441 Cytoplasmic [56] 15/16
gnd spr0335 Cytoplasmic [34] 13/16
Histidine triad proteins PhtA spr1061 Lipoprotein [55] 6/16
PhtB spr1060 Lipoprotein [55] 9/16
PhtD spr0907 1TMD [55] 14/16
PhtE spr0908 Secreted [55] 10/16
Others PcsB spr2021 Secreted [54] 12/16
PppA spr1430 Cytoplasmic [59] 6/16
PpmA (PrsA) spr0884 Lipoprotein [62] 8/16
SlrA spr0679 Cytoplasmic [60] 11/16
AmiA spr1707 Lipoprotein [61] 5/16
AliB spr1382 Lipoprotein [61] 9/16
AliA spr0327 Lipoprotein [61] 7/16
PfbB spr0075 Cell Wall [63] 8/16
PsrP sp_1772 Cell Wall [64] 0/16
spr0785 spr0785 Cytoplasmic [49] 1/16
spr1176 spr1176 Cytoplasmic [58] 1/16
spr2010 spr2010 .1TMD [58] 1/16
spr1875 spr1875 1TMD [57] 8/16
doi:10.1371/journal.pone.0070365.t002 
proteins, whereas in CDM+EA this percentage was 43%). A total 
of 254 surface proteins were identified in the set of the 16 isolates 
(TableS1  and  SDS 2  a n d 3 ), and the  yields  of  surface   protein 
identification ranged between 20% and 40%, approxi- mately 
(Figure 1A). Within the different categories of surface proteins  
recognized     for    Gram-positive      bacteria,     and      particularly 
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for streptococci, most of them (114+64 = 178, i.e. 70%) had some 
transmembrane domain, 24 (9.4%) were predicted by LocateP as 
secreted, 35 (13.8%) as lipoproteins and 17 (6.7%) as possessing an 
LPXTG-anchoring motif to the cell wall (Figure 1B). Figure 1C 
shows the GO annotations according to their biological function, 
with a high number of proteins with unpredicted functions, which 
make them highly interesting for further studies on molecular 
characterization, participation in virulence or pathogenesis, or 
assay of protection activity. 
The ‘‘shaving’’ approach has already  demonstrated  its  
power for identifying most of the previously discussed protective 
protein antigens in other streptococcal species, even when the 
number of clinical isolates used is low [15,16]. Our pan-
surfomic analysis included 40 out of the 44 proteins that have 
shown to induce protection against pneumococcal infection 
[34,40–64] (Table  2). Among these proteins, 13 are 
predicted as cytoplasmic. Although many proteins pertaining 
to this category have been reported both to be surface-located 
and to induce protection, the targets of our analysis were 
those ones for which subcellular localization algorithms 
predicts undoubtedly to be exported outside the cell. 
Interestingly, we identified in a high proportion of clinical 
isolates some of the best candidates described so far: the 
membrane protein PspA [53] and the predicted extracellular 
proteins CbpA [41] and PcsB [54]. Three out of the four 
protective antigens not detected in our study were the pilin 
proteins RrgA,  RrgB  and RrgC. Previous works have 
shown that  Gram-positive  pilus subunit proteins are 
resistant to trypsin treatment [65], and proteolysis with a 
non-specific protease such as proteinase K is required  to  
identify  them  [15,16,66,67]. 
To be considered as a promising vaccine candidate, a given 
protein should ideally be surface-exposed, highly expressed, and 
distributed as widely as possible [36] in order to overcome the 
limitations of serotype-dependent polysaccharide vaccines [14]. 
However, experimentally identifying a high number of proteins 
common to all the analyzed strains, can be a hard task. Actually, 
Dreisbach et al. found in Staphylococcus aureus that only 7 proteins 
(less than 10% of total identified) were common to the 4 isolates 
analyzed [39]. We have reported very similar results in a low 
number of pneumococcal strains (12 proteins, i.e. 10.5% of total, 
in 5 isolates). But, as the number of analyzed isolates increases, the 
probability of finding some proteins common to all of them 
diminishes. In fact, we did not find any common protein to the 39 
Streptococcus suis clinical isolates in a recent report [37]. In  the 
search for pneumococcal surface proteins to be proposed as 
potential new vaccine candidates, we established a threshold for 
the presence of a protein in at least 50% of the analyzed clinical 
isolates; otherwise, a very stringent criterion would lead us to 
identify   the   already   described   protective   antigens.   Thus,   32 
proteins  surpassed  this  threshold  (Table  3).  As  expected, 
cell wall-anchored, for which 10 proteins were identified, was 
the category of surface proteins with the highest number of 
items above this limit. Spr0075 was just identified in 50% of the 
isolates;the other 9 cell-wall proteins were present in $11 strains. 
Threelipoproteins were also found according to the selected 
criterion, including the protective antigens PhtD and AliB (see 
Table 3), as well as 7 proteins with one transmembrane domain 
(that included protective antigens PspA and Spr1875) and other 7 
proteins with more than one transmembrane helix. Finally, 5 
predicted proteins to be secreted to the extracellular milieu were 
also found, including the highly protective candidates CbpA and 
PcsB (annotated in the R6 genome as Spr2021). As cell-wall 
proteins with the LPXTG- anchoring motif are those most 
protruding and exposed on the streptococcal surface [68], they are 
expected to be found most frequently within a collection of 
clinical isolates.  
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Figure 2. Topology representation of the predicted membrane  proteins  in  the  ‘‘pan-surfome’’  of  the  16  S.  pneumoniae  clinical 
isolates that have been identified in at least 50% of the analyzed strains. The TMHMM algorithm was used to predict transmembrane 
domains (TMD) and signal peptides after prediction of subcellular localization by LocateP. In red are shown the peptides experimentally identified 
by LC/MS/MS. A) Proteins with only one predicted TMD. B) Proteins with more than one TMD.
doi:10.1371/journal.pone.0070365.g002 
Actually, we have reported very similar results in the pan-surfome 
of 39 S. suis clinical isolates, where 13 cell wall proteins (out of 17 
identified, and out of 20 predicted in the database used) were 
identified in $50%  of strains  [37]. 
Although predicted membrane proteins (i.e. those with $1 
transmembrane domain) are normally the most abundant surface 
protein group identified in ‘‘shaving’’ experiments, they represent 
the lowest percentage compared to  the  corresponding  total 
number of predicted proteins in databases, compared to the other 
groups [15,16,69]. Cell-wall anchored, secreted proteins and 
lipoproteins  are  completely  surface-exposed,  except  some  small 
regions  embedded  within  the  cell  wall  and/or  the  capsule. 
Therefore, any portion of them would be a priori good for cloning 
in order to produce recombinant fragments for vaccine testing (in 
the case they were too large to select the whole sequence). 
However, membrane proteins are theoretically more embedded 
under the surface, and therefore  their  extracellular  domains  are 
less exposed. In addition, those with more than one transmem- 
brane domain are generally dificult to obtain  in  a  recombinant 
way, because of solubility problems. The best strategy to use them 
in protection assays would consist of selecting those domains that 
are experimentally confirmed to be surface-accessible. Figure 2 
shows the peptides identified after LC/MS/MS analysis over the 
topology predictions for the corresponding sequences of the  
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Figure 3.  Western  blot  analysis  of  five  selected  surface  proteins  against  human  sera.  Detection  of  both  IgG  (left)  and  IgM  (right)  was 
carried out. In all the cases, antibody reaction was observed against the positive control (pneumococcal protein extract; see Materials and Methods for 
further details), and no reaction against the negative control (trypsin; see Materials and Methods for further details). 
doi:10.1371/journal.pone.0070365.g003 
14 membrane proteins shown in Table 3. For 9 proteins, experi- 
mental assignments of identified peptides were in agreement with 
the predicted topologies (i.e. peptides corresponded to extracellu- lar 
domains). However, for the other 5 proteins (Spr0086, Spr0334, 
Spr0907, Spr1370 and Spr2045), discrepancies were observed, as we 
identified peptides belonging to predicted cytoplasmic domains. 
These disagreements have also been reported in other works 
[16,69,70], although in S. pyogenes it has been experimentally 
demonstrated by flow cytometry assays that some of these predicted 
cytoplasmic domains are actually surface- located [16], thus showing 
that prediction algorithms do  not always correctly predict the 
topology of all the membrane proteins. Moreover, a deeper view on 
the identified peptides for each individual isolate may provide ‘‘hot 
zones’’ (i.e. those identified in many strains) that might be best for 
selection of cloning fragments, in case of very large proteins 
(SDS2.4). 
  Finally, we evaluated the power of ‘‘pan-surfomics’’ for the 
selection of protein antigens with vaccine potential, by measuring 
the immunoreactivity in sera from infected patients. Thus, we 
selected five proteins from those identified in common in at least 
50% of the isolates, and performed a Western-blot analysis  to detect 
both IgG and IgM reaction. Of these proteins, four had not 
previously been assayed for protection. We also selected PspA 
(Spr0121), whose protection capacity against infection is well 
known [53], to validate the utility of this approach. As a positive 
control, we used a total protein extract from pneumococcus, and 
as a negative control, commercially available trypsin. As shown in 
Figure 3, IgG antibodies were raised against the five proteins, even 
in the three sera used as healthy controls, which might be due to 
previous asymptomatic pneumococcal colonization. Regarding IgM 
response, two out of the three patients raised these antibodies against 
the five selected proteins; the other patient  (patient #1) produced 
IgM antibodies against three proteins (Spr0121, Spr0328 and 
Spr0561). The three healthy donors raised IgM antibodies against 
Spr0561. In addition, control #3 showed anti- Spr0012 IgM 
antibodies. As observed in the figure, both the IgG and IgM 
responses against Spr0561 were very intense, which could mean that 
it is strongly immunogenic. This high immuno- genicity, which may 
be due to its highly surface exposure and size (it is a 2,144-amino acid 
cell-wall protein) could be also responsible for the presence of IgM 
antibodies in healthy donors if they had been previously colonized by 
pneumococcus. 
We have previously shown the utility of the detection of 
immunoreactivity against selected surface proteins for the discov- 
ery of diagnostic biomarkers of infection both in children and in 
adults [19]. In that study, we demonstrated that five known 
protective antigens raised antibodies in convalescent patients. In 
addition, a cell-wall protein, the alkaline pullulanase PulA, not 
previously tested at protection level, was shown to induce antibody 
response. Here we show the potential of four novel surface 
proteins (Spr0012, Spr0328, Spr0561 and  SP670_2141)  for 
vaccine testing, because of their capacity to raise immune response 
in infected patients. As expected, an IgM response against most of, 
or all the selected proteins, was obtained in the infected patient 
sera (2 out of 3), but much less in the control individuals (as stated 
above, only against Spr0561 in the three healthy donors and 
against Spr0012 in control #3). On the contrary, the five proteins 
induced IgG production both in the infected and the control 
people. The detection of IgG antibodies in healthy, control 
individuals may be explained by non-symptomatic carriage, which 
can mask a true discrimination among markers of  disease. 
Therefore, IgM detection should be a priori a better indicator of 
antigen exposure. However, the lower levels of these antibodies 
make them more difficult to detect, and factors such as timing in 
taking the samples may represent some limitations [71]. More 
sensitive, large scale formats for IgM-based protein  antigen 
detection are needed, as customized protein chips or Luminex 
assays. 
In conclusion, this study shows the utility of pan-surfomic 
approach in the high-trhoughput screening of proteins that could 
enter the pipeline for new vaccine discovery. The selection of the 
candidates from the proteomic analysis must be complemented 
with immunogenicity studies to determine the capacity of such 
proteins to raise an effective immune response. Further research is 
needed to test the protection capacity of the proposed proteins in 
animal models of infection, either individually or as ‘‘antigen 
cocktail’’ formulations. Although the main application field of such 
an approach is the discovery of new protein vaccines, the 
development of serological tools for detecting diagnostic biomark- 
ers, and/or the application in programs of epidemiological 
surveillance, is also very promising, especially if large-scale formats 
(protein arrays, Luminex assays) are set up. 
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4. Supporting Information
Table S1 Surface proteins identified in the 16 Streptococcus 
pneumoniae clinical isolates analyzed. Shown are the  locus 
numbers, gi accession numbers, protein function descriptions, 
subcellular localization according to LocateP, presence of the 
proteins in each isolate, and number of isolates in which each 
protein has been found. 
Dataset S1 Recombinant fragments produced in this work from 
the selected gene products. In gray are highlighted the sequences 
amplified (from the corresponding genes) and produced as 
recombinant polypeptides (from the corresponding amino acid 
sequences). Number of nucleotides amplified and amino acids 
expressed are indicated for each protein, as well as primers used 
for DNA amplification. 
Dataset S2 Sequest raw data of protein and peptide identifica- 
tions for S. pneumoniae clinical isolates 5074-5, 5104- 8, 5231-9V, 
5278-14, 5284-9V, 5330-7F, 5333-19A and 5334-8. Each isolate’s 
data are given separately in one or more datasheets.  
Dataset S3 Sequest raw data of protein and peptide identifica- 
tions  for  S.  pneumoniae  clinical  isolates  5335-5,  5337-7F,  5341-1, 
5342-3, 5343-14, 5344-19A, 5345-1 and 5431-12F. Each isolate’s 
data are given separately in one or more datasheets.  
Dataset S4 Representation of the sequences identified belonging 
to membrane proteins over the 50% threshold (see Table 3), and 
their frequency in the ‘‘pan- surfome’’ of the 16 Streptococcus 
pneumoniae clinical isolates analyzed. 
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1. Introduction 
Children are the most affected population group by pneumococcal disease. In fact, at least one 
child dies of pneumococcal disease every minute in the world, making it the leading cause of 
childhood pneumonia deaths in the developing world and the number one vaccine-
preventable cause of death in children worldwide (World Health Organization, Global 
Immunization Data, January 2008, page 2). Limitations in vaccination with polysaccharide 
conjugated vaccines were summarized previously, as well as the need for development of new 
serotype independent protein-based vaccines. In order to discover novel potential protein 
vaccine candidates, surface digestion of 24 clinical isolates from children was carried out and 
several survival assays, using the most promising protein vaccine candidates derived from the 
analysis, were done. Moreover, since there is evidence that early introduction of adequate 
therapy is critical for the final outcome, to discover new diagnostic biomarkers that allow a 
faster diagnosis with high sensitivity is necessary (1-3). Unfortunately, hospital-based 
surveillance frequently underestimates the burden of pneumococcal disease. Actually, the 
classical microbiological methods, such as Gram-staining and culture have a low sensitivity 
(they only detect 10% to 20% of pneumococcal pneumonia cases (4)), and there is a delay 
before results are available. Recently, new diagnostic tools have been developed. The 
BinaxNOW test, which measures Teichoic acid in urine, shows high sensitivity and specificity in 
adults (2). However, from a recently published cohort study in adults, was found that detection 
of teichoid acid in urine by immunochromatography when females with a pneumococcal 
colonization rate of 25% were included, the test sensitivity was 4.2% with a specificity of 97% 
and only 3% of the females with pneumococcal nasopharyngeal colonization were found to be 
positive (2). Other antigens have been studied to develop more sensitive and specific assays, 
such as PCR from blood against spn9802, pneumolysin gene (ply) or pcpA, although in serum it 
seems to be less sensitive than blood culture in adults (5-8). More recent studies, using more 
sensitive quantitative assays, have shown the opposite for lytA (9, 10), which have been shown 
to be more sensitive than detection of techoic acid in urine (11) and could be a useful tool for 
the assessment of the severity of pneumococcal pneumonia, since high genomic load was 
associated with higher likelihood of more severe disease and death (10). However, PCR has a 
high cost and the need for sophisticated instruments, infrastructure requirements and 
technical skills among personnel. 
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For all the reasons described above, development of diagnostic tools based in new candidates 
with better discriminatory ability to differentiate between healthy individuals and patients 
with pneumococcal disease is needed. For that purpose, LC/MS/MS after cell shaving is also a 
powerful tool thanks to the ability to select the most exposed areas (those areas most 
identified in a protein from multiple lines). Then, 95 pneumococcal proteins or fragments 
derived from pan-surfomic analysis were cloned and faced to 24 sera from human (healthy 
controls and pneumococcal disease patients) to test immunoreactivity of each one. All these 
analyses provided candidates to be tested for early detection of pneumococcal infection by 
serological tests.  
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2. Materials and Methods 
2.1. Ethics Statement for Human Sera Sampling and Use 
This research was performed according to the principles expressed in the Declaration of 
Helsinki. All human sera were obtained from patients admitted to Hospital Universitario 
Infantil Virgen del Rocío (HUIVR) in Seville, Spain. Sera were drawn either from patients with a 
diagnosis of pneumococcal infection, determined by isolation of the microorganism from a 
sterile site (blood or pleural fluid) according to standardized protocols or from healthy control 
children aged <8 years old. All sera from patients were obtained within ten days of hospital 
admission. Written informed consent was obtained from parents or legal guardians of 
participating children and the Hospital Universitario Virgen del Rocío Ethic Committee 
approved the study (code no. 010470, certificate no. 14/2010), for sera to be used within the 
project in which this work was designed. 
2.2. Bacterial strains and growth 
Pneumococcal strains used in the “shaving” of live cells were isolated from human patients. All 
the strains were kept at -80ºC, plated on Columbia blood agar base containing 6% (v/v) sheep 
blood and grown at 37ºC and 5% CO2 until in a chemically-defined medium (CDM) (54), 
supplemented with 20 μg/ml ethanolamine (CDM+EA) as the source of aminoalcohol (55).  
2.3. Molecular Genotyping 
MLST was performed using standard methodology (56). In brief, internal fragments of 7 
housekeeping genes (aroE, gdh, gki, recP, spi, xpt and ddl) were amplified by polymerase chain 
reaction and sequenced on each strand. Conventional primers were used, whose sequences 
are available at the MLST database (http://www.mlst.net). Alleles were assigned by comparing 
the sequence at each locus to all known alleles at that locus, and the combination of 7 alleles 
determined the sequence type (ST). Allele and ST designations were made using the MLST 
website, hosted at Imperial College London, and funded by the Wellcome Trust. 
2.4. ‘‘Shaving’’ of Live Pneumococcal Cells with Trypsin 
Bacteria from 100ml of culture were harvested by centrifugation at 3500×g for 10min at 4 °C, 
and washed twice with PBS. Cells were resuspended in one-hundredth volume of PBS 
containing 30% sucrose (pH 7.4) as trypsin incubation buffer. Tryptic digestions were carried 
out with 5 μg trypsin (Promega) for different times at 37 °C. The digestion mixtures were 
centrifuged at 3500×g for 10min at 4 °C, and the supernatants (the “surfomes” containing the 
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peptides) were filtered using 0.22-μm pore-size filters (Milipore). Surfomes were re-digested 
with 2 μg trypsin overnight at 37 °C with top–down agitation. Before analysis, salts were 
removed using Oasis HLB extraction cartridges (Waters). Peptides were eluted with increasing 
concentrations of acetonitrile/0.1% formic acid, according to manufacturer's instructions. 
Peptide fractions were concentrated with a vacuum concentrator (Eppendorf), and kept at 
−20°C until further analysis. 
2.5. LC/MS/MS Analysis 
All analyses were performed with a Surveyor HPLC System in tandem with an LTQ-Orbitrap 
mass spectrometer (Thermo Fisher Scientific, San Jose, USA) equipped with nanoelectrospray 
ionization interface (nESI), as described [19]. The separation column was 150 mm60.150 mm 
ProteoPep2 C18 (New Objective, USA) at a postsplit flow rate of 1 ml/min. For trapping of the 
digest a 5 mm60.3 mm precolumn Zorbax 300 SB-C18 (Agilent Technologies, Germany) was 
used. One fourth of the total sample volume, i.e. 5 ml, was trapped at a flow rate of 10 ml/min 
for 10 minutes and 5% acetonitrile/0.1% formic acid. After that, the trapping column was 
switched on-line with the separation column and the gradient was started. Peptides were 
eluted with a 60-min gradient of 5–40% of acetonitrile/0.1% formic acid solution at a 250 
nl/min flow rate. All separations were performed using a gradient of 5–40% solvent B for 60 
minutes. MS data (Full Scan) were acquired in the positive ion mode over the 400–1,500 m/z 
range. MS/MS data were acquired in dependent scan mode, selecting automatically the five 
most intense ions for fragmentation, with dynamic exclusion set to on. In all cases, a nESI spray 
voltage of 1.9 kV was used. 
2.6. Protein Identification by Database Searching 
Tandem mass spectra were extracted using Thermo Proteome-Discoverer 1.0 (Thermo Fisher 
Scientific). Charge state deconvolution and deisotoping were not performed. All MS/MS 
samples were analyzed using Sequest (Thermo Fisher Scientific, version v.27), applying the 
following search parameters: peptide tolerance, 10 ppm; tolerance for fragment ions, 0.8 Da; 
b- and y-ion series; oxidation of methionine and deamidation of asparagine and glutamine 
were considered as variable modifications; maximum trypsin missed cleavage sites, 3. The raw 
data were searched against an in-house joint database containing the protein sequences from 
all the sequenced and annotated S. pneumoniae strains available at the UniprotKB site. 
Peptide identifications were accepted if they exceeded the filter parameter Xcorr score vs 
charge state with SequestNode Probability Score (+1 = 1.5, +2= 2.0, +3= 2.25, +4= 2.5). With 
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these search and filter parameters, no false-positive hits were obtained. Proteins were 
accepted if were identified from two or more peptides. Strain R6 was used as reference for 
providing the accession numbers of the identified proteins; whenever a protein belonging to 
another strain was found, homology with a corresponding protein of strain R6 was given by 
using protein- BLAST. If homology with R6 or TIGR4 proteins was not observed, then the 
protein accession numbers of the other strains were used. 
2.7. Bioinformatic analysis 
Primary predictions of subcellular localization were assigned by using the web-based algorithm 
LocateP (http://www.cmbi.ru.nl/ locatep-db/cgi-bin/locatepdb.py). They were contrasted by 
several feature-based algorithms: TMHMM 2.0 (http://www.cbs.dtu. dk/services/TMHMM-
2.0) for searching transmembrane helices; SignalP 3.0 (http://www.cbs.dtu.dk/services/SinalP) 
for type-I signal peptides: those proteins containing only a cleavable type-I signal peptide as 
featured sequence were classed as secreted; LipoP (http://www.cbs.dtu.dk/services/LipoP) for 
identifying type-II signal peptides, which are characteristic of lipoproteins. Topological 
representations of membrane proteins were performed with the web-based TOPO2 software 
(http://www.sacs.ucsf.edu/TOPO2/). GO annotations were retrieved from the UniProt 
Knowledgebase (http://www.uniprot.org/). GO annotations were annoted using a webserver 
from The University of Adelaide (http://genomes.ersa.edu.au/BacteriaGO/submissions.php). In 
silico prediction of protein vaccine candidates was done first using the protein vaccine design 
server Jenner-Predict (http://117.211.115.67/vaccine/job_submission.html). Evolutionary 
relationship of pneumococcal strains used in “shaving” live cells experiments was performed 
using eBurst v3 (http://spneumoniae.mlst.net/).  
2.8. Pneumococcus recombinant proteins 
Recombinant proteins were produced as GST-tag recombinant fragments using the pSpark® 
vector, Canvax Biotech, Córdoba, Spain, and expressed in Escherichia coli BL21. 
2.9. Protein Array 
2.9.1. Microarray fabrication/Protein immobilization 
Protein arrays were printed by quintuplicate as is detailed in FIG SX with split pins (pin tool 
4x4) using a robotic array spotter (Genomic Solutions, BioRobotics MicroGrid II 610). Proteins 
were distributed into 384-well plates at 2 wells per sample and 30 μL per well. Each 
component was prepared at 250 μg/mL in print buffer (150 mM Phosphat, pH 8.5, 0.01 % 
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sarkosy) onto Nexterion Slide H 3-D glass slides. The pins were dwelled into the sample wells 
and blotted 15 times before printing. The humidity level in the arraying chamber was 
maintained at 55-60% during printing. Each of the components was printed five times in a grid 
of 140 μm diameter spots with 175 μm pitch. Twelve complete arrays were printed on each 
slide. Printed slides were placed in a slide humidity chamber overnight at 75% relative 
humidity and stored at -20°C until use. 
2.9.2. Microarray binding assay 
The binding experiment was carried out in duplicate. Slides were blocked with 25 mM 
ethanolamine in 100 mM sodium borate buffer (final pH 8.5) and washed 3 × 1min in PBST 
(PBS with 0.05% Tween 20) and 1 x 1 min in diH2O. Then the slides were allowed to dry by 
centrifugation (350 x g for 15 min). Then were assembled on 16-well slide holders (Nexterion 
Slide H MPX 16) and 45µl of a dilution of different sera (1:200 in PBST) were allowed to 
incubate for 1 h protected from light at room temperature. The different samples were 
washed with 100µl of PBST 2 x 2 min and then incubated with IgG-Cy3 (1:1000) or IgM-Cy5 
(1:200) depending of the assay, covered tightly with a seal strip, and allowed to incubate for 1 
h at room temperature. The slides were removed from holders, washed 2 × 10 min in PBST, 1 x 
10 min in PBS and then centrifuged 350 x g for 15 min. 
2.9.3. Image processing 
Slides were scanned with a Genepix 4000B microarray scanner (Molecular Devices 
Corporation, Union City, CA) at PMT voltage settings where no saturated pixels were obtained. 
Image analysis was carried out with Genepix Pro 4.1 analysis software (Molecular Devices 
Corporation, Union City, CA). Spots were defined as circular features with maximum diameter 
of 140 μm. Local background subtraction was performed and corrected median feature 
intensity, F532median-B532, was used for initial data processing. 
2.9.4. Statistics 
Statistical analyses were performed using SPSS v 21.0.0.0 and MultiExperiment Viewer 
(MeV4.9.0). Student’s t test (2-tailed) was applied for experiments involving pairwise 
comparisons. To microarray analysis, outlier values (upper and lower) for each spot were 
removed and normalization was carried out in Microsoft Excel. Normalized data were run in 
the MeV software. A t-test assuming equal group variances with p-values bases on t-
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distribution adjusting FDR with standard Bonferroni correction was carried out. ROC curves 
analyses were carried out with MedCalc 12.7.8. 
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3. Results and Discussion 
3.1. Strains collection 
For the present study, we analyzed 24 clinical isolates collected from children patients with 
invasive pneumococcal disease (IPD), which corresponded to 12 different serotypes. These 
serotypes included the five most prevalent ones found in IPD among young people in Spain 
during the most recent years (1, 19A, 3, 7F and  14) (12, 13) and 85% of pneumococcal cases in 
the last ten years in Spain according to Pneumococcal Molecular Epidemiology Network 
(PMEN) (http://www.sph.emory.edu/PMEN). Serotypes 9V and 19F had been circulating 
significantly in this population in pre- and post-PCV7 periods. Because genetic diversity of 
pneumococcal surface proteins is capsular independent, we genotyped all clinical isolates by 
MLST. Twenty clonal types were found including several major global clones recognized by the 
PMEN as shown in Table 1.  
Nevertheless, evolutionary relationship between them was poor (SDS 3.1). The most relevant 
among then were: ST156 (Spain9V-3), one of the most successful clones worldwide that has 
been especially responsible for the expansion of serotype 14 in IPD in various countries during 
recent years (14); ST306 (Sweden1-28), a highly circulating genotype associated with the 
increase in the incidence of pleural empyema in children and adults in the last decade (15, 16); 
ST180 (Netherlands3-31), most commonly found clonal type in serotype 3 that is associated to 
increased risk of mortality in pneumococcal pneumonia (17, 18); and finally, ST191 
(Netherlands7F-39), the dominant clonal type associated to the emerging serotype 7F during 
the post-PCV7 period (19). 
3.2. Pan-surfomic analysis on pneumococcal clinical isolates from 
children 
In order to overcome the limitations of serotype-dependent polysaccharide capsule 
vaccines (20), we applied the optimized “shaving” protocol for pneumococcus to the 
collection of 24 children clinical isolates (21). A total of 624 surface proteins were 
identified (Table S1 o.f. and SDS2 o.f.), and the yields of surface protein identification ranged 
between 20% and 40%, approximately (Figure 1C), the same as in the pan-surfome of 
clinical isolates from adults. Most of them, (158+320 = 478, i.e. 51.3%) were predicted as 
proteins with one (1TMD) or more than one (>1TMD) respectively by LocateP, 54 (8.6%) 
as lipoproteins, 38 (6.1%), as possessing an LPXTG-anchoring motif to the cell wall and 54 
(8.6%) as secreted (Figure 1A).  
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Isolate ST 
Allelic profile 
(MLST)* 
Serotype PMEN clone** 
1 R6 (NT) - 2 
2 304 13,8,13,4,17,4,8 1 Sweden1-40 
3 306 12,8,13,5,16,4,20 1 Sweden1-28 
4 228 12,8,1,5,17,4,20 1 
5 228 12,8,1,5,17,4,20 1 
6 228 12,8,1,5,17,4,20 1 
7 260 26,9,15,14,9,16,19 3 
8 180 7,15,2,10,6,1,22 3 Netherlands3-31 
9 1221 7,5,1,5,15,12,14 4 
10 1223 16,12,9,1,6,33,33 5 SLV-Colombia5-19*** 
11 191 8,9,2,1,6,1,17 7F Netherlands7F-39 
12 156 7,11,10,1,6,8,1 14 Spain9V-3*** 
13 2204 5,6,1,95,6,3,54 14 
14 62 2,5,29,12,16,3,14 14 
15 113 7,2,1,1,10,1,21 18C Netherlands18C-36 
16 113 7,2,1,1,10,1,21 18C Netherlands18C-36 
17 276 2,19,2,17,6,22,14 19A SLV-Denmark14-32 
18 276 2,19,2,17,6,22,14 19A SLV-Denmark14-32 
19 202 8,16,19,15,6,40,26 19A 
20 88 5,5,7,7,8,5,7 19F 
21 81 4,4,2,4,4,1,1 23F Spain23F-1 
22 1876 7,25,4,12,15,20,28 6A 
23 94 5,6,1,2,6,3,54 6B 
24 386 32,28,1,1,15,52,14 6B 
25 838 7,11,10,1,6,8,90 9V SLV-Spain9V-3 
Table 1. Sequence types (STs) and serotypes among 25 Streptococcus pneumoniae invasive isolates recovered from adult 
patients. *Allelic profiles for each gene in multilocus sequence typing (MLST) are presented in the following order: aroE, gdh, gki, 
recP,spi, xpt and ddl. **PMEN clones are global clones recognized by pneumococcal molecular epidemiology network. ***SLV = 
single locus variant (i.e. differs at only one MLST locus and thus is a closely-related genotype). 
140 (22.4%) were predicted as protein vaccine candidates by Jenner-Predict (Table S1). Figure 
3.1B shows the GO annotations according to their biological function. We observed a high 
number of proteins with unpredicted functions (373, 59.8%) and among those with biological 
assignment, the most abundant were those related to metabolism (154, 28.5%), cellular (133, 
24.6%) and single-organism processes (108, 20.0%). Interestingly, all surface proteins 
annotated as pathogenesis-related in the reference   strain R6, where   902 of   2042   (44.17%) 
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proteins are annotated with GO, were identified in the pan-surfome analysis. As well as in 
Chapter II, most of proteins that have shown to induce both protection against pneumococcal 
infection in animal models or immunoreaction using human sera (Appendix II) were identified 
in our pansurfomic, such as PspA (22), CbpA (23) and PcsB (24).  
As mentioned, to consider a protein as good vaccine candidate, this must be surface and highly 
expressed under the conditions of infection and distributed as widely as possible (25). 
Although experimentally identifying a high number of proteins common to all the analyzed 
strains is difficult either low or high number of clinical isolates (21, 26-28) we identified 17 
common proteins in the pan-surfome of clinical isolates from adults (FstH, StrH (Spr0057), 
PspA, PulA, Spr0328, Spr0334, PrtA, BgaA (Spr0565), ZmpB (Spr0581), PhtD, PhtE, Spr0931, IgA 
(Spr1042), AliB, Spr1403, NanA, PcsB) applying the threshold of presence for a given protein in 
at least 50% of clinical isolates analyzed. In total, 43 surface proteins surpassed this threshold 
(Table 2). Although proteins with >1TMD was the category of surface proteins with the highest 
number of proteins, this is due to more loose blast conditions applied in this work in order to
Figure 1. Pan-surfomic analysis of pneumococcal 
children clinical isolates. A) Subcellular localization of 
the predicted surface proteins, according to LocateP 
(TMD: transmembrane domain. B) Gene Ontology 
annotations of the biological functions of the identified 
surface proteins. Go annotated code: metabolic process 
(MP), cellular process (CP), cellular component 
organization or biogenesis (CC), biological regulation 
(BR), single-organism process (SO), response to 
stimulus (RS), developmental process (DP), 
establishment of localization (EL), biological adhesion 
(BA), multi-organism process (MO), reproduction (Re), 
cell killing (CK), localization (Lo). C) Yield of surface 
protein identification after trypsin treatment in each of 
the 25 analyzed isolates. 
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define more rigorously the common areas of homologous proteins. In fact, 8 zinc 
metalloproteases ZmpB and 6 immunoglobulin A1 proteases were identified from the different 
databases. Five proteins with 1TMD (that included protective antigens PspA and PhtD) and 
other 15 cell wall-anchored proteins were found, including the protein vaccine tested in 
human PrtA; the most immunogenic protein in a survival assay using extracellular vesicles 
from pneumococcal serotype 8 in a mice model, LytC (spr1431) (see in Chapter IV); and two of 
the most widely distributed in adults too, PulA and Spr0328 (annotated in the R6 genome as 
cell wall surface anchor family protein). All of these were present in more than 50% of clinical 
isolates analyzed. Two lipoproteins were also found, AliA (Spr0327) and AliB, whose protective 
activity has been previously reported (Appendix II). Finally, 4 secreted-predicted proteins were 
identified, including PhtE and PcsB. Of special interest is also the protein PblB (Sph_0062), a 
bacteriophage protein, found in more than 80% of clinical isolates. On one hand, it is 
annotated as cytosolic by LocateP, but with inconclusive results in PsortB. On the other hand, 
this protein is an example of the need to expand the search to the maximum possible number 
of database because it is not found in the R6 and TIGR4 strains, so it would have been 
impossible to identify.There are two versions, i.e., SP670_0091 and SP670_2139, in the 
different databases which differ in the N-terminal end, which can be shorter, losing a prophage 
endopeptidase tail which is probably acting as endopeptidases. If we consider one function-
one protein, although differences in primary structure were noted, the results given by the 
repeats homologous proteins, LPXTG-anchoring motif are the most protruding and surface 
exposed on the pneumococcal surface (29) as we have reported in previously results of 
streptococcal pan-surfomes (21, 27, 28).  
3.3. Selection of proteins and fragments for cloning 
Any portions of surface-exposed regions are a priori good for cloning in order to produce 
recombinant fragments for vaccine candidates or serological testing. Thus, cell-wall anchored, 
secreted proteins and lipoproteins, except for some small regions, are almost completely 
surface-exposed, as well as different fragments of the predicted membrane proteins (i.e. those 
with one or >1TMD). In “shaving” experiments, although predicted membrane proteins were 
normally the most abundant surface protein group, they represented the lowest percentage 
compared to other groups of the corresponding total number of predicted proteins in 
databases (30-32). If they were too long to select the entire sequence, we had to choose those 
areas most surface-exposed taking into account the theoretical areas embedded in the poly-
Ph. D. Thesis – Alfonso Olaya Abril Chapter III 
134 
Ph. D. Thesis – Alfonso Olaya Abril Chapter III 
135 Ta
b
le
 2
. 
S
u
rf
a
ce
 p
ro
te
in
s 
id
en
ti
fi
ed
 i
n
 $
5
0
%
 c
li
n
ic
a
l 
is
o
la
te
s 
b
y
 ‘
‘s
h
a
v
in
g
’’
 S
tr
ep
to
co
cc
u
s 
p
n
eu
m
o
n
ia
e 
ce
ll
s 
fo
ll
o
w
ed
 b
y
 L
C
/M
S
/M
S
 a
n
a
ly
si
s.
 P
ro
te
in
 c
at
eg
o
ri
es
 w
er
e 
es
ta
b
li
sh
ed
 a
cc
o
rd
in
g
 t
o
 L
o
ca
te
P
 
su
b
ce
ll
u
la
r 
p
re
d
ic
ti
o
n
s:
 l
ip
o
p
ro
te
in
s 
w
er
e 
th
o
se
 p
re
d
ic
te
d
 a
s 
li
p
id
-a
n
ch
o
re
d
 p
ro
te
in
s;
 c
el
l 
w
al
l 
p
ro
te
in
s,
 a
s 
th
o
se
 h
av
in
g
 a
n
 L
P
X
T
G
 m
o
ti
f;
 s
ec
re
to
ry
 p
ro
te
in
s,
 a
s 
th
o
se
 p
o
ss
es
si
n
g
 a
n
 S
P
1
-t
y
p
e 
si
g
n
al
 p
ep
ti
d
e;
 
m
em
b
ra
n
e 
p
ro
te
in
s 
w
it
h
 o
n
e 
tr
an
sm
em
b
ra
n
e 
d
o
m
ai
n
 (
T
M
D
),
 a
s 
th
o
se
 p
o
ss
es
si
n
g
 e
it
h
er
 a
 C
- 
o
r 
an
 N
-t
er
m
in
al
ly
 a
n
ch
o
re
d
 t
ra
n
sm
em
b
ra
n
e 
re
g
io
n
; 
m
em
b
ra
n
e 
p
ro
te
in
s 
w
it
h
 >
1
T
M
D
, 
th
o
se
 p
re
d
ic
te
d
 a
s 
m
u
lt
i-
tr
an
sm
em
b
ra
n
e 
p
ro
te
in
s;
 ‘
‘s
u
rf
ac
e 
p
ro
te
in
s’
’ 
m
ea
n
s 
th
e 
su
m
 o
f 
th
e 
fi
v
e 
p
re
v
io
u
s 
ca
te
g
o
ri
es
; 
an
d
 c
y
to
p
la
sm
ic
 p
ro
te
in
s,
 t
h
o
se
 w
it
h
o
u
t 
an
y
 e
x
p
o
rt
in
g
 o
r 
so
rt
in
g
 s
ig
n
al
, 
an
d
 p
re
d
ic
te
d
 a
s 
in
tr
ac
el
lu
la
r 
p
ro
te
in
s.
 G
en
e 
O
n
to
lo
g
y
 a
n
n
o
ta
ti
o
n
s 
o
f 
th
e 
b
io
lo
g
ic
al
 f
u
n
ct
io
n
s 
o
f 
th
e 
id
en
ti
fi
ed
 s
u
rf
ac
e 
p
ro
te
in
s.
 G
o
 a
n
n
o
ta
te
d
 c
o
d
e:
 m
et
ab
o
li
c 
p
ro
ce
ss
 (
M
P
),
 c
el
lu
la
r 
p
ro
ce
ss
 (
C
P
),
 c
el
lu
la
r 
co
m
p
o
n
en
t 
o
rg
an
iz
at
io
n
 o
r 
b
io
g
en
es
is
 (
C
C
),
 
b
io
lo
g
ic
al
 r
eg
u
la
ti
o
n
 (
B
R
),
 s
in
g
le
-o
rg
an
is
m
 p
ro
ce
ss
 (
S
O
),
 r
es
p
o
n
se
 t
o
 s
ti
m
u
lu
s 
(R
S
),
 d
ev
el
o
p
m
en
ta
l 
p
ro
ce
ss
 (
D
P
),
 e
st
ab
li
sh
m
en
t 
o
f 
lo
ca
li
za
ti
o
n
 (
E
L
),
 b
io
lo
g
ic
al
 a
d
h
es
io
n
 (
B
A
),
 m
u
lt
i-
o
rg
an
is
m
 p
ro
ce
ss
 (
M
O
),
 
re
p
ro
d
u
ct
io
n
 (
R
e)
, 
ce
ll
 k
il
li
n
g
 (
C
K
),
 l
o
ca
li
za
ti
o
n
 (
L
o
).
 J
P
=
P
re
d
ic
te
d
 a
s 
p
ro
te
in
 v
ac
ci
n
e 
ca
n
d
id
at
e 
b
y
 J
en
n
er
-P
re
d
ic
t 
al
g
o
ri
th
m
. 
#
N
u
m
b
er
 o
f 
cl
in
ic
al
 i
so
la
te
s 
(o
f 
2
5
) 
in
 w
h
ic
h
 t
h
es
e 
p
ro
te
in
 h
av
e 
b
ee
n
 i
d
en
ti
fi
ed
. 
Ph. D. Thesis – Alfonso Olaya Abril Chapter III 
136 
-saccharide capsule, possible solubility problems and degree of conservation among different 
strains. The best strategy to use them as vaccine or diagnostic tool candidates would be to 
select those domains that are experimentally confirmed to be surface-accessible. For this 
reason, we represented the peptides identified after LC/MS/MS analysis over the topology 
predictions for the corresponding sequences of the 22 membrane proteins shown in Table 2 
(Figure 2). For 13 proteins, peptides identified were in agreement with the predicted 
topologies corresponding to extracellular domains. However, discrepancies were observed, 
not in the location of the identified peptides, but the subcellular localization predicted by 
LocateP. PbpA (Spr1823) was originally annotated as 1TMD protein by LocateP and TMHMM 
but Psort, PsortB and SignalP predicted its location as secreted protein. For this reason is not 
shown in Figure 2. Similar occurred with PhtD, which was predicted as 1TMD protein by 
LocateP, but TMHMM did not recognize any transmembrane domain and SignalP any 
exporting signal sequence; however, Psort and PsortB recognized 1TMD. Discrepancies were 
also observed in other 8 proteins. Six of them are different homologous of the same protein, 
the multi-transmembrane domain protein (by LocateP) IgaA. However, all IgaAs are predicted 
as cell-wall anchored proteins by PsortB and most of them have 3 transmembrane domains 
recognized by TMHMM, except IgA, for which discrepancies were observed because identified 
peptides correspond to the only transmembrane domain predicted by TMHMM and an 
exporting-signal peptide is recognized by SignalP. Six of these IgaAs (Sp70585_1207, 
Spap_1059, Spg_1053, Spn23F10580, Spr1042 and Spt_1181) showed identified peptides 
belonging to predicted cytoplasmic domains, which could be due to residual lysis or because 
prediction algorithms do not always correctly predict the topology, as has been previously 
reported (31-33) or even experimentally demonstrated (31). A deeper analysis on the 
identified peptides for each individual isolate provided the “hot zones” (i.e. those identified in 
more strains) for selection of cloning fragments in case of very large proteins. 
Finally, 95 fragments were cloned for the selection of protein antigens with vaccine and 
diagnostic potential. To choose these proteins (listed in Appendix II) we used the pan-surfomic 
analysis of clinical isolates from children and we selected those common proteins identified in 
at least 50% of the isolates, others previously identified as vaccine candidates and others 
selected in silico. Fragments cloned for each protein, as well as primers used and peptides 
identified are shown in SDS3 o.f.. 
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Figure 2. Topology representation of the predicted membrane proteins in the ‘‘pan-surfome’’ of the 25 S. pneumoniae clinical 
isolates that have been identified in at least 50% of the analyzed strains. The TMHMM algorithm was used to predict 
transmembrane domains (TMD) and signal peptides after prediction of subcellular localization by LocateP. In red are shown the 
peptides experimentally identified by LC/MS/MS.  
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4. Pneumococcal protein microarray construction and hybridation The 
interest in serological diagnosis of pneumococcal infection has been renewed by the 
identification of new diagnostic tests based on pneumococcal surface proteins 
seroreactivity (1, 3, 34). Although some epidemiological studies were carried out, they 
were based on a reduced set of proteins that showed unclear patterns of antibody 
response when applied to heterogeneous cohorts of patients (34-36). Serological diagnosis 
of pneumococcal disease is a challenging task because it may be able to discriminate 
between antibody responses due to non-symptomatic colonization and disease and 
difficulties in obtaining acute and convalescent sera from pediatric  patients (3). Thus, to 
investigate the establishment of the humoral immunity during invasive pneumococcal 
disease (IPD), mainly empyema, and to evaluate their potential as serological test to 
diagnose pneumococcal infection, we developed an array for testing 95 pneumococcal 
proteins (or fragments of them) (previously described). Proteins were linked to the array in 
quintuplicate and ordered from 1 to 95 (plus negative and buffer controls) for each 
replicate (Figure 3). We used sera from patients with pleural empyema (PE) because this 
severe complication of pneumonia has been increasing worldwide over the last decade and 
it is generally difficult to diagnose etiologically with microbiological culture due to high 
rates of antibiotic treatment prior to sample collection (37-40) (Table S3). Moreover PE 
incidence increased significantly after PCV7 introduction and the second generation of 
conjugate pneumococcal vaccines included additional serotypes that targeted those 
capsular types more commonly identified in this pulmonary complication (38, 39, 41-43). 
Arrays were probed with a collection of sera obtained from patients with 
proven pneumococcal pulmonary infections and different ages that ranged from 8 to 113 
(Group 1: 5 sera from 0 to 24 months, Group 2: 5 sera from >24-60 and Group 3: 7 >60 
months) (Figure 4) shows a representative image of the microarray hybridized with the 
patient sera. Their serological reactivity for IgG (A) and IgM (B) is shown as a heatmap 
where the antigens are sorted by increasing normalized global mean intensity, with bright 
green having the weakest intensity, red being the strongest, and black in between. 
To establish a serological marker for pneumococcal disease we were interested in determining 
the most seroprevalent antibodies in the IPD and how their humoral response compared with 
the negative control group (healthy patients). Antigens reacting with the most seroprevalent 
antibodies were defined as those having significantly most elevated signal mean intensity 
(SMI) values and most marked changes in SMI antigen reactivity compared to healthy sera and 
without homology to other close commensal species. However, this last requirement is really 
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difficult due to commensal relationships with other streptococcal species such as S. mitis or S. 
sanguinis. According to the SMI values (SDS3.4a, 3.4b, 3.4c, 3.4d o.f.), we found in the top-25  
Figure 3. Protein distribution on array chip. Each protein was printed in quintuplicate as far as possible. 
IgG and IgM serodominant antigens, among which are included many previously characterized 
antigenic proteins such as CbpA, PcsB, Ply, PhtE or Eno (Spr1036), but also others no 
previously characterized as PrtA, Spr1875, LytC, PulA and the C-terminal fragment of PblB 
(Table 3). The SMI to the top-25 serodominant antigens was 5,068 in pneumococcal patients 
and 11,650 in healthy individuals for IgG response and 1,661 and 1,389 for IgM response 
respectively. By age groups, we observed an age-dependent increasing SMI (Group 1: 4,131; 
Group 2: 5,250; and Group 3: 5,567) and (Groups 1: 1,509; Group 2: 1,722; and Group 3: 
1,738) for IgG and IgM response respectively.  
3.5. Identification of antigens correlative with pneumococcal disease 
To determine stage-specific biomarkers of pneumococcal disease, the normalized 
serological profiles of patients with pneumococcal disease were compared to those found 
in healthy patients. Serodiagnostic antigens were defined as having an IgG and IgM response 
significantly different in patients as compared to the negative control groups adjusted p-
values <0,01. Comparing all problem sera against healthy sera, we observed 22 proteins 
that met the requirement previously described for IgG analysis (SDS3.4e o.f.). Among 
these   proteins   we found  novel vaccine  candidates,  such as, PulA, PrtA, LytC and 
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Figure 4. Prevalence of the serodominant anti-pneumococcal proteins IgGs (A) and IgM (B) in the study population. (C, D) 
Two-way hierarchical cluster of the top-25 serodominant antibodies against IgG and IgM respectively (rows), and serum specimens 
(columns) from pneumococcal patients and healthy individuals (n = 8). (E) Two-way hierarchical cluster of statically different 
protein in IgG analysis. The color scale ranks the antigens with red being the strongest, bright green the weakest, and black in 
between.3.2.5. IgG and IgM antibody profile of patients with pneumococcal infections. 
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Table 3. The 25 most serodominant antigens in pneumococcal patients in IgG and IgM analysis. 
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PblB_ct, which could be explained because they are among the most surface-exposed 
ones according to our pan-surfomic analysis. We observed other pneumococcal proteins 
such as Ply, Eno, PcsB, PppA or CbpA, both cytosolic and surface-located, which could be 
possibly due to autolysis (44, 45) and/or membrane-derived vesicles release (46-48). It is 
noteworthy that all proteins that were significantly different due to their SMI were lower in 
patients compared to controls.
To this regard, antibody levels to pneumococcal proteins increase over time in 
younger children following NP colonization and acute otitis media (AOM) but with 
significant differences in quantity of antibodies both among these antigens and children 
(49). Lower IgG responses in cases than in control have been found for anti-PcpA 
antibody titers in sera collected in the acute phase of pediatric pneumococcal community 
acquired pneumonia. (34). In addition, otitis prone children compared to non-otitis 
prone children have lower percentages of memory B cells to 3 pneumococcal protein 
antigens (PhtD, PhtE, and Ply) and reduced antigen-specific immunoglobulin G 
concentrations (50). On the other hand, younger infected children (> 6 months of age) have 
reduced global antibody responses against proteins compared to control, likely because 
maternal derived antibodies are depleted during infection and there is not a  significant 
own humoral response. Whether lower pre-existing natural antibodiy titers against these 
proteins in patients are a marker for increased susceptibility to pneumococcal pneumonia 
and/or reflect early antibody consumption during pneumococcal pneumonia before a 
significant humoral response in the host occurs, should be elucidated in future studies with 
larger number of patients and age-adjusted controls along with strict time points for 
sampling patients during early course of disease). When stratifying by age groups, we 
found that 10 proteins had significantly lower SMI levels than controls in all groups 
compared to healthy controls (LytA, Eno, PulA, PrtA, PcsB, Spr1527, Spr0747, Spr0334, 
PblB_ct and PppA). GlnP (Spr1120), predicted as having more than one transmembrane 
domain protein and found in 12 clinical isolates in the pan-surfomic analysis and was the 
only antigen that showed significantly higher SMI level in problem cases. Spr1527 and 
Spr0747 are predicted lipoproteins and selected by in silico criterion, which shows that 
pan-surfomic analysis must be completed with in vitro approaches seeking to replicate what 
happens in vivo. In an IgM SMI response analysis we did not observe proteins significantly 
different in patients compared to healthy controls (in all or by any age-groups): only SpxB 
(Spr0642), RrgA, Spr1875, RrgC, ComA (Spr0043), Spr1403, Spr0601 and Spr1221 were 
close to show statistically significant differences (data not shown). SpxB is common to IgG 
SMI analyses, which suggest that IgG and IgM antibodies are produced against this antigen 
over a long phase of infection. 
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RrgA and RrgB, predicted as cell-wall anchored proteins, are pilus-component element and 
have been described as virulence factors (51). Spr0601 and Spr1221 were selected according 
to an in silico criterion.  
If antibody  titers to different proteins changes over time in healthy individuals and a 
diminished IgG response to many proteins  is present in the acute phase of pneumococcal 
disease it is important to analyze whether changes in the  more immunoreactive proteins 
occur related to age or disease status. We found that the same proteins were in the top-10 by 
age-groups with regard to IgG response: CbpA, Ply, PcsB, LytA (Spr1754), our protein vaccine 
candidate PrtA, PfbB, Spr0286 (HysA), and Spr0693. The last two, a cell wall-anchored and one 
transmembrane domain proteins, were chosen for this analysis by in silico criterion. In the top- 
25 we found other protein vaccine candidates from our pan-surfomic analysis as LytC, Spr0328, 
PulA, Spr1785 and PblB. In contrast, IgM response varied with age and we found differences in 
the top-10. Only LytA is present in the first position in all groups and then we found Eno, Ply, 
PhtA, SpxB, CbpA and Spr1645 (an ABC transporter substrate-binding protein chosen by in 
silico criterion).  However, none of these criteria is capable, by itself, to grant a valid candidate 
to discriminate patients with pneumococcal disease with healthy children in any group-age 
(Figure 4 and 5). Only   when we used those candidates  present  in the top25 SMI ranking 
and the most significantly different (FDR <0.02) from controls for each groups, we improved 
the results (Figure 5 E and J). Using all   sera we obtained  four protein candidates, LytA, PulA, 
PblB and PrtA, which were able to distinguish fairly well a state of pneumococcal disease 
compared to healthy controls. When we compared children under 5-years with healthy 
controls, we could reduce to PrtA and Eno. Comparing up to 2-years children with controls we 
found that Eno, Ply, LytA and PcsB were able to distinguish illness from health. 
Nevertheless, according to our serodominant definition, 8 fragments of our cloned proteins 
met the 3 first requirements in the IgG analysis: PcsB, Ply, Eno, PrtA, LytC, PulA, PblB and LytA. 
In order to check possible homologies with closer species, Blast-analysis excluding S. 
pneumoniae was carried out. PblB and LytA presented the best results because they showed 
homologies only with streptococcal phages. The other fragments presented homologies with 
other streptococcal species such as Streptococcus pseudopneumoniae, S. parasanguinis, S. 
mitis, S. australis and S. infantis, from 92% of PrtA, LytC and PulA with S. parasanguinis, S. mitis 
and S. pseudopneumoniae, respectively, to 99% for the rest of fragments with the same 
species. Considering this requirement, Eno, PcsB and Ply were discarded. With the resulting 
candidates (Table 4) we tried to improve the sensitivity and  accuracy of  the serodiagnostic 
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test using multiple independent antigens (52). To this aim, we used two-way hierarchical 
cluster analysis on positive and negative sera and receiver operating characteristic (ROC) 
curves to study the discriminatory power of different sets of proteins. In the two-way 
hierarchical cluster, we found that a combination of PblB, LytA, PrtA, PulA and LytC proved 
Figure 5. Prevalence of the serodominant anti-pneumococcal proteins IgGs and IgM in the study population by age-groups. 
(A) IgG analysis of age-groups 1 and 2 (G1+G2) of all proteins contained in the array. (B) Two-way hierarchical cluster of the top-25 
serodominant antibodies against IgG in G1+G2. (C) Two-way hierarchical cluster of the most statically different protein in IgG 
analysis in G1+G2. (D) IgM analysis of G1+G2 of all proteins contained in the array. (E) Two-way hierarchical cluster of the top-25 
serodominant antibodies against IgM in G1+G2. (F, G, h, I, J). The same order in age-groups 2 and 3 (G2+G3). The color scale ranks 
the antigens with red being the strongest, bright green the weakest, and black in between. 
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satisfactory to discriminate between healthy and diseased sera of all ages-group (Figure 6A). 
Moreover, we found successful combinations for the age groups of <5 years (groups 1 and 2) 
and in >2 years (groups 2 and 3). In the first case, LytA, LytC and PulA improved the sensitivity
Table 4. Statistic of final candidates by age-groups. Results were obtained for IgG analysis in the different age-groups using 
MEV4 software. 
and accuracy of serodiagnostic test; we observed that in a two-way hierarchical cluster 
analysis, left panel included all positive cases except sera #50 and the right panel the negative 
controls (Figure 3.6B). Similarly occurred in the second group (composed by PblB, LytA and 
PrtA), Cluster I contained all healthy individuals and only one problem and Cluster II contained 
the rest of pneumococcal patients (Figure 3.6C). In ROC analysis, ROC curves were generated 
for individual serodiagnostic antigen and the area under the ROC curves (AUC) for each 
antigen is listed in Table 5 and showed in Figure 3.6 (with interactive dot diagram). In all 
groups, all protein candidates had an AUC greater than 0.88, with LytA (AUC 0.93 and p-value 
<0.0001) giving the best single antigen discrimination.  
Then, we extended the analysis to combinations of antigens using a combination of ROC curves 
analysis. As inputs to the classifier, we used the highest-ranking AUC antigens in combinations 
of 2, 3, 4 and 5 proteins and the results were validated with 10 runs of three-fold cross-
validation. Increasing the antigen number from 1 to 2, 2 to 3 and 3 to 4, improvements were 
obtained in accuracy, AUC and  statistical was observed in all sera age-group (Table 6, Figure 
6). But  as  the antigens  increased to 5, a reduction  in AUC   was observed. In <5 years group,  
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AUC SEa 95% CIb z statistic
Significance level 
P (Area=0.5)
Optimal criteriona Sensitivity Specificity Accuracy
spr1754 0,93 0,0721 0,748 to 0,994 5,959 <0,0001 ≤13237,2708 100 87,5 92,96875
spr0561 0,883 0,0698 0,686 to 0,977 5,483 <0,0001 ≤7472,3542 75 100 89,0625
spr0247 0,875 0,0895 0,676 to 0,973 4,191 <0,0001 ≤3391,4583 87,5 87,5 87,5
Sph0062 0,867 0,0992 0,667 to 0,970 3,7 0,0002 ≤4001,1042 100 75 85,9375
spr1431 0,836 0,106 0,629 to 0,954 3,169 0,0015 ≤7086,3542 87,5 87,5 87,5
spr1754 0,944 0,0597 0,718 to 0,999 7,44 <0,0001 ≤10012,6042 100 87,5 93,8575
spr0247 0,889 0,09 0,644 to 0,987 4,319 <0,0001 ≤3391,4583 88,89 87,5 88,206954
spr1431 0,833 0,12 0,577 to 0,966 2,769 0,0056 ≤5743,6042 88,89 87,5 88,206954
spr1754 0,932 0,071 0,718 to 0,996 6,085 <0,0001 ≤13237,2708 100 87,5 92,075
spr0561 0,875 0,0908 0,644 to 0,980 4,131 <0,0001 ≤7472,3542 81,82 100 93,34612
Sph0062 0,864 0,101 0,630 to 0,976 3,613 0,0003 ≤4001,1042 100 75 84,15
G1+G2+G3
G1+G2
G2+G3
Table 5. Antigenic biomarkers of the pneumococcal patients and test operating characteristics of the individual clinical 
biomarkers.
  a
 DeLong et al., 1988, 
b
 Binomial exact. 
we observed that the best combination was with 3 proteins and in the >2 years group, with 2. 
Using the most significant diagnostic antigens (in order to rank according to their AUC in each 
age-group) in their optimal criterion, the classifier predicted 100% (95% CI) sensitivity, 87.5% 
(95% CI) specificity, and from 92.075% to 93.65% (95% CI) accuracy in diagnosis of 
pneumococcal IPD from the negative controls (healthy patients). 
Figure 6. ROC-individual antigens. Two-way hierarchical clusters, ROC curves and interactive dot diagram of serodiagnostic 
candidate markers by age-group (from top to bottom: G1+G2+G3, G1+G2, G2+G3). The graph shows the ROC curves generated 
using different pneumococcal serodiagnositc antigens. 
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3.6. Survival assays of selected pneumococcal proteins 
On the other hand, in order to found a new protein vaccine candidate, 7 proteins were 
assayed. Spr0328, an endo-alpha-N-acetylgalactosaminidase [EC:3.2.1.97] predicted as cell  
AUC SEa 95% CIb z statistic
Significance level 
P (Area=0.5)
Optimal criteriona Sensitivity Specificity Accuracy
2Prot 0,945 0,057 0,770 to 0,997 7,815 <0,0001 ≤14887,2708 100 87,5 92,96875
3Prot 0,945 0,057 0,770 to 0,997 7,815 <0,0001 ≤10622,3819 100 87,5 92,96875
4Prot 0,945 0,057 0,770 to 0,997 7,815 <0,0001 ≤8468,4375 100 87,5 92,96875
5Prot 0,938 0,0645 0,759 to 0,995 6,778 <0,0001 ≤8633,6375 100 87,5 92,96875
2Prot 0,931 0,0728 0,698 to 0,997 5,911 <0,0001 ≤6198,7917 100 87,5 93,8575
3Prot 0,917 0,0859 0,680 to 0,995 4,851 <0,0001 ≤5841,7014 100 87,5 93,8575
2Prot 0,943 0,0601 0,734 to 0,998 7,37 <0,0001 ≤14887,2708 100 87,5 92,075
3Prot 0,943 0,0601 0,734 to 0,998 7,37 <0,0001 ≤10593,7153 100 87,5 92,075
All groups
G1+G2
G2+G3
Table 6. Different sets of antigenic biomarkers of the pneumococcal patients and test operating characteristics of the 
clinical biomarkers. 
a
 DeLong et al., 1988, 
b
 Binomial exact. 
wall-anchored protein of 1,767 aminoacids, was found in 19 clinical isolates and Jenner-Predict 
positive without human homologs. The lipoprotein Spr1975 (AdcA) was tested too. This is a 
zinc ABC transporter substrate-binding protein containing 501 aminoacids found in 12 clinical 
isolates and Jenner-Predict positive without human homologs. Spr1875 is a 380 aminoacids 
hypothetical secreted protein that contains one LysM domain and Jenner Predict positive 
without human homologs. This LysM domain was evaluated as vaccine candidate with positive 
results (53) using D39 pneumococcal strain as infection agent. PulA, is a 1,256 aminoacids 
alkaline amylopullulanase (EC:3.2.1.1) found in 15/25 clinical isolates from children and 11/16 
in adults ((28)). Although it is Jenner-Predict negative, its immunoreactivity in sera from 
infected adult patients as well as the high number of clinical isolates in which we found it, 
make it a good candidate for a vaccine candidate. Another protein, Spr0561, a 2,144 
aminoacids cell wall-associated serine proteinase PrtA (EC:3.4.21.-), that was common in 22/25 
clinical isolates from children and 13/16 from adults, was used as vaccine in an animal survival 
assay although it has been already used in human with unsatisfactory results according to the 
serological measurement (187). It’s annotated as implicated in molecular process and 
biological regulation and as Jenner-Predict positive without human homologs. Also it was the 
second one protein with more peptides identified from the pan-surfome analyses with more 
than 1,300 peptides. Another secreted protein, LytC was evaluated. This is a 1,4-beta-N-
acetylmuramidase (EC:3.2.1.17) that contain 501 aminoacids. It was found in 14/25 clinical 
isolates from children and 5/16 in adults, being also the most immunogenic protein in a 
survival  assay  when   protective   extracellular   vesicles    from  a  serotype  8  pneumococcal
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strain were used (Chapter IV). It is metabolism process related and Jenner-Predict positive 
without human homologs. Finally, PblB, previously described, was tested too as vaccine. This 
protein was  present in 15/25 clinical isolates from children and although its biological function 
is still  unknown and the   Jenner-Predict   prediction   is negative,   it  does   not   have   human    
Figure 7. ROC curves of combination of different sets of antigenic biomarkers of the pneumococcal patients in all age-
groups. (A) In all age-groups, (B) in G1+G2 and (C) in G2+G3.  
homologs and was the protein with more peptides identified from the pan-surfome analysis 
with more than 1,500 peptides, thus suggesting that it’s a highly surface-exposed protein. 
Thus, we vaccinated female Balb/c mice (n = 7/group) with the selected proteins in aluminium 
adjuvant by intramuscular injection. We used 10 μg/dose and tested their protective activity in 
a survival model after intranasal challenge with 4.5  105 CFU of the serotype 8 pneumococcal 
strain. The survival test revealed that no immunised animals survived to the challenge and, as 
well as in all the animals of the control group (those receiving adjuvant alone), died after 3 
days of challenge (Figure 9). 
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3.7. Conclusions 
In this work, 24 pediatric clinical isolates corresponding to 16 different ST were used for the 
highest pneumococcal pan-surfomic analysis carried out to date. This allowed selecting 6 novel 
protein vaccine candidates to survival test in mice. Although no protection (only one of them 
was statistically different from the control group with adjuvant alone) was observed, these 
proteins seem good candidates to be tested in a “cocktail” of antigens. 
Figure 3.9. Protective activity, assayed as survival test, of pneumococcal proteins in immunised mice (10 μg protein/dose) against 
intranasal infection by 4.5 x 10
5
 CFU of S. pneumoniae serotype 8. n = 7 each group. Statistical significance of results is P=0.0287 
for Spr0247 (PulA), P=0.0538 for Spr0561 (PrtA), P=0.31 for Sph_0062-C-terminal end (PblB), P=0.53 for Spr1431 (LytC), 
P=0.141 for Spr1875 and Spr1975 (AdcA) and P=0.0538 for Spr0328 according to log-rank test. NC = adjuvant (aluminum 
hydroxide) alone. 
Moreover, from surfomic analysis, 95 proteins or fragments of them were cloned and used in a 
serological profile analysis in order to discover novel candidates to perform a fast, accurate 
and cheap biomarker tool (although further analysis with new sera are necessary). Then, using 
a combination of 4 antigens (PblB, LytA, PulA and PrtA), pneumococcal disease could be 
detected with 100% (95% CI) sensitivity, 87.5% (95% CI) specificity, and 92,96% (95% CI) 
accuracy in all age-group sera; the same sensitivity and specificity but with 93,87% accuracy 
was observed in G1+G2 using a combination with LytA and PulA; and 92,075% (95%CI) in 
G2+G3 with a mix of LytA and PrtA. Then, this work, when completed, will serve, on one hand, 
to discover new protein vaccines, as well as to develop a serological tool for detecting 
diagnostic biomarkers. On the other hand, pneumococcal proteins could be used for their 
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application in programs of epidemiological surveillance as well as to define high-risk groups 
according to their basal antibody levels against a subset of proteins. 
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Supplementary dataset 
Table S3. Sera used in this study 
# Age (m) Diagnosis 
Problem 
1 113 empyema 
2 95 empyema 
3 37 empyema 
4 51 empyema 
5 70 empyema 
6 112 empyema 
7 40 empyema 
8 21 empyema 
9 18 empyema 
10 8 empyema 
11 64 empyema 
12 13 empyema 
13 91 empyema 
32 96 empyema 
34 18 empyema 
36 31 empyema 
Controls 
49 143 healthy 
50 97 healthy 
51 19 healthy 
52 80 healthy 
53 164 healthy 
54 74 healthy 
55 59 healthy 
56 81 healthy 
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Abstract 
Extracellular vesicles are produced by many pathogenic microorganisms and have varied 
functions that include secretion and release of microbial factors, which contribute to virulence. 
Very little is known about vesicle production by Gram-positive bacteria, as well as their 
biogenesis and release mechanisms. In this work, we demonstrate the active production of 
vesicles by Streptococcus pneumoniae from the plasma membrane, rather than being a 
product from cell lysis. We biochemically characterized them by proteomics and fatty acid 
analysis, showing that these vesicles and the plasma membrane resemble in essential aspects, 
but have some differences: vesicles are more enriched in lipoproteins and short-chain fatty 
acids. We also demonstrate that these vesicles act as carriers of surface proteins and virulence 
factors. They are also highly immunoreactive against human sera and induce immune 
responses that protect against infection. Overall, this work provides insights into the biology of 
this important Gram-positive human pathogen and the role of extracellular vesicles in clinical 
applications. 
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Biological significance 
Pneumococcus is one of the leading causes of bacterial pneumonia worldwide in children and 
the elderly, being responsible for high morbidity and mortality rates in developing countries. 
The augment of pneumococcal disease in developed countries has raised major public health 
concern, since the difficulties to treat these infections due to increasing antibiotic resistance. 
Vaccination is still the best way to combat pneumococcal infections. One of the mechanisms 
that bacterial pathogens use to combat the defense responses of invaded hosts is the 
production and release of extracellular vesicles derived from the outer surface. Little is known 
about this phenomenon in Gram-positives. We show that pneumococcus produces 
membrane-derived vesicles particularly enriched in lipoproteins. We also show the utility of 
pneumococcal vesicles as a new type of vaccine, as they induce protection in immunized mice 
against infection with a virulent strain. This work will contribute to understand the role of 
these structures in important biological processes such as host-pathogen interactions and 
prevention of human disease. 
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1. Introduction 
Evolutionary processes of pathogenic microbes that confer ability to survive in a host include, 
among other factors, the production of extracellular vesicles (EVs) derived from the outer 
surface, which can serve to combat host defense responses, and/or as a biophysical 
mechanism to release cellular stress [1]. Vesicle release is a conserved phenomenon among 
Gram-negative bacteria, including pathogenic and non-pathogenic species [2]. EVs have been 
mainly described in vitro, although numerous studies have also shown that they can act in vivo 
as carriers of toxins that lack canonical exporting/secretion signal sequences [3], promote cell-
cell communication [4] and other biological processes. Additionally, when used as 
immunogens, EVs can be antigenic and induce a host immune response that protects against 
infection [5]. 
The production of EVs in Gram-positive bacteria and fungi had been overlooked until recently, 
largely because it was assumed that the existence of a thick, rigid cell wall would prevent the 
release of membrane blebs. In addition, some studies on mesosomes in streptococcal species 
dating to the 1960’s were abandoned as they were thought afterwards to be an artifact [6, 7]. 
During recent years, both fungi [8-11] and certain Gram-positive microorganisms [12-14] have 
also been found to produce EVs, suggesting that vesicle formation is a widespread process 
among microbes, including those with outer cell walls. Nonetheless, compared to those of 
Gram-negative bacteria, little is known about fungal and Gram-positive EVs, especially 
regarding their biogenesis and role in host-pathogen interactions. Among Gram-positive 
organisms, EVs have been shown to carry toxins in Bacillus anthracis [14] and Staphylococcus 
aureus [15, 16]; fuse with host cells, inducing their death [13, 15, 16]; induce a 
proinflammatory response in vitro and in vivo in Mycobacterium spp. [13], and elicit a 
protective immune response against infection [14]. 
Streptococcus pneumoniae, also known as pneumococcus, is a Gram-positive bacterium that 
colonizes the human respiratory tract and has the potential to become invasive, which is 
associated with high morbidity and mortality rates worldwide, especially in developing 
countries [17]. The burden of pneumococcal disease, particularly pneumonia, is also increasing 
in developed countries, where it has raised major public health concerns because resistance to 
antibiotics has made these infections more difficult to treat [18]. Prevention by vaccination is 
considered as the most effective way to combat pneumococcal infections. However, the 
efficacy of currently licensed pneumococcal vaccines, which are based on the capsule 
polysaccharide, is less robust in high-risk population groups, including the elderly and those 
with HIV infection, particularly against pneumonia [19]. In addition, current polysaccharide-
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based pneumococcal vaccines do not cover all circulating serotypes, and pneumococcal 
conjugate vaccines have led to serotype replacement and capsular swithching [20]. Moreover, 
they are expensive, especially for underdeveloped countries. In recent years, recombinant 
protein-based vaccines are being tested as potentially universal vaccines to protect against all 
serotypes, but such agents are not yet commercially available [21]. 
In this study, we demonstrate that pneumococcus produces EVs that, although resembling the 
plasma membrane in composition, are biologically and biochemically different. We also 
provide evidence that these vesicles are derived from the membrane and do not result from 
lysis of dead cells. Furthermore, we show that EVs are more enriched than the membrane 
fraction in lipoproteins. Finally, we show that EVs are highly immunogenic, and that EV 
immunization of mice protects against challenge with a virulent pneumococcal strain. These 
findings could lead to new types of vaccines to prevent pneumococcal infections. 
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2. Materials and Methods 
2.1. Mice and human sera and Ethics statement 
This research was performed according to the principles expressed in the Declaration of 
Helsinki. All human sera were obtained from pediatric patients admitted to Hospital 
Universitario Infantil Virgen del Rocío in Sevilla (Spain) with pneumococcal infection, 
corresponding to three cases of empyema in children of 32, 34 and 36 months of age, and 
three control sera, corresponding to healthy children of 50, 51 and 52 months of age. Written 
informed consent was obtained from the parents or legal guardians of the children. Mouse 
sera were obtained after intramuscular injection of 5 μg of pneumococcal recombinant protein 
Spr1918 (MalX) or isopropanol-inactivated R6 cells in three doses on days 0, 7 and 14. Both 
human and mice sera were taken after the approval of the Hospital Universitario Virgen del 
Rocío Ethic Committee (code no. 010470, certificate no. 14/2010). 
2.2. Bacterial strains and growth 
Streptococcus pneumoniae strains (R6, serotype 2; ST1, serotype 1; ST6B, serotype 6B; ST8, 
serotype 8 and ST23F, serotype 23F) were grown at 37ºC in Todd-Hewitt broth (THB). Growth 
was monitored turbidimetrically in 4-ml tubes using a spectrophotometer (ThermoSpectronic, 
Thermo) at 600 nm. 
2.3. Sample preparation 
EVs were isolated as described [13], with minor modifications. Briefly, cells at different ODs 
were pelleted from 1-L cultures and the supernatants were filtered through a 0.22-μm–pore 
size polyvinylidene difluoride filter (Millipore Express Plus). The supernatants were then 
centrifuged at 100,000 × g for 1.5 h at 4 °C to sediment the vesicular fraction into a pellet. The 
supernatant was then recovered to produce the secretome fraction by trichloroacetic acid 
precipitation and the pellet was suspended in 1 ml of PBS (“crude” vesicles). This pellet was 
mixed with 2 ml of Optiprep solution (Sigma-Aldrich), yielding 35% (w/v) Optiprep final 
concentration. The crude vesicle sample was then overlayed with a series of Optiprep gradient 
layers with concentrations ranging from 35%–5% (w/v). The gradients were centrifuged 
(100,000 × g, 16 h), and 1 ml fractions were removed from the top. The fractions were then 
centrifuged at 100,000 × g for 1 h at 4 °C and recovered. Finally, vesicles were air-dried, 
weighed, suspended in PBS and quantified for protein amount (Bradford protein assay, 
BioRad). For pneumococcal cell extracts, cells were pelleted (centrifuged at 100,000 × g for 1 h 
at 4 °C), washed twice with PBS and resuspended in 8 M urea. Samples were sonicated with 6 
cycles of 20 s. Then, they were precipitated using 100% trichloroacetic acid/ 0.4% sodium 
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deoxycholate. After 1 h incubation at -20ºC, samples were centrifuged for 15 min at 13,000 
rpm and washed twice with 50mM Tris-HCl pH 8 and twice with cold ethanol. Finally, pellets 
were resuspended in 8 M urea. For plasma membrane fraction, cells were pelleted, washed 
twice with PBS and suspended in PBS. Samples were sonicated with 6 cycles of 20 s. Then, 
samples were centrifuged at 5000 × g for 15 min and supernatants were filtered through a 
0.22-μm–pore size polyvinylidene difluoride filter (Millipore Express Plus). The supernatants 
were then centrifuged at 100,000 × g for 1 h at 4 °C to sediment the membrane fraction into a 
pellet. Finally, pellets were air-dried, weighed and suspended in 8 M urea. 
2.4. Size exclusion chromatography 
Samples (EVs or PM) were suspended in PBS. The suspensions were eluted through Superdex 
200 10/300 (Sigma) in a glass column (30 × 1.0 cm) with a particle size of 24-44 µm. Volumetric 
flow rate was 0.5 ml/min and signal was monitored at 214 nm at room temperature. Every ml 
from the effluent of gel filtration was collected in a fraction, dried with a Speed-vac and 
suspended in PBS. Calibration was done using 20 μg Blue Dextran (2,000,000 Da), 10 μg ferritin 
(440,000 Da), 140 μg BSA (64,700 Da) and 200 μg ribonuclease A (15,400 Da). 
2.5. LC/MS/MS Analysis 
Samples were treated with Rapigest according to the manufacturer's instructions. Then, they 
were digested with 5 μg trypsin overnight at 37 ºC with agitation. All analyses were performed 
with a Surveyor HPLC System in tandem with an LTQ-Orbitrap mass spectrometer (Thermo 
Fisher Scientific, San Jose, USA) equipped with nanoelectrospray ionization interface (nESI). 
The separation column was 150 mm × 0.150 mm ProteoPep2 C18 (New Objective, USA) at a 
postsplit flow rate of 1 µl/min. For trapping of the digest a 5 mm × 0.3 mm precolumn Zorbax 
300 SB-C18 (Agilent Technologies, Germany) was used. One fourth of the total sample volume, 
i.e. 5 µl, was trapped at a flow rate of 10 µl/min for 10 minutes and 5% acetonitrile/0.1% 
formic acid. After that, the trapping column was switched on-line with the separation column 
and the gradient was started. Peptides were eluted with a 60-min gradient of 5–40% of 
acetonitrile/0.1% formic acid solution at a 250 nl/min flow rate. All separations were 
performed using a gradient of 5-40% solvent B for 60 minutes. MS data (Full Scan) were 
acquired in the positive ion mode over the 400-1,500 m/z range. MS/MS data were acquired in 
dependent scan mode, selecting automatically the five most intense ions for fragmentation, 
with dynamic exclusion set to on. In all cases, a nESI spray voltage of 1.9 kV was used. 
2.6. Protein identification by database searching 
Tandem mass spectra were extracted using Thermo Proteome-Discoverer 1.0 (Thermo Fisher 
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Scientific). All MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, version 
v.27), applying the following search parameters: peptide tolerance, 10 ppm; tolerance for
fragment ions, 0.8 Da; b- and y-ion series; oxidation of methionine and deamidation of 
asparagine and glutamine were considered as variable modifications; maximum trypsin missed 
cleavage sites, 3. The raw data were searched against an in-house joint database containing 
the protein sequences from all the sequenced and annotated S. pneumoniae strains available 
at the NCBI ftp site. Peptide identifications were accepted if they exceeded the filter 
parameter Xcorr score vs charge state with SequestNode Probability Score (+1 = 1.5, +2= 2.0, 
+3= 2.25, +4= 2.5). With these search and filter parameters, no false-positive hits were 
obtained. For proteins identified from only one peptide, fragmentations were checked 
manually. Strain R6 was used as reference for providing the accession numbers of the 
identified proteins; whenever a protein belonging to another strain was found, homology with 
a corresponding protein of strain R6 was given by using protein-BLAST. If homology with R6 or 
TIGR4 or Hungary19A-6 proteins was not observed, then the protein accession numbers of the 
other strains were used.  
2.7. Bioinformatic prediction of protein subcellular localization  
Primary predictions of subcellular localization were assigned by using the web-based algorithm 
LocateP (http://www.cmbi.ru.nl/locatep-db/cgi-bin/locatepdb.py). They were contrasted by 
several feature-based algorithms: TMHMM 2.0 (http://www.cbs.dtu.dk/services/TMHMM-2.0) 
for searching transmembrane helices; SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP) for 
type-I signal peptides: those proteins containing only a cleavable type-I signal peptide as 
featured sequence were classed as secreted; LipoP (http://www.cbs.dtu.dk/services/LipoP) for 
identifying type-II signal peptides, which are characteristic of lipoproteins. GO annotations 
were retrieved from the UniProt Knowledgebase (http://www.uniprot.org/). 
2.8. MALDI-TOF/TOF mass spectrometry and protein identification 
Spots were excised automatically in a ProPic station (Genomic Solutions, U.K.), digested with 
modified porcine trypsin (sequencing grade; Promega) and loaded onto the MALDI plate, by 
using a ProPrep II station (Digilab Genomic Solutions Inc., U.K.). The gel specimens were 
destained twice over 30 min at 37 °C with 200 mM ammonium bicarbonate/40% acetonitrile. 
Gel pieces were then subjected to three consecutive dehydratation/rehydratation cycles with 
pure acetonitrile and 25 mM ammonium bicarbonate in 50% acetonitrile, respectively, and 
finally dehydrated for 5 min with pure acetonitrile and dried out over 4 h at room 
temperature. Then, 20 µl trypsin, at a concentration of 12 ng/µl in 25 mM ammonium 
bicarbonate was added to the dry gel pieces and the digestion proceded at 37 º C for 12 h. 
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Peptides were extracted from gel plugs by adding 1 µl of 10% (v/v) trifluoracetic acid (TFA) and 
incubating for 15 min. Then, they were desalted and concentrated by using µC-18 ZipTip 
columns (Millipore) and directly loaded onto the MALDI plate using α-cyano hydroxycinnamic 
acid as the matrix.  Mass analysis of peptides (MS) of each sample was performed with a 
MALDI-TOF/TOF (4800 Proteomics Analyzer, Applied Biosystems) mass spectrometer in the 
m/z range 800 to 4,000, with an accelerating voltage of 20 kV. The most abundant peptide ions 
were then subjected to fragmentation analysis (MS/MS).  Mascot 2.0 search engine (Matrix 
Science Ltd., London) was used for protein identification running on GPS ExplorerTM software 
v3.5 (Applied Biosystems) over the National Center for Biotechnology Information (NCBI) 
protein database (updated monthly). Search setting allowed one missed cleavage with the 
selected trypsin enzyme, a MS/MS fragment tolerance of 0.2 Da and a precursor mass 
tolerance of 100 ppm. 
2.9. Protein separation by SDS-PAGE 
30 μg of different samples were separated by 12% SDS-PAGE and stained with Colloidal 
Comassie G-250 (Sigma) according to the manufacturer’s instructions. Gels were scanned in a 
GS-800 densitometer (BioRad).  
2.10. Western blotting 
For reactivity with mice sera raised against recombinant pneumococcal proteins, 40 μg of total 
extract (TE), extracellular vesicles (EVs) and secretome (Sc) were separated by 12% SDS-PAGE 
and transferred to nitrocellulose membranes. For reactivity against human sera, 2 μg of TE and 
EVs were used. Immunodetection was carried out as described [22]. Anti-Ply (Abcam, 
ab71810) and anti-PspA (Thermo Scientific, Pierce, MA1-10835) antibodies were diluted 
1:1,000 to test their presence on TE, EVs and Sc. Anti-MalX mice sera were diluted 1:10 to 
detect presence of these proteins in TE, EVs and Sc. As secondary antibodies, rabbit anti-
human IgG and rabbit anti-human IgM conjugated to horseradish peroxidase (Sigma) were 
used, diluted respectively 1:10,000 and 1:5,000; and 1:2,500 anti-mouse IgG-HRP conjugated 
(Sigma) in cases where mice sera had been used. 
2.11. Electron microscopy 
For scanning electron microscopy, samples were fixed in 2.5% glutaraldehyde, 0.1 M sodium 
cacodylate, 0.2 M sucrose, 5mM MgCl2 pH 7.4, and examined in a Zeiss Supra Field Emission 
Scanning Electron Microscope using an accelerating voltage of 5 KV. For transmission electron 
microscopy, samples were fixed in 2.5% glutaralhedyde/2% paraformaldehyde in 0.1 M sodium 
cacodylate buffer for 4 h and post-fixed in 1% osmium tetroxide for 1 h at 4 ºC in the same 
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buffer. After dehydration in an ascendant series of ethanol, the pieces were transferred to 
propylene oxide and sequentially infiltrated in Embed 812 resin. After staining in aqueous 4% 
uranyl acetate and Sato’s lead citrate 39, the sections were observed in a Philips CM10 
electron microscope. 
2.12. Immunogold labeling 
EVs were stained with CFSE (Invitrogen) at a 10-μM final concentration in PBS for 30 min at 37 
°C. Cells in growth media were fixed with 4% paraformaldyhyde/0.4% glutaraldehyde in 0.2 M 
PHEM buffer, embedded in 5% gelatin, cubed, infiltrated with 2.3 M sucrose, and frozen in 
liquid nitrogen. Sections (80nm) were cut at -120 ºC, picked up in a combination of sucrose 
and methyl cellulose, stained with 4% uranyl acetate and viewed on a JEOL 1200EX 
transmission electron microscope at 80kV. 
2.13. Flow cytometry analysis 
Flow cytometry analysis was carried out as described [23] (Chapter I). 
2.14. Fatty acid analysis 
EVs and PMs were analyzed by gas chromatography. Samples were suspended in heptane. 
Then, 500 μl of 2N KOH/methanol was added. Finally, samples were vortexed and incubated 
15 min at 4 ºC prior to separation in a Varian CP-3800 instrument, using a column FactorFour 
VF-23ms (60m × 0.25mm × 0.25μm) at 1.1 ml/min flow. 
2.15. Quantification of capsule 
The amount of capsule was determined using the Stain-all assay (Sigma) for detecting acidic 
polysaccharides. Bacteria were cultured in THB to OD600 = 0.5, then 5 ml were centrifuged for 
10 min at 5,000 × g, washed with PBS and resuspended in 0.5 ml 0.85% NaCl. Ten µl were 
removed to make dilutions in PBS for plating out to quantify the number of bacteria. To the 
remaining bacterial suspension, 2 ml of a solution containing 20 mg Stain-all (1-ethyl-2(3-
ethylnaphthho-(1,2-d)thiazolin-2-ylidene)-2methylpropenyl)naphthoo-(1,2-d)thiazolium 
bromide) and 60 µl glacial acetic acid in 100 ml 50% formamide was added by triplicate, and 
the OD640  was determined; 0.5 NaCl with 2 ml Stains-all solution was used as a blank. The 
values for 1 × 107 cfu were calculated from the colony counts of the plated bacteria. 
2.16. LTA Measurement 
Samples were diluted with 50 mM carbonate buffer (pH 9.6) coated in a microplate, except 
cells, that were diluted 1:10 in THB. Plates were kept at 37 ºC overnight. The sample-precoated 
plates were brought to room temperature and blocked with 1% BSA for 1 h at room 
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temperature. The plates were washed using PBS. 200 𝜇L per well of anti-mouse lipoteichoic 
acid antibody (Pierce) 1:1,000 were incubated at room temperature for 1 h. Then, wells were 
washed again and diluted 1:5,000 PA-conjugated anti-mouse was added and incubated at 
room temperature for 1 h. BCIP/NBT substrate (Sigma) was added to the well and incubated 
for 30 min in darkness according to the manufacturer’s instructions. The reaction was stopped 
by adding 1M H2SO4 and incubated for 10 min in darkness. The plates were read at 450 nm 
with the reference at 620 nm using an ELISA reader.  
2.17. Mice survival assay 
Female Balb/C 6-8 weeks old (n = 7/group) were immunized intramuscularly with 10µg ST8 EVs 
using an aluminium hydroxide adjuvant.  Each animal received a boost at 2 weeks.  Serum 
samples were collected from each mouse at 1 and 3 weeks after the first immunization. Sera 
were used to determine the levels of antigen specific antibodies and for immunoblot analysis. 
One week after the second immunization, animals were challenged intranasally with 4.5 × 105 
CFU of S. pneumoniae ST8. Survival was recorded over 7 days. 
2.18. Statistics 
Statistical analyses were performed using SPSS v 21.0.0.0. Student’s t test (2-tailed) was 
applied for experiments involving pairwise comparisons. Log-rank test was used in the mice 
survival assay. P < 0.05 was considered significant. 
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3. Results 
3.1. Pneumococcus produces EVs that are not derived from dead cells 
We investigated the production and release of EVs by using the acapsular reference strain 
S. pneumoniae R6, whose genome is fully sequenced and annotated [24]. First, we 
tested whether the bacteria released membranous material into the culture medium by 
filtering and ultracentrifuging the supernatant when the bacterial culture reached an OD600 
= 0.5, which corresponded to late-exponential phase. We observed a pellet that might 
represent EV material, with a very similar aspect to that of the plasma membrane fraction 
coming from a sonicated cell lysate (Fig. 1A). We checked the presence of spherical vesicle-
like structures in the putative EV pellet by TEM after preparing the samples in ultrathin resin-
included sections. Vesicle-like material was observed, although it seemed to be accompanied 
by some impurities (Fig. 1B). We then used an Optiprep density gradient fractionation 
protocol to purify and separate the putative EVs from other fractions, e.g. debris coming 
from cell wall rupture and protein aggregations. Two bands corresponding to the Optiprep 
layers of 20 and 25% were clearly visualized and differentiated from the rest of the more 
aqueous fractions, although that of 25% was much more abundant than the other one (Fig. 
S.1). Negative staining TEM of both fractions, where membrane units cannot be appreciated, 
revealed the presence of numerous spherical structures (Fig. 1C). We merged both 
fractions and observed again the resulting sample by TEM after fixation in a resin, in which 
vesicles were observed (Fig. 1D). The yield of EVs was about 38 mg ± 10 mg/l of culture 
medium.  
We considered the possibility that part of the EVs came from plasma membrane 
fragments released during/after lysis of dead or dying cells. To address this, we determined 
cell survival at the time of EV isolation. We observed the highest production of EVs (as 
referred in % considering the total membrane material as the sum of EVs + plasma 
membrane) during the late-exponential phase. Lower amounts were obtained at mid-
exponential phase (OD600 = 0.275) and from an overnight culture, in which the cell viability, 
measured by flow cytometry, decreased dramatically to 5% (Fig. 1E). In contrast, cell survival 
in mid- and late-exponential phases was approximately 99%. The decrease in the amount of 
membranous material that was secreted into the medium during the overnight culture was 
not accompanied by a decrease in total membrane recovered by sonication of pelleted cells. 
Moreover, when we killed bacterial cells by 1-h isopropanol treatment, inoculated fresh 
broth with these inactivated bacteria and then left the culture to proceed as for the control 
for EV production (Fig. S2), no material was obtained after ultracentrifugation of the dead-
culture supernatants and no bands were revealed when an SDS-PAGE was performed 
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Figure 1. Production of extracellular vesicles (EVs) by pneumococcus. (A) Membranous pellets obtained after ultracentrifugation 
of culture supernatant (left) or cell lysate by sonication (right), corresponding to EVs and plasma membrane, respectively. (B) 
Transmission electron micrograph of culture ultracentrifugation pellet, before Optiprep purification. (C) Negative-staining 
transmission electron microscopy of vesicle-like structures present in the two non-aqueous Optiprep fractions (see Fig. S1). (D) 
Transmission electron micrograph of EVs after Optiprep purification. (E) Yields of EVs (bars), and cell survival as measured by flow 
cytometry (solid triangles), in different phases of pneumococcal growth (MEP, mid-exponential phase; LEP: late-exponential phase; 
O/N, overnight culture). (F) SDS-PAGE profile of different subcellular fractions (TE: total cell extract; TS: total secretome, i.e. 
proteins recovered from culture supernatant after single centrifugation; S: secretome, i.e. fraction resulting from the supernatant of 
ultracentrifuging the TS fraction; EV: membrane vesicles). For numbers 1, 2 and 3, see scheme of the experiment in Fig. S2. EV- 3 
corresponds to EVs obtained from a culture inoculated with isopropanol-killed bacteria. Statistical significance of results is shown as 
* (P < 0.05) according to the Student’s t-test. 
Figure S1 (left). Purification of pneumococcal extracellular vesicles by Optiprep gradient. Arrows show the non-aqueous 
fractions in which spherical structures were observed by transmission electron microscopy after negative staining (see Fig. 1C) and 
then merged into a unique sample (see Fig. 1D). Figure S2 (right). Scheme of the experiment to demonstrate that pneumococcal 
extracellular vesicles do not come from cell lysis. A 150-ml culture in THB of R6 strain at OD=0.5 was divided in 3 different 50-
ml cultures, from which 4 fractions were recovered: total extract (TE), total secretome (TS), secretome (S) (obtained both by 
trichloroacetic/deoxycholate (TCA/DOC) precipitation) and membrane-derived vesicles (EVs). In culture 3 we killed bacteria with 
isopropanol treatment before re-inoculation in 500 ml of fresh THB medium. 
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with different subcellular fractions (Fig. 1F).  These experiments show an association 
between EV production with live cultures and the absence of EVs in suspensions of dead 
cells. 
Scanning electron microscopy images showed that the acapsular R6 cells were surrounded 
by spherical particles (Fig. 2A). We examined bacterial cells by TEM to search, at 
the ultrastructure level, for the presence of putative membranous blebs within the cells. We 
found that some cells showed the presence of numerous spherical blebs inside (Fig. 2B). 
The size distribution for the internal observed blebs and vesicles recovered from the 
supernatant (previously shown in Fig. 1D) was very similar, ranging between 20 and 75 nm 
in diameter (Fig. 2C). In most cases, blebs inside the cells were located and accumulated 
near the cell division septum, which presumably could serve as the area for their release 
since this zone is an area in which the cell wall is very thin or even absent (Fig. 2D). 
Further observations suggested that the origin of these intracellular blebs might be 
associated with events of cell membrane invagination (Fig. 2E).  
Figure 2. Ultrastructure characterization of putative S. pneumoniae R6 extracellular vesicles (EVs). (A) Scanning electron 
microscopy of pneumococcal cells showing some spherical blebs surrounding the bacteria. (B) Transmission electron micrographs 
of S. pneumoniae showing vesicle-like structures inside the cells. (C) Size distribution (diameter) of internal (red bars) and released 
(blue bars) EVs. (D) Transmission electron micrographs of several pneumococcal cells showing accumulation of internal blebs in 
the division septum region. (E) Transmission electron microscopy of a pneumococcal cell showing the generation of a membranous 
invagination from the plasma membrane. 
EVs were also isolated from four strains (Fig. 3A), representing invasive serotypes included in 
the currently licensed polysaccharide and polysaccharide-conjugate vaccines. The size 
distribution of EVs from these strains was in the same range as those from R6, i.e. between 20 
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Figure 3. Production of extracellular vesicles (EVs) by 
pneumococcal isolates. (A) Transmission electron 
microscopy images of isolated EVs from four different 
pneumococcal capsulated isolates. (B) Size distribution 
(diameter) of isolated EVs from the indicated isolates. (C) 
Yield of EV production of the four different pneumococcal 
isolates, compared to R6 strain. Statistical significance of 
results is shown as * (P < 0.05) according to the Student’s t-
test. 
and 80 nm diameter (Fig. 3B). However, 
the amount of EVs recovered in the culture 
supernatants of these isolates was variable 
and generally lower (3 to 40-fold) than that 
of R6 (Fig. 3C). One potential explanation 
for this difference is that the isolates have 
thick capsules that could hinder or trap EV 
release, as revealed by scanning electron 
microscopy (Fig. S3) and quantified by a 
colorimetric assay (Table 1), in contrast to 
the acapsular R6 strain. 
3.2. Biochemical characterization of 
EVs 
To better understand the relationship 
between EVs and bacterial plasma 
membranes, we compared in the R6 strain 
Strain Relative Capsule Mean (±S.E.) (n = 3) 
R6 0 (±0) 
ST1 0.509 (±0.006) 
ST6B 0.501 (±0.004) 
ST8 0.366 (±0.007) 
ST23F 0.209 (±0.021) 
Table 1. Capsule quantification in pneumococcal 
strains. 
the biochemical composition and content 
of EVs with the plasma membrane fraction 
obtained from disrupted bacterial cells. To 
do this, we performed such analyses using 
the corresponding pelleted materials after 
ultracentrifuging either culture medium (for EVs) or lysed bacterial suspension (for plasma 
membrane). These samples were considered as “crude fractions” without further 
manipulation. Proteomic analysis revealed that EVs contained many membrane-associated 
proteins (both transmembrane and lipoproteins), sharing a significant proportion with the 
membrane fraction,  while also having unique   proteins (Fig. 4A and S3A).   Particularly, EVs 
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were enriched in lipoproteins (15, i.e. 7.1% of total identified proteins in EVs; 10, i.e. 5% in 
plasma membrane) and multitransmembrane proteins (25, i.e. 11.8% of total identified 
proteins in EVs; and 14, i.e. 7% in plasma membrane). In addition, most of the content 
correspond to predicted cytosolic proteins (SDS 1 and 2), which  could be due to the fact that
Figure 4. Biochemical composition and protein content of pneumococcal extracellular vesicles (EVs). (A) Identification of the 
protein content of “crude” EVs and plasma membrane fraction (PM), by LC/MS/MS proteomic analysis. Numbers refer to the 
percentages of groups of proteins, according to their subcellular localization (cytosol, lipoproteins, secreted proteins, cell wall, 
membrane proteins with 1 transmembrane domain = 1 TMD, and membrane proteins with more than 1 transmembrane domain = 
mt1 TMD). The Venn diagram represents the absolute numbers of proteins identified in common or exclusively for each fraction.  
(B) Fatty acid profile of EVs (red bars) and plasma membrane (green bars). (C) Lipoteichoic acid (LTA) detection in EVs and PM. 
Commercial lipoteichoic acid and R6 cells were used as positive control (PC). As negative control (NC), purified pneumolysin (Ply) 
was used. (D) Proteomic analysis of Optiprep-purified EVs of all the isolates. For the meaning of the numbers, see (A). Pictures 
show transmission electron micrographs pictures of immunogold staining of vesicles with anti-Ply antibody (left) and the 
corresponding negative controls without the anti-Ply antibody (left). (E) Immunoblot detection of three selected proteins in different 
subcellular fractions (total extract = TE; membrane vesicles = EV; and secretome = Sc) of R6 strain and the four clinical isolates, as 
revealed by Western blotting. (F) Electrophoretic profile of different R6 subcellular fractions (total cell extract = TE; membrane 
vesicles = EV; total secretome (i.e. non-ultracentrifuged culture medium) = TS; plasma membrane = PM), as revealed by SDS-
PAGE. Statistical significance of results is shown as * (P < 0.05) according to the Student’s t-test. 
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Figure S3. Scanning electron microscopy of pneumococcal isolates. Shown are pictures of isolates ST1, ST6B, ST8 and 
ST23F. 
a portion of the cytoplasm is trapped during EV biogenesis. However, lipidomic analysis 
showed that although EVs and membrane fractions had similarities, EVs had a different fatty 
acid composition, with an enrichment in short-chain saturated fatty acids such as C12 (lauric 
acid), C14 (myristic acid), C16 (palmitic acid), and an unidentified compound that could be C15 
(pentadecanoic acid) (Fig. 4B). Although some cell-wall proteins were surprisingly identified by 
proteomics (around 2% of total identified proteins for both fractions), EVs were free of cell 
wall material, as revealed by the absence of lipoteichoic acid, a characteristic molecule on the 
surface of Gram-positive organisms (Fig.4C). Both membrane fraction and EVs also had 
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different chromatographic profiles when analyzed by size-exclusion chromatography (Fig. 
S4A). SDS-PAGE analysis of bacterial subcellular fractions (Fig. 4F and Fig. S4B) showed that the 
global electrophoretic profiles of EVs were different than that of the membrane and the other 
fractions (i.e. total cell extract and “secretome”), as well as the proteins identified in them by 
LC/MS/MS analysis (Fig. S4C). These results indicate that although EVs and the cell membrane 
are similar in some aspects, their composition exhibits significant biochemical differences. 
Figure S4. Additional biochemical analysis of pneumococcal extracellular vesicles (EVs). (A) Size-exclusion chromatography of 
EVs and PM prepared in PBS and run in the same buffer as solvent. (B) Protein identifications by LC/MS/MS of three different 
subcellular fractions (TE, total cell extracts; EVs, membrane vesicles; Sc, secretome) in all the pneumococcal strains used in this 
work. Intersections represent the common proteins for each pair/three fractions. (C) Electrophoretic profiles of different subcellular 
fractions of pneumococcal isolates ST1, ST6B, ST8 and ST23F, as revealed by SDS-PAGE. 
Then, we carried out a comparative proteomic analysis of EVs of the other encapsulated 
strains used in this study, including also that of R6. For this purpose, we did not use “crude”  
EVs (i.e. those isolated directly after ultracentrifugation of the culture supernatant), but 
purified them by Optiprep gradient as previously described  (Fig. 4D, and SDS 4 and 4). 
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This was because the presence of capsule polysaccharide contamination before Optiprep in 
strains ST1, ST6B, ST8 and ST23F made the handling of the samples, and therefore the 
proteomic analysis, much more difficult to cope with. To make the analysis comparable, R6 EVs 
were also subjected to Optiprep. Essentially, analyses of “crude” and Optiprep-purified R6 
were quite similar, both in terms of total number of identified proteins (211 for “crude” 
fraction vs 184 for the Optiprep-isolated one) and of the proportions of the different 
categories of predicted proteins. For this latter, the only remarkable difference was the 
identification of some predicted secreted proteins in the R6 Optiprep-purified EVs, which were 
not found in the “crude” preparation. When the different strains were compared, we found 
that, at a qualitative level, the profiles were very similar: predicted cytoplasmic proteins were 
those most abundant (71-74%), followed by multitransmembrane proteins (7.5-11.3%), 
membrane proteins with one TMD (6-10.5%) and lipoproteins (3.3-7%). Eleven proteins 
(among the categories considered as surface proteins, including cell wall, secretory, membrane 
or lipoproteins) were found in at least 4 out of the 5 strains studied in this work. They included 
6 lipoproteins and 3 membrane proteins with 1 TMD (Table 4.2). Two out of the 6 lipoproteins 
were present in all the strains. 
6 1 6B 8
5 TMD)
TMD)
in
protein in
in
TMD)
in
in
Table 2. Proteins identified in membrane vesicles of ≥4 strains. aProtein categories were established according to LocateP 
subcellular predictions: lipoproteins were those predicted as lipid-anchored proteins; cell wall proteins, as those having an LPXTG 
motif; secretory proteins, as those possessing an SP1-type signal peptide; membrane proteins with one transmembrane domain 
(TMD), as those possessing either a C- or an N-terminally anchored transmembrane region. 
Identification of EV proteins by proteomics was confirmed by Western blot analysis using sera 
raised in mice against corresponding recombinant proteins. We selected a lipoprotein (MalX), 
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a transmembrane protein (PspA), and pneumolysin (Ply), a known toxin that is secreted even 
though it lacks an exporting signal and is predicted to be a cytoplasmic protein. Immunoblots 
revealed that EVs were clearly enriched in both PspA and MalX, compared to the other 
fractions. Pneumolysin was found by immunoblotting mainly both in total cell extracts and in 
the culture supernatant, although more slightly in EVs of most of the pneumococcal isolates. 
However, EM-immunogold staining showed that EVs from all the isolates contained 
pneumolysin as part of their protein cargo (Fig. 4D). 
3.3. EVs are immunogenic and protect mice against infection
Finally, we analyzed the immunogenicity of pneumococcal EVs and their ability to 
elicit protective immune responses against pneumococcal infection. EVs from all the 
serotypes, including R6, were highly immunoreactive when tested against sera from 
infected human patients, even much so than their equivalent protein amounts of total cell 
extracts (Fig. 5) in terms of intensity and number of bands detected. Sera from control 
(non-pneumococcus infected) patients also reacted with the EVs, although overall the 
intensity of the reactions was lower. Similar patterns of reactivity were observed 
between IgG and IgM-recognizing pneumococcal proteins, although the IgM response 
was less intense than that of IgG. We selected 19 bands for MALDI-TOF analysis 
that were either unique or the most immunoreactive when compared to the total 
cell extracts. A total of 15 proteins were identified from all the bands, corresponding to 7 
cytosolic proteins and 8 proteins predicted to be surface-located or exported (Table 3): 4 
were lipoproteins (MalX, ABC-SBP, AmiA and AliA), 1 was a secreted protein (LytC), 2 
were transmembrane proteins (IgA1 protease and PspA) and one protein containing the 
LPXTG-cell wall anchoring motif (putative surface-anchored -galactosidase precursor). 
Next, we immunized mice with serotype 8 EVs (10 μg/dose) and tested their protective activity 
in a survival model of lung infection after intranasal challenge with 4.5  105 CFU of the same 
pneumococcal strain. Sera were collected from both immunized and control animals to detect 
EV-specific antibodies. IgG was detected by ELISA in immune sera at 3 weeks, but not in the 
controls (Fig. 6A). In addition, we detected two reactive bands by Western blotting in sera of 
animals immunized for 3 weeks that were absent in control mice (Fig. 6B). MALDI-TOF/TOF 
analysis revealed that they contained the predicted secretory 1,4--N-acetylmuramidase LytC 
and the elongation factor Tu. The survival experiment revealed that 6 out of the 7 immunized 
animals survived challenge, whereas all the control animals died 2 days after challenge (Fig. 
6C). These results indicate that EVs are structures with a high immunogenic capacity and are 
able to induce protective responses when used as immunizing agents.  
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Figure 5. Immunoreactivity of pneumococcal extracellular vesicles (EVs) with human sera. Western blot analysis of serum 
immunoreactivity against EVs from all the pneumococcal strains compared to total cell extracts (TE). Three sera from non-infected 
people, and three sera from pneumococcus-infected patients were used to probe the membrane blots. Detection of IgG and IgM 
antibodies was carried out. Immunoreactive proteins of interest are labeled with numbers for further MALDI-TOF/TOF analysis.  
Figure 6. Immunogenicity and protective activity of extracellular vesicles (EVs) against pneumococcal infection. (B) IgG levels 
in mice sera immunized with 10 μg serotype-8 EVs (NC: non-immunized mice) at 1 and 3 weeks. (B) Immunogenicity of serotype-8 
EVs as revealed by Western blot, using pre-immune and immune sera of mice immunized with 10 μg EVs. NC: non-immunized. 1w: 
1 week. 3w: 3 weeks. (C) Protective activity, assayed as survival test, of serotype-8 EVs in immunized mice (10 μg EVs/dose) against 
intranasal infection by 4.5  105 cfu of S. pneumoniae serotype 8. n = 7 each group. Statistical significance of results is shown as * (P 
< 0.05) according to the Student’s t-test. 
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4. Discussion 
For many decades, it was assumed that only Gram-negative bacteria produced and released 
vesicles derived from the outer membrane (OMVs). From the 1960’s to 1980’s, several studies 
with the Streptococcus genus identified intracellular membranous structures termed 
‘mesosomes’ or even ‘chondrioids’ [25, 26] that appeared to be related to the cell division 
process [26]. Although these findings were considered by some to be artifacts stemming from 
electron microscopy preparations, in recent years it has been demonstrated that archaea, 
fungi and Gram-positive bacteria also produce EVs. Nevertheless, the mechanisms by which 
vesicles are produced and released still remain largely unknown in fungi and Gram-positives, 
because it was believed that their external cell walls would limit the studies. Here we show 
that the clinically important pathogen S. pneumoniae also produces EVs, as recently shown for 
other Gram-positive bacteria [12-14], and demonstrate that their production is active, not the 
result of auto-sealing of plasma membrane fragments from lysis of dead cells. We found that 
EV production increased from early to late exponential phase, with a culture viability of around 
100%, whereas in the late stationary phase when viability was reduced to 5%, EV production 
was significantly less. The size range of pneumococcal EVs (20-80 nm) is quite similar to that of 
the closely related genus Staphylococcus [12], but smaller than those described for Gram-
negative species [27]. Thus, according to the results obtained and the available 
recommendations for EV isolation, the pneumococcal structures described here can be 
considered as “bona fide” EVs [28]. 
In Gram-negative bacteria, OMV production is explained as a shedding process serving 
different purposes, e.g. a stress response, quorum sensing, avoiding the host immune system, 
and/or attacking the host [2]. Deatherage et al. showed that Salmonella typhimurium releases 
OMVs from both the division septum and the cell body [5]. The type of release depends on 
interactions among proteins from the outer membrane, inner membrane and the 
peptidoglycan layer in the periplasmic space. We wondered about the biogenesis of EVs in 
pneumococcus, an organism with a physical barrier, namely a thick peptidoglycan cell wall that 
could hinder production or export. To our knowledge, there is only one tentative model to 
explain the formation (but not the release) of EVs from organisms with external cell wall. 
Recently, Rodrigues et al have proposed the phenomenon of “inverted macropinocytosis” in 
yeast [29], by which the cell membrane undergoes a reshaping process through invagination 
and traps a portion of the cytoplasm. This could explain how proteins lacking known secretion 
signals may be exported, but no explanation for the release mechanism has been provided. 
Our data show that pneumococcal EVs originate from the plasma membrane by invagination 
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Band Locus Protein Name
Protein 
Score
%Coverage Subcellular locationa 
1 spr0565 BgaA 46 12 Cell Wall
2 spr1431 LytC 66 25 Secretory
3 spr1343 Tuf 72 31 Cytosolic
4
spr1343 Tuf 77 31 Cytosolic
spr1918 MalX 96 38 Lipoprotein
5 spr2020 RpsB 74 39 Cytosolic
6 spr0195 RpsC 95 56 Cytosolic
7 spr2020 RpsB 90 37 Cytosolic
8 SP70585_0899 RpsA 98 36 Cytosolic
9 spr0121 PspA 244 35 Membrane (1TMD)
10 SP70585_1722 SP70585_1722 86 36 Lipoprotein
11
spr2020 RpsB 81 37 Cytosolic
spr1343 Tuf 55 27 Cytosolic
12 spr1065 NrdE 90 36 Cytosolic
13 spr1707 AmiA 77 30 Lipoprotein
13 spr0327 AliA 71 29 Lipoprotein
14
spr1785 AsnA 88 53 Cytosolic
spr1343 Tuf 45 23 Cytosolic
15 spr1825 GapA 85 33 Cytosolic
16 SP_0071 Iga 41 9 Multitransmembrane
17 spr0121 PspA 372 38 Membrane (1TMD)
18 - Not found - - -
19 spr1431 LytC 147 44 Secretory
Table 3. Protein identification by MALDI-TOF/TOF analysis of immunoreactive bands of pneumococcal membrane vesicles 
with human sera. 
a
Protein categories were established according to LocateP subcellular predictions: lipoproteins were those 
predicted as lipid-anchored proteins; cell wall proteins, as those having an LPXTG motif; secretory proteins, as those possessing an 
SP1-type signal peptide; membrane proteins with one transmembrane domain (TMD), as those possessing either a C- or an N-
terminally anchored transmembrane region; membrane proteins with more than one transmembrane domain, those predicted as multi-
transmembrane proteins; “surface proteins” means the sum of the five previous categories; and cytosoliic proteins, those without any 
exporting or sorting signal, and predicted as intracellular proteins. 
and accumulate predominantly in the division septum region. In addition, we have preliminary 
experiments showing that EVs can escape the cell from the division septum region during the 
division process, and that the presence of the cell wall is required for EV release (results not 
shown). However, further research is needed to contrast this hypothesis, in order to propose a 
mechanism by which EVs are released in Gram-positive bacteria.  
We observed by SEM that the R6 strain is surrounded by vesicle-like particles. Similarly, atomic 
force microscopy has shown vesicles surrounding Staphylococcus aureus cells [16]. The thick 
and irregular capsules of the encapsulated strains used in this study made it impossible for us 
to distinguish vesicles from polysaccharide material by SEM. In fact, the presence of 
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polysaccharide capsules may explain why we recovered less amounts of EVs from serotypes 1, 
6B, 8 and 23F than R6. Nonetheless, the fact that these strains did produce EVs suggests that 
EV production is widespread in pneumococcus and it could have a role in host-pathogen 
interaction. 
Our data show that EVs are derived from the bacterial plasma membrane. Consequently, the 
composition of both fractions is quite similar, although some features differentiate them. 
Comparative proteomic analysis revealed that most of the EV proteins were predicted as 
cytoplasmic. This is not surprising, as proteomics studies of membrane fractions often yield a 
high proportion of this group of proteins that remain attached despite careful fractionation 
methods [30, 31]. Previous proteomic analyses of EVs from other Gram-positive species have 
also revealed a predominance of cytoplasmic proteins [12-14]. We tried to reduce cytoplasmic 
proteins by treating both fractions with sodium carbonate followed by ultrafiltration through a 
100,000-kDa membrane, but the results did not change significantly when compared to the 
respective non-ultrafiltered fractions (results not shown). However, the proteomic analysis 
revealed that EVs were more enriched than the plasma membrane in the lipoproteins group, 
which has been also observed in EVs from Mycobacterium spp. [13]. 
Our biochemical characterization of EVs also revealed a higher proportion of short-chain fatty 
acids (C12 to C16) than in the plasma membrane. This would provide, at least in part, a 
biophysical explanation for why such vesicles separate from the rest of the membrane, since 
the shorter (and more unsaturated) the fatty acid composition is the more fluid a membrane is 
[32]. Whether this is a mechanism to release stress or whether it has other biological purposes 
requires further study. These results, together with those of proteomic analysis, size-exclusion 
chromatography and electrophoretic profiles, reveal that EVs and plasma membrane resemble 
one another in essential aspects, but have some different biochemical features. 
It has been reported that EVs act as transporters of toxin cargo [14, 16] that is delivered to 
host cells [16, 33]. We show here that pneumococcal EVs carry many reported immunogenic 
protein antigens [22]. Three of them were confirmed by Western blot using sera raised against 
recombinant proteins. One is the toxin Ply, the most widely studied pneumococcal protein 
virulence factor [34]. Its presence in pneumococcal EVs was also validated by EM-immunogold 
staining. This protein lacks any kind of known exporting/secretion signal sequence(s). 
Traditionally, it has been thought that its release is mediated by autolysis of bacterial cells [35, 
36] via a process of “fratricide” that is thought to protect and ensure the survival of sibling
cells [37]. However, it has recently been suggested that Ply can be released in a non-autolysin 
dependent way whose mechanism remains yet undefined [38]. Thus, the existence of EVs 
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could explain, at least partially, how this crucial virulence factor is exported, although it cannot 
be ruled out that Ply is released simultaneously by several mechanisms including autolysis. 
The immunogenicity and protective activity of pneumococcal EVs in this study suggests that 
they could hold promise as antigens in future vaccine formulations. EVs were more 
immunoreactive with human sera than equivalent amounts of total pneumococcal cell 
extracts. Nevertheless, quantifying EVs by using protein concentration can be controversial, as 
no linear correlation is always achieved between protein amount and number of EV particles 
[28]. However, no other criterion can be used for comparing them with total cell extracts, and 
although we cannot exclude that the number of EV particles among different preparations and 
strains may vary, the amount of protein used for comparing both fractions was the same.  
Nearly half of the immunoreactive proteins identified by MALDI-TOF MS analysis were 
cytoplasmic. This is not surprising, as there is extensive literature reporting immunogenic and 
protective capacities of bacterial cytoplasmic proteins [39-48]. The way in which these proteins 
become immunogenic is not yet clear, although their transport in vesicles might be an 
explanation for how they could be exposed to the immune system [49]. We have also 
identified 8 predicted surface proteins in our EVs, most of which were significantly enriched in 
EVs compared to total cell extracts. One of the identified proteins was a predicted cell wall 
protein, the -galactosidase precursor, whose predicted molecular weight is 246 kDa. 
However, given that we identified the protein from a band of ca. 120 kDa, it cannot be ruled 
out that the protein found in the EVs is a truncated version that lacks the LPXTG cell wall-
anchoring motif. This has been described for other streptococal cell wall proteins, such as 
DNase, for which a secreted version is found in S. pyogenes [50]. In addition, the reaction of 
sera from non pneumococcal-infected patients to EV proteins can be due to the fact that those 
people may have been colonized (asymptomatic carriers). Actually, the identification of 
proteins by MALDI-TOF/TOF from control-2 serum (bands 16-19, Fig. 4.5) indicates that specific 
antibodies against such antigens are produced in those individuals. 
Finally, we have demonstrated that pneumococcal EVs are immunogenic in mice, and that 
immunization of animals with them protects against infection with a virulent strain. EVs 
induced antibodies against LytC, whose protective activity has not been assayed so far, but 
whose immunogenicity and implications in virulence and complement evasion has already 
been studied [51-53]. By using the “shaving” approach of live bacterial cells [23, 54, 55], we 
have identified LytC in 16 out of 27 paediatric pneumococcal clinical isolates (unpublished 
data). Previously, Rivera et al showed that immunization of mice with Bacillus anthracis EVs 
induced antibodies that protected against experimental anthrax [14]. We chose serotype 8 for 
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immunization and challenge because this serotype is not included in the currently licensed 
polysaccharide-conjugate vaccine and has emerged as a replacement serotype [56, 57]. 
In conclusion, we report that pneumococcus actively produces EVs from the plasma 
membrane, to which they have biochemical similarities, but also some unique features. 
Pneumococcal EVs are strongly immunogenic and induce protection against infection, thus 
making it possible to use them in vaccine formulations, once standardization of their 
production and composition was carried out. Our work raises important questions regarding 
the participation of some of the proteins found in their composition in the biogenesis, release, 
immunomodulation, immunogenicity or protection. Thus, our work opens new areas of 
research with direct relevance to pneumococcal pathogenesis and prevention of human 
disease. 
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1. Introduction 
Microbial life has evolved over the millennia to survive and thrive in a wide variety of 
environments across the globe. Many diverse species live in a temperate environment, with 
some, like as bacterial pathogens, specialized to colonise host organisms. Other organisms, as 
archaea, occupy the extreme environments of the world. Regardless of the location, microbes 
have needed to evolve tools to cope with and grow within a changing environment. One such  
that has develop to facilitate microbe-microbe, microbe-host and microbe environment
interactions is the production of membrane-derived extracellular vesicles (EVs). EVs are typically
10–300 nm spherical blebs that originate from the outermost cell membrane, although their size 
range can vary depending on the species. EVs are distinct from membraneous blebs (1-3)
produced during cell lysis as they are produced as a regulated, selective secretion event (4-7). 
For nearly five decades, the study of EV formation by prokaryotes has focused on Gram-negative
bacteria (8, 9), for which the production is a conserved phenomenon, both in pathogenic and 
non-pathogenic species (10). To this regard, several studies have provided important evidence 
supporting the hypothesis that OMV production represents a pathway for the secretion of 
specific proteins (11, 12), as well as formation mechanism (13-15) and production modulation by 
altering levels of envelope proteins, temperature, oxidative stress or contact with host cells (5, 
16-20). Only more recently, attention has turned to determining if EV production is an
evolutionarily conserved process that also occurs for Gram-positive species since it was assumed
that the existence of a thick, rigid cell wall would prevent the release of membrane blebs. In 
addition, some studies addressing mesosomes in streptococcal species during the 1960’s had 
been abandoned as they were thought afterwards to be an artifact (21, 22). Still, existence of EV 
production in Gram-positive has been recently demonstrated (23). However, while EV produced
by Gram-negatives derived from the outer membrane (and therefore are termed “OMV”), in
Gram-positive possible mechanism for the production has been proposed, although none have
been directly tested or proven (1, 24). Similarly, production modulation and formation 
mechanism of extracellular vesicles in Gram-positive bacteria remains unclear (25).
EVs are related with offense and defense roles. One of the benefits of EV production for bacteria
is their ability to function as a secretion mechanism for complex mixtures of soluble and 
insoluble factors. Due to the small size, complex composition and protective aspect of EVs, they
are capable of facilitating the dissemination of a concentrated cohort of protease-protected 
virulence factors at a distance (2, 25), as well as transfer these into host cells (26) and modulate
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or suppress the immune system (1, 27-30). On the other hand, EV mechanism could be used to
promote cell-cell communication or competence with other species and establish a niche in the 
host (20), as decoy functions (31), release internal stress (5, 15) or contribute to polymicrobial 
communities (1, 32, 33). Furthermore, concentrating toxins in the vesicles appear to have 
relevance in folding and antigen presentation (34), and to facilitate the necessary interactions 
between them (2). Finally, EVs can attach to host cells and fuse with the host cell membrane (35)
or become internalized by the host cell (36, 37) to different purposes. In laboratory-based 
applications, EV are may be used as a new heterologous protein production system because of 
their property of concentrating certain types of proteins inside them, trying to improve problems 
of folding and post-traductional modifications (38). Moreover, EVs may be used too as diagnostic
tools, as Ziegenbalg et al. proposed for Mycobacterium tuberculosis (39) and because of its high
contain in virulence factors, adhesins and other proteins for pathogenesis. Therefore, their 
characterization could be useful for discovering new protein vaccine candidates. 
In this preliminary study, it is demonstrated that virulence factors transported by EV are
transferred to J774 macrophage host cells by membrane fusion and modulate the immune 
response. These findings could lead to new types of drugs to prevent pneumococcal infections.  
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2. Material and Methods 
2.1. Cell line and growth conditions 
J774 macrophages were cultured at 37 ºC in a 5% CO2 atmosphere in air, in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 10% NTCC and 1% non-
essential aminoacids (Gibco BRL, Grand Island, NY, USA). 
2.2. Sample preparation 
2.2.1. Extracellular vesicles purification
Vesicles were isolated as described (30), with minor modifications. The basic protocol involved a 
combination of serial differential sedimentation and density gradient purification. Briefly, cells at 
different ODs were pelleted from 1-L cultures and the supernatants were filtered through a 0.22-
μm–pore size polyvinylidene difluoride filter (Millipore Express Plus). The supernatants were then 
centrifuged at 100,000 × g for 1.5 h at 4 °C to sediment the vesicular fraction into a pellet. The 
supernatant was then recovered to produce the secretome fraction by trichloroacetic acid 
precipitation and the pellet was suspended in 1 ml of PBS (137 mM NaCl, 2,7 mM KCl, 10 mM 
Na2HPO, 2 mM KH2PO, pH 7.4). Different batches were washed with PBS and centrifuged again at 
100,000 × g for 1.5 h at 4 °C. The resulting pellet was suspended in Na2CO3 or in PBS and mixed 
with 2 ml of Optiprep solution (Sigma-Aldrich) (yielding 35% [w/v] Optiprep final concentration). 
The crude vesicle sample was then overlayed with a series of Optiprep gradient layers with 
concentrations ranging from 35%–5% (w/v). The gradients were centrifuged (100,000 × g, 16 h), 
and 1 ml fractions were removed from the top. The fractions were then centrifuged at 100,000 × 
g for 1 h at 4 °C and recovered. Finally, vesicles were suspended in PBS and quantified for protein 
amount (Bradford protein assay, BioRad).  
2.2.2. Macrophage total extracts 
Cells were washed twice with PBS and recovered with a cell scrapper in 8 M urea. Then, samples 
were sonicated with 3 cycles of 10 s at 70% of intensity. Finally, samples were centrifuged at 
5000 × g for 15 min, cell debris was discarded and supernatant proteins were quantified.  
2.3. Western blotting  
Immunochemical detection of proteins was performed by Western blot analysis. To detect 
presence of pneumococcal proteins in J774 macrophages after stimulation with EV, 400 μg of 
macrophage total extract were loaded in the case of Ply and PspA and 200 μg in the case of 
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bacterin (serum from mice infected with isopropanol-innactivated pneumococcal strain R6). 
Nonspecific sites were blocked by incubation with 5% non-fat milk (BioRad) in T-TBS (10 mM 
Tris–HCl pH 8.0, 150 mM NaCl, 0.01% v/v Tween) for 45 min. After two washes with T-TBS, a 
second 1h incubation of the membrane with different antibodies was carried out. Anti-Ply 
(Abcam, ab71810) and anti-PspA (Thermo Scientific, Pierce, MA1-10835) antibodies were diluted 
1:100. As secondary antibodies, 1:2,500 anti-mouse IgG-HRP conjugated (Sigma) was used. 
Following 1 h incubation, membranes were washed three times with TBS and afterwards 
revealed with ECL Plus Prime Western Blotting Dectection System (GE Healthcare) according to 
the manufacturer’s instructions in a ChemiDoc (BioRad). For NFƙB and Cathepsin D analysis, 30 
μg of macrophage lysates were separated by SDS-PAGE and then transferred to PVDF 
membranes. The blots were blocked with 5% (w/v) nonfat dry milk in PBS for 1 h at room 
temperature and subsequently incubated overnight at 4 °C with 1:1,000 rabbit NFƙB–antibody 
(Invitrogen), 1:200 goat polyclonal IgG Cathepsin D antibody (SantaCruz Biotechnology, C-20) and 
1:5,000 β-actin HRP-conjugated (SantaCruz Biotechnology) in PBST with 5% (w/v) nonfat dry milk. 
Following 3 washes of 5 min each with PBST, the blots were incubated with horseradish 
peroxidase–conjugated rabbit anti-goat IgG (for Cathepsin D) and goat anti-rabbit (for NFƙB) IgG 
(Southern Biotech) in blocking buffer for 1 h at room temperature. After 3 washes with PBST, the 
blots were developed by chemiluminescence using the ECL-pico Western Detection Kit (Pierce) 
and exposed to X-ray film (Kodak XAR5). Measurements were performed using ImageJ 1.40g 
software (N.I.H., U.S.A.). 
2.4. Transmission electron microscopy 
Electron microscopy samples of about 1 ml of cultured cells were pre‐fixed for 15min in an equal 
volume of glutaraldehyde‐paraformaldehyde mixture in 0.1 M cacodylate buffer until final 
concentrations of fixatives were 1.25 and 1% respectively. Then, cells were pelleted by 
centrifugation at 5,000 rpm for 10 min at 4 °C in Eppendorf tubes and the following processes 
were performed in the same tubes. Cell pellets were fixed in a mixture of 2.5% glutaralhedyde-
2% paraformaldehyde in 0.1 M sodium cacodylate buffer for 4 h and post fixed in 1% osmium 
tetroxide for 1 h at 4 ºC in the same buffer. After dehydration in an ascendant series of ethanol, 
the pieces were transferred to propylene oxide and sequentially infiltrated in Embed 812 resin. 
The sequence propylene oxide‐resin 2:1, 1:1 and 1:2 throughout 24 h was used. After that, 
samples were transferred to pure resin for 24 h. Then, the tubes were transferred to an oven at 
65 ºC and allowed to resin polymerization for 48 h. Once removed from the tubes, the resin 
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blocks were sculpted and sectioned in an Ultracut Reicher ultramicrotome and sections were 
mounted on nickel grids. After staining in aqueous 4% uranyl acetate and Sato’s lead citrate 39, 
the sections were observed in a Philips CM10 electron microscope. Pictures were taken at 
different magnifications using a digital camera. We obtained low magnification pictures to 
evaluate cell sizes. Higher magnifications were used to get pictures of a few EV. On higher 
magnification pictures, we measured diameters of individual EV in and out the cells in each 
experimental group. Measurements were performed using ImageJ 1.40g software (N.I.H., U.S.A.). 
2.5. Confocal microscopy 
For analysis by confocal microscopy, coverslips were washed twice with PBS, fixed with PBS/4% 
paraformaldehyde 15 min at 4 ºC, washed twice with PBS and mounted with PBS/70% glycerol. 
Confocal microscopy was carried out using a NIKON D-Eclipse C1 Confocal Laser with a NIKON 
Eclipse 90i Microscope. Images were captured with a NIKON colour camera (24 bit), using aplan 
Apo NIKON 60X and 100X objective(s). Fluorescence was recorded at 488 nm (green; FITC), and 
543 nm (red; rhodamine isothiocyanate B-R18). The images were adjusted and assembled in 
Adobe Photoshop 7.0. Quantification of fluorophore colocalization in confocal stacks was done 
using NISElements AR 3.2 software (Nikon). Pearson’s colocalization coefficients (rp) were 
calculated from quantitative data obtained from five confocal stacks. For morphologic analyses of 
mitochondria, acquired images were analyzed with ImageJ Version 1.43u software (National 
Institutes of Health).  
2.6. Immunogold labeling 
EV were stained with CFSE (Invitrogen) at a 10-μM final concentration in PBS for 30 min at 37 °C. 
Cells in growth media were fixed 1:1 with an equal volume of 4% paraformaldyhyde/0.4% 
glutaraldehyde in 0.2 M PHEM buffer, embedded in 5% gelatin, cubed, infiltrated with 2.3M 
sucrose, and frozen in liquid Nitrogen.  Sections (80nm) were cut at -120°, picked up in a 
combination of sucrose and methyl cellulose, stained with 4% Uranyl Acetate and viewed on a 
JEOL 1200EX transmission electron microscope at 80kV. 
2.7. Membrane fusion assay 
To assess membrane fusion between S. pneumoniae EV and J774 macrophage cells, 50 µg of EV 
were labeled with rhodamine isothiocyanate B-R18 (Molecular probes) at a saturated 
concentration (1 mg/ml) for 1h at room temperature. Fluorescence of this probe is quenched at 
high concentrations in bilayer membranes, and dequenched when the probe is diluted due to 
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membrane fusion Unlabeled probe was removed by centrifugation at 100,000 × g (60 min, 4 ºC). 
After a washing step (PBS), B-R18-labeled EV were resuspended in 1 ml PBS. Subsequently, the 
host cell plasma membrane was labeled with FITC-conjugated cholera toxin B subunit (CtxB) 
(Sigma-Aldrich) at a concentration of 8 mg/ml for 1 h prior to the incubation with EV. CtxB binds 
to lipid raft-enriched GM1 ganglioside in the plasma membrane and is widely exploited as a 
marker to visualize lipid rafts. B-R18-labeled EV were then applied to the apical side of J774 
macrophages so that the EV were diluted 1:4 relative to the volume of DMEM medium in the 
wells. Cells were incubated with EV for different times at 37 ºC. When applicable, the cholesterol-
sequestering agent Filipin III was added at a final concentration of 10 mg/ml 30 min prior to the 
addition of EV. After the incubation with EV, cell samples were analyzed by confocal microscopy 
as described below. 
2.8. MTT assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was employed for 
macrophage growth assessment. Briefly, 5 × 104 cells were added into each well in a 96-well 
plate. After 24 hours, samples (pneumococcus, EV or Ply) at different concentrations were 
added. After stimulation (2, 4, 6, 8, 10 and 12 h), 175 μl of medium were removed and MTT was 
added for 2 h. Then, dimethyl sulfoxide was added to wells and absorbance at 570 nm was 
recorded in a microplate reader after over-night incubation. 
2.9. Cytokine measurement 
Macrophage culture supernatants of 5 × 104 cells stimulated with 20 μg/ml EV for 6, 9 and 12 h 
were assayed for a panel of mouse proinflammatory 7-Plex Ultra-Sensitive Kit ELISA (Mesoscale 
Discovery Systems Inc.), according to the manufacturer’s specifications. 
2.10. Statistics 
Statistical analyses were performed using SPSS v21.0.0.0. Student’s t test (2-tailed) was applied 
for experiments involving pairwise comparisons.  
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5.3. Results
5.3.1. Host cells respond to stimulation by EVs 
The ability of pneumococcal EV to elicit a response in cultured eukaryotic host cells as aasessed. 
Murine macrophages were stimulated with different concentrations of EV (10, 20 and 50 μg/ml) 
and assayed for survival. First, we used the MTT cytotoxicity assay, which measures cell viability, 
preferentially in an apoptotic way. As positive controls, we infected the macrophages with each 
strain (MOI = 10:1); as negative controls, we used the same bacteria after killing by treatment 
with isopropanol for 1 h (Fig. 5A). As expected, live bacteria induced cell death, whereas killed 
bacteria did not. When EV were added to the cultured macrophages, cell death occurred in a 
dose-dependent manner, being the highest at 50 μg/ml (Fig. 1B). For all doses and strains, a 
transitory death cell effect was observed, with the highest death rates occurring 8 h after EV 
stimulation. In all treatments, cytotoxic effects disappeared with time, as survival recovered to 
initial rates. The highest cell death rates corresponded to EV from serotypes 1, 8 and 23. 
Alternatively, we used the LDH cytotoxicity assay, which measures the amount of this enzyme 
released by the cells, and is preferentially associated to necrotic cell death. No significant 
reduction of cell lysis was observed (Fig. 2).
Next, we evaluated the capacity of EV to produce a pro-inflammatory response in macrophages 
by measuring cytokine production after stimulation with a EV concentration of 20 μg/ml (Fig. 1C). 
We used a multiplex assay including six representative cytokines and one chemokine (IFN-, IL-10, 
IL-12 p70, IL-1, IL-6, TNF- and mKC). For most times and strains, the peaks of production were 
obtained at 9 h after stimulation. EV from serotype 8 caused a stronger induction effect than the 
other serotypes. EV also induced the production of cathepsin D, a well-known marker of 
apoptosis, thus supporting cytotoxicity data obtained with the MTT assay. Finally, we also 
measured the levels of NF-B as a mediator of the cellular response to infections and other types 
of stress and cathepsin D as apoptotic marker. Both were also induced in the macrophages by EV 
stimulation. Together, these results indicate that pneumococcal EV are biologically active and 
induce an immune response in cultured cells. 
Figure 1. Murine macrophage responses to extracellular vesicle (EV) stimulation. (A) Survival MTT assay of cultured J774 
macrophages representing the controls of EV stimulation. As positive controls, infection with the different pneumococcal strains and 
pneumolysin (Ply) was carried out. As negative controls, infection was performed with isopropanol-inactivated bacteria. (B) Time-
dependent survival MTT assay of macrophages stimulated with EV from the different pneumococcal strains, at three EV concentrations. 
(C) Cytokine production by macrophages in response to EV stimulation, at a concentration of 20 μg/ml. Levels of cathepsin D and NF-
B were normalized with β-actin. Statistical significance of results is shown as * (P < 0.05) according to the Student’s t-test. 
Ph.D. Thesis – Alfonso Olaya Abril   Chapter V 
198 
Figure 2. Murine macrophage responses to extracellular 
vesicle (EV) stimulation. Survival LDH assay of 
macrophages stimulated with 20 µg/ml EVs from the different 
pneumococcal strains, at different times.
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3.2. EV release their content into host cells via membrane fusion Whether 
EV transfer their cargo to infected cells was investigated then, as well as the mechanism by 
which this occurs. macrophages were incubated with EV and the presence of pneumococcal 
proteins in macrophage cells was assessed at different time points by immunoblot of 
macrophage lysates using an anti-bacterin serum (i.e. a serum against killed bacteria). These 
experiments revealed that the EV content was transferred to the macrophages as early as 30 
min after incubation (Fig. 3A). In contrast, no bacterial proteins were detected in controls (non-
treated and time 0 macrophages). The same results were observed when we used antibodies 
to Ply and PspA, although for Ply, the transfer of the protein to the macrophages was not as 
clearly observed for EV of the strains from which they were isolated. 
Then, EV were labeled with rhodamine-R18, a fluorescent dye that emits light after 
dequenching when it concentration diminishes. The rationale for this experiment was to add a 
high concentration of the dye to the EV, such that it would be quenched and no emission could 
be recorded. Light emission would only occur after fusion with another membrane, because of 
rhodamine-R18 dequenching by dilution. Confocal microscopy analysis of cultured 
macrophages revealed a clear increase in red fluorescence after 30 min incubation with 
rhodamine-labeled EV that was not observed in non EV-treated macrophages (Fig. 3B).
The ability of bacteria to release EV within the macrophages once they had been ingested by 
phagocytosis, using transmission electron microscopy analysis of the macrophages infected 
with all the serotypes and by anti-Ply immunogold staining in the case of S. pneumoniae 
serotypes 8 and 23F macrophage infection, was tested. Although EV release was not 
unambiguously observed (Fig. 4), we found that the gold particles were concentrated in an 
area very close to the cell division septum after immunogold staining with anti-Ply antibody 
(Fig. 4C), suggesting that Ply release could be directed through areas of cell wall lability or 
absence.   
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Figure 3. Fusion of pneumococcal extracellular vesicles (EVs) with the plasma membrane of cultured macrophages. (A) 
Transfer of EV content to macrophages, analyzed by Western blotting. Macrophages infected with EV were cultured at different time 
points (0, 30, 60 and 90 min), washed twice with 1X PBS and hybridized with anti-bacterin serum and sera raised against Ply and 
PspA. As control (lane M), infected macrophages with each strain at time 0 were used, as well as uninfected macrophages. The same 
results were obtained. (B) immunofluoresence microscopy analysis of the interaction between macrophages and EV. Macrophage cell 
membranes were labeled with the lipid rafts-marker CtxB conjugated with FITC (green fluorescence, left column), and EV were 
labeled with rhodamine-R18 (red fluorescence). EVs (20 μg/ml) fused to macrophage membranes after 30 min incubation (second 
column). Merge of both fluorescence emmision lights is represented in the right column. (C) Anti-Ply immunogold labeling of 
macrophages infected with pneumococcal cells. The top picture represents two bacterial cells from which Ply appears to be secreted 
from an area very close to the cell division septum. The three following pictures show gold particles in areas close to the 
phagolysosome within bacterial cells are found. Bottom picture is a negative control, with no primary (anti-Ply) antibody employed. 
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Figure 4. Transmission electron microscopy of macrophages infected with pneumococcus. Shown are pictures of murine 
J774 macrophages after 1 h infection with R6, ST1, ST6B, ST8 and ST23F pneumococcal strains.  
4. Discussion 
The proposed biological functions of bacterial EV include that they can confound the host 
immune system, making it put their efforts against such vesicles, instead of bacterial cells. At 
the same time, vesicles could function as offensive weapons that pathogens may use to 
damage the host immune system from a distance. Here we report that stimulation of cultured 
macrophages with pneumococcal EV has a transient effect on survival, causing a decrease in 
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viability in a dose-dependent manner. This cell death might take place preferentially by 
apoptosis, as macrophages were sensitive to the MTT assay and because of the induction of 
cathepsin D. In addition, no cell death was observed with the LDH cytotoxicity assay. These 
results suggest that host cell death is more likely to occur by apoptosis than necrosis, although 
it cannot be excluded that both could take place. Previous reports describe the cytotoxic effect 
of bacterial EV on host cells, both in Gram-positives (25, 37) at long time exposures (24 h) of 
epithelial cells to S. aureus EV, and Gram-negatives, at shorter exposures (8 h) of epithelial 
cells to P. aeruginosa OMV (40). It also show that pneumococcal EV promote a
proinflammatory response in macrophages as measured by cytokine production, consistent 
with previous reports on S. aureus (41) and Mycobacterium (30). However, this putative 
offense function would be inconsistent with the fact that these structures are capable of 
stimulating protection against infection by the same species that produces them (Chapter IV). 
Thus, this suggests that the real biological function of membrane vesicle production is 
addressed in a complex process in which interspecific factors probably occur (20). 
It has been shown that EV fuse to host cell membranes and transfer their content into 
macrophages. For Gram-positive and Gram-negative organisms (25, 37, 40) this fusion is 
cholesterol-dependent and mediated by lipid rafts. Test this with pneumococcal EV and 
murine macrophages using the cholesterol-blocking agent Filipin III was carried out, but 
positive results were not obtained. Neither was definitively demonstrated that the fusion of EV 
to the macrophage cell membrane occurs through lipid rafts, as clear overlaps of both 
rhodamine-R18 and FITC-CtxB were not observed. However, confocal microscopy data clearly 
show that EV fuse to host cell membranes, regardless the mechanism by which this occurs. 
The EV content was transferred to macrophages as soon as 30 min after contact, as revealed
by Western blot analyses. However, that part of this transfer may be due to phagocytosis of EV 
by the macrophages cannot be excluded. To understand whether EV could be produced in vivo 
within host cells, macrophages were infected with serotypes 8 and 23F. Although we could not 
observe EV release from bacteria in phagolysosomes, immunogold staining with an anti-Ply
antibody revealed that the gold particles were concentrated in very specific areas close to the 
division septa. This finding reinforces the hypothesis that EV are released near the cell division 
septum and suggests that this could be a way in which Ply is secreted. 
In conclusion, here it is reported that vesicles modulate the host immune system, inducing a 
proinflammatory response and transitory death of macrophages, which is mediated by their 
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fusion with the plasma membrane of host cells and transfer of their cargo. Thus, this work 
opens new areas of research with direct relevance to pneumococcal pathogenesis and 
prevention of human disease. 
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In this work, 40 clinical isolates (corresponding to 29 different ST) without evolutionary 
relationship (Appendix III) plus reference strains R6 and TIGR4 were analyzed by the surfomic 
approach, as well as four strains of different clinical manifestations (serotype 1, 6B, 8 and 23F) 
were used for extracellular membrane-derived vesicles characterization. Immunoreactivity of 
95 pneumococcal recombinant proteins was tested by different techniques against sera from 
patients with pleural empyema caused by pneumococcal infection and against healthy patients 
or with other non-pneumococcal related clinical manifestations. This allowed us to select a set 
of a few proteins (PrtA, PulA, LytC, LytA and PblB) to develop a fast and reliable test of 
pneumococcal disease in children from 0->5 years old. This biomarker tool of pneumococcal 
disease would solve the problems in diagnostic methods above described and it is also an easy 
to use and inexpensive to produce. 
On the other hand, survival assays carried out using a virulent strain of serotype 8 as infecting 
agent let us describe the protective capacity of 7 novel fragments of 
pneumococcal recombinant proteins. One of them, PulA, was statically different to the 
control but with very low degree of protection against our fatal assay in mice. 
However, when serotype 8 extracellular membrane-derived vesicles (EVs) were used, high 
level of protection was observed. These MVs could be compared with the whole cell 
vaccines, where a high number of antigens are used in a single use. Nevertheless, the 
same problems are found (described above), and therefore LytC, the most immunogenic 
protein contained in them in the survival assay, was tested as a vaccine in an independent 
experiment with no good results.
Then, although this work represents the highest pan-surfomic and serological analysis 
carried out in pneumococcus to date and let us finding a statically correct serological 
test for pneumococcal disease and discover novel protein vaccine candidates, some 
considerations must be kept in mind. For example, the number of clinical isolates subjected 
to the “shaving” protocol should be increased and should make an attempt to approach more 
to in vivo models. This would reveal the possible differential expression occurred in an 
infection process and would help to select those proteins associated with disease and not 
with colonization. This is one of the drawbacks of current pneumococcal vaccines, which do 
not differentiate between the two states and eliminates all pneumococci, including 
the colonizing ones. This differentiation may serve to maintain protection under 
pneumococcal colonization and not cause big changes in the ecology of the nasopharynx 
(157), which could be devastating in individuals with chronic respiratory diseases such as 
cystic fibrosis, or immunocompromised. On the other hand, as the most exposed and 
conserved regions of the proteins can be selected 
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by proteomics, more pneumococcal strains that those currently used (Appendix II) should be 
used in survival assays to increase the number of strains against the new vaccine protects (as 
for example serotype 8 used in this work). In addition, further research is needed to test the 
protection capacity of the proposed proteins in animal models of infection in ‘‘antigen 
cocktail’’ formulations, which could bring the given conditions when mice are immunised with 
vesicles or whole cell vaccines. Also to this regard, it must be considered that cellular 
immunity, in which interleukin 17A is considered to be very important (153), should be 
measure to ensure that these vaccine candidates stimulate immunity adequately to protect 
against disease but not against colonization. Moreover, the number of sera included in the 
analyses has to be increased in order to the representativeness of the results due to the 
heterogeneity arising from the large number of existing strains of pneumococcus and by the 
high prevalence of colonization. Finally, elucidating the real functions of pneumococcal EVs 
and its role in vivo together with its possible role with other related species with which it 
shares the ecological niche, will be important both in developing new strategies against 
pneumococcal infection and even for diagnosis. This is because it seems pointless that 
structures produced by pneumococcus are able, firstly, to modulate the immune response 
and, moreover, stimulates protection to the host against pneumococcal infection. 
Thus, although this study is not definitive, it could be a key to the development of new 
vaccines that meet all the requirements, as well as diagnostic tools necessary to detect 
pneumococcal disease in early phases of infection and let keep doing the puzzle that composes 
the molecular biology of pneumococcus. 
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1. “Shaving” live cells with proteases of Streptococcus pneumoniae is possible, although 
cell lysis is both intrinsic and due to experimental manipulation (Chapters I, II and 
III). 
2. The “pansurfome” of a collection of clinical isolates provides, in addition to vaccine 
candidates, antigens that could be used to develop serological tests (Chapters I, II 
and III) 
3. Immunization of mice with individual proteins selected from the analysis of 
“shaving” digestion of live cells of a set of pneumococcal clinical isolates from adults 
and children is not sufficient to confer immunity to infection by Streptococcus 
pneumoniae serotype 8 (Chapter III) 
4. Combination of 4 proteins (LytA, PrtA, PulA and PblB) proved as the best for the 
diagnosis of pneumococcal pneumonia with a sensitivity of 100% and a specificity of 
87.5% (Chapter III) 
5. Streptococcus pneumoniae produces extracellular membrane-derived vesicles that 
are able to transport virulence factors as well as modulate host immune response 
and protect from death to infected mice (Chapters IV and V) 
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1. Introduction: the importance of surface
proteins 
For any biological system, the interaction with the environ- 
ment takes place at, on, within or across the surface of cells 
that are in physical contact with the surrounding medium. 
Such a communication can be mediated by almost all the 
categories of biological molecules. However, proteins are 
undoubtedly the most relevant ones, because of their variety 
regarding structure, function and localization. To be able to 
interact with the surrounding environment, proteins must be 
exposed to some extent to the exterior of the organism. Those 
fulfilling this feature are both secreted (either freely soluble or 
encapsulated within a vesicle structure) and surface-attached 
proteins. The surface of biological systems can be very 
variable, comprising just a plasma membrane (as for most 
eukaryotic cells of pluricellular organisms), an outer lipid 
membrane (in the case of Gram-negative bacteria), a cell wall 
of polymeric nature (either peptidoglycan, chitin or others, as 
for Gram-positive bacteria and yeast-like, unicellular fungi) or 
a tegument (normally made of chitin, as is the case for many 
larvae and encapsulated forms of worm parasites). These 
different types of surfaces may be externally recovered by 
other structures like polysaccharide capsules (in the case of 
many bacteria) or extracellular matrices, which can be either 
loosely or tightly bound to the layer under them. 
The importance of surface proteins resides in the wide 
variety of functions that they carry out [1]: they can act as 
transporters of nutrients or ions; be receptors for molecules in 
order to trigger signal transduction cascades; be binding factors 
to other cells or biological surfaces; have enzymatic activities 
(for anchoring other proteins or molecules to the surface of the 
organism, e.g. sortases in Gram-positive bacteria; degrading 
molecules or structures of the own or others' organism(s), e.g. 
hydrolases such as proteases, lipases, hyaluronidases); etc. In 
the case of pathogenic microorganisms and parasites, surface 
proteins play key roles in the interaction with their hosts, as 
these proteins participate in important processes for the 
development of infections, such as adhesion to and/or invasion 
of tissue or organ surfaces, toxicity (mediated by released 
toxins) and immune evasion. But also, as being highly exposed, 
they have the highest chances to interact with the elements of 
the host immune systems, and therefore to be recognized as 
antigens. That is the reason why surface proteins are one of the 
best targets for drug and vaccine development [2,3]. 
Since the decade of the 1990s, in which the first complete 
and annotated genome sequence of an organism was released 
[4], biological sciences entered a new era that has made possible 
the massive analysis of a great number of biomolecules (genes, 
transcripts, proteins and metabolites) in a single or a few 
experiments. These technologies are generally termed as 
“omics” and are characterized by performing in a high- 
throughput manner the analysis and identification of hundreds 
and even thousands of molecules using automated platforms. 
The availability of genome sequences has grown exponentially, 
so that nowadays the scientific community has the possibility 
to analyze differences among varieties,  subspecies,  strains, 
etc. of a certain species by comparative “omic” analysis using 
metadata whose initial source is the collection of sequences of a 
given organism. 
The analysis of genome sequences through structural 
genomics tells us what can happen in an organism because 
of the genetic information contained in such a genome. 
However, the expression of genes and their effects on the 
phenotype are studied by the other “omics” (transcriptomics, 
proteomics, metabolomics) that are known as “functional 
genomics”, as the sole presence of genes in a genome does not 
inform us about what, when and to what extent a gene is 
expressed. The final molecular effectors of the gene functions 
in the cells are the proteins. Gene expression can be indirectly 
measured by using transcriptomic technologies (e.g. determin- 
ing the levels of  mRNA expression). But  both mRNA and 
protein levels are hardly correlated in most cases, because of 
post-translational phenomena that proteins undergo (post- 
translational modifications, degradation, turnover, etc.). There- 
fore, proteomics have emerged as a necessary tool for the 
identification of the set of proteins of a biological system (the 
“proteome”) integrating the information provided by genome 
sequences with the experimental analysis through mass 
spectrometry. In addition, proteomics provides experimental 
proofs of actual cell compartment localization of proteins. 
However, the study of proteins is more difficult than that of 
DNA or RNA, because of the enormous variations regarding 
physico-chemical features, abundance, subcellular location and 
interaction with other molecules or structures [5]. Thus, the 
preparation of the biological sample becomes one of the critical 
steps  for  further  analysis  and  identification,  especially  for 
avoiding or minimizing contamination by undesirable proteins. 
Concerning surface-attached proteins, these are especially 
hard to work with when compared to other types of proteins. 
This is mainly because of two reasons: their abundance is 
generally  low,  compared  to  proteins  from  other  cellular 
compartments, especially the cytoplasm; and many of them 
are quite insoluble, particularly those with transmembrane 
spanning domains [6]. Because of these attributes, Rabilloud 
wrote an article on the subject entitled “Membrane proteins 
and proteomics: love is possible, but so difficult” [7]. When 
using first-generation proteomics (i.e. protein separation by 
Ph. D. Thesis – Alfonso Olaya Abril  Appendix I
218
166 J  O U R N A L  O F  P R O T E O M I C S  9 7  ( 2 0 1 4 )  1 6 4 – 1 7 6 
2-DE followed by MALDI–TOF analysis), membrane proteins 
are generally underrepresented, as their low solubility in most 
rehydration buffers makes them precipitate during IEF. This 
problem does not exist for extracellularly secreted proteins, 
whose high solubility makes them more amenable for 
their study by this approach. Although new solutions have 
been proposed to overcome these limitations, as the use of 
alternative reducing agents (e.g. DeStreak) or loading methods 
(e.g. cup loading, paper-bridge loading) [8] that increase the 
number of membrane proteins identified from a 2-D gel, an 
important point cannot be addressed: the topological infor- 
mation of the proteins is lost. 
Second-generation proteomics uses gel-free approaches, 
based on LC/MS/MS analysis, for the identification of hundreds 
or thousands of species (generally peptides, after sample 
treatment with a protease) in a liquid sample. The wide array 
of combinations derived from these approaches makes possible 
to overcome the limitations attributed to gel-based proteomics 
regarding membrane proteins, as well as a more accurate 
quantification through both labeling and non-labeling 
strategies (see a comprehensive review by Speers and Wu, [9]). 
Moreover, the topological information of proteins spanning 
across a lipid membrane  can be obtained by different 
combinations of protease digestion and pH on membrane 
preparations, in order to “shave” selectively the outer and the 
inner domains, in a sequential manner [10,11]. 
2. The origin of the “shaving” procedure
As stated before, surface-accessible molecules of infectious or 
parasite organisms are among the best targets for host 
immunity [12]. Therefore, the rationale followed for the 
discovery of subunit-based vaccines lies on the fact that the 
immunogenic capacity of surface proteins may confer protec- 
tion against infection. This is particularly useful for infections 
caused by extracellular pathogens or parasites, for which the 
immune response is  predominantly  mediated by  humoral 
elements (B-cell type). In the pre-genomics era, the discovery 
of new protective protein vaccine candidates was made one- 
at-a-time, being very time consuming [13]. With the advent of 
the “omics” age, bioinformatics has grown in parallel to allow 
the processing of such a huge amount of information 
generated by  high-throughput, massive analyses. Thus, in 
2000 a revolutionary conception of protein vaccine candidate 
selection was born: the “reverse vaccinology” [14]. According 
to this, given the whole sequenced and annotated genome of 
a pathogen, it is possible to predict all the surface-exposed 
proteins by applying algorithms of subcellular localization (in 
silico selection of candidates). Genes coding for those proteins 
are then cloned and the recombinant proteins purified (with 
some restrictions: those theoretically very hydrophobic are 
discarded) and validated through any immunochemical 
technique (usually flow cytometry), in order to confirm the 
real surface exposure and, above all, the accessibility to 
antibodies. Those being positive in this test are further assayed 
for their protective capacity in animal models. This strategy, 
which was first applied for the group B meningococcus [15], 
allows to shorten the timetable to discover new candidates, 
compared to the classical, pre-genomics methods, in several 
years. This has a great impact from both health and commercial 
points of view. However, this method has an inconvenient 
aspect in that around one third of the genes of any organism 
code for surface-exposed proteins (including membrane pro- 
teins, lipoproteins, secreted proteins, etc.), which means at least 
hundreds of potential candidates. This implies that only very 
large research groups or companies are able to perform such 
an approach whose aim is finding some protective antigen. 
In addition, the uncertainty of real  antibody recognition is 
relatively high, as many of the proteins tested are negative 
when tested immunochemically [3]. Therefore, to find an 
alternative way for protein candidate selection became neces- 
sary, which overcame these two main issues, thus ensuring 
both a reduction of the initial set of candidates to be tested and 
the success rate of real surface exposure of those selected for 
further protection assays. 
The answer came from proteomics. Seeking the applied 
objective of identifying a highly reliable set of proteins to serve 
as vaccine candidate reservoir, a protocol was developed 
according to the second-generation proteomic principles: 2-DE 
would be discarded to avoid the forementioned problems 
derived from membrane proteins (in any microbial genome, 
the genes encoding membrane proteins are by far those 
predominant, when compared to those coding for other surface 
proteins). In addition, the procedure should recover the exposed 
domains of expressed surface-associated proteins, which 
cannot be predicted in silico. Two previous ideas were the 
source of inspiration of such a new protocol: on one hand, the 
possibility to selectively identify by MS/MS the regions of 
proteins located at one side of  a membrane after protease 
treatment [10,11]; and, on the other hand, the work by El-Hage 
et al. in which cultured live cells of Borrelia burgdorferi were 
treated with proteases aiming at identifying both protease 
sensitive and insensitive surface proteins that had been previ- 
ously selected [16]. In this work, protein identification was carried 
out by Western blotting and immunofluorescence microscopy 
using monoclonal antibodies against the studied proteins. 
Then, Rodríguez-Ortega and coworkers [17] designed an 
approach taking into account these two facts, and added the 
shotgun proteomic workflow for developing an innovative 
protocol of protease digestion of live bacterial cells, so that the 
exposed moieties of surface proteins could be recovered by 
centrifugation and filtration, and further analyzed by LC/MS/ 
MS (Fig. 1). Conceptually, if cell lysis is absent or minimized, 
the procedure should provide a collection of peptides corre- 
sponding to surface proteins, according to subcellular locali- 
zation algorithms. The idea was tested in the Gram-positive 
pathogen Streptococcus pyogenes (or GAS, Group A Streptococcus), 
as Gram-positive bacteria are expected to be more resistant to 
osmotic lysis because of their thick cell wall. After 30 min 
treatment with both a specific (trypsin) and an unspecific 
(proteinase K) protease, 72 proteins were identified, of which 
only 4 (6%) were predicted as cytoplasmic. Viability of treated 
cells was evaluated by colony-forming units (CFU) plate 
counting, and no significant differences were found when 
compared to the undigested bacteria. Prediction of subcellular 
localization was done using the PSORT algorithm [18]. Eigh- 
teen proteins (25%) were found in common to both protease 
digestions, whereas only 11 were exclusively identified by 
proteinase K. 
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After that, the real expression of the proteins on the cell 
surface and their accessibility to the antibodies were validated 
by flow cytometry analysis. Sera were obtained immunizing 
mice with recombinant GAS proteins, and 84% of the tested 
proteins were positive, thus indicating that the strategy can 
identify a highly reliable and reduced set of protein candi- 
dates that are immunogenic and with potential for further 
protection assays. In addition, for the 37 transmembrane 
proteins found, the topology of the domains with some 
identified peptide was calculated, according to PSORT pre- 
dictions. For most of the cases, both the predicted and the 
experimental topologies were in agreement. Nevertheless, 
discrepancies were found for 11 out  of the 37 membrane 
proteins. Seven out of these 11 proteins with large enough 
inter-transmembrane domains were tested by flow cytome- 
try, and 5 were positive, thus indicating that those domains 
carrying identified peptides by MS/MS are surface-exposed. A 
clear example is illustrated in Fig. 2, which shows the topology 
prediction of protein Spy0184, for which PSORT predicts 6 
TMD. However, the PSORT score for the fourth TMD was too 
low; if this TMD is not considered, the domain in C-term after 
the last TMD would be located outside of the membrane, 
instead of at the cytoplasmic side. The flow cytometry analysis 
using a serum against that domain (for which two peptides 
were identified by MS/MS) revealed a strong positive signal, 
thus indicating its actual surface localization [17]. 
The procedure also demonstrated its utility for new vaccine 
candidate discovery: a cell wall protein whose protective 
capacity had not been previously described, conferred protec- 
tion against infection in vivo. This strategy can be considered as 
a variation of the “reverse vaccinology”: the difference is the 
way of selecting the candidates, using experimental results 
(proteomics) instead of bioinformatics predictions (in silico). 
That is the reason why it was named as “the next chapter in 
reverse vaccinology” [19]. 
3. Variations of the “shaving” approach
To date, the strategy has been employed in a wide variety of 
organisms, not only with the aim of identifying the  whole 
array of surface-exposed proteins (either as descriptive or 
applied purposes, e.g. searching of a new protective antigen 
against infection), but to confirm one particular protein to be 
surface-located and protease-sensitive. In total, 24 different 
species, both prokaryotic and eukaryotic, have been subject to 
the “shaving” of their surfaces for further LC/MS/MS analysis 
of the generated peptides (which are referred to as “surfome” 
or “surfaceome”) (Table 1). The group of organisms for which 
the procedure has been most widely  applied is that of Gram-
positive bacteria (10 species in total), especially the 
streptococci: S. pyogenes [17,20,21], Streptococcus agalactiae [22], 
Streptococcus suis [23–26], Streptococcus pneumoniae [27] and 
Streptococcus equi [28]. Other Gram-positive bacteria studied 
by “shaving” are Bacillus subtilis [29], Staphylococcus aureus
[30–35], Enterococcus faecalis [36,37], Lactococcus lactis [38,39] and 
Mycobacterium avium subsp. paratuberculosis [40,41]. Eight 
Gram-negative bacterial species have been studied by this 
approach: Chlamydia trachomatis [42], Escherichia coli [43–45], 
Salmonella enterica [44], Capnocytophaga canimorsus [46], three 
species of Borrelia (B. burgdorferi, Borrelia garinii and Borrelia
afzelii) [47] and the marine planctomycete Rhodopirellula baltica
[48]. The shaving has been also used in 6 eukaryotes: the 
unicellular fungi Saccharomyces cerevisiae [49,50] and Candida
albicans [51,52], and the larvae of the helminth parasitic worms 
Schistosoma mansoni [53], Schistosoma bovis [54], Fasciola hepatica
[55] and Taenia solium [56]. 
So far, this strategy has allowed the identification of up to 
some tens of typically predicted surface proteins in some 
surfomes, i.e. those possessing some exporting/retention 
signal. However, no comparison can be made among species 
Fig. 2 – Correction of the topology of the Streptococcus pyogenes membrane protein Spy0184. A) The algorithm PSORT predicts 6 
transmembrane domains for  this  protein.  Two peptides  were  identified after  protease  “shaving”,  corresponding  to  a 
theoretically cytoplasm-located domain at the C-term. B) Elimination of the fourth transmembrane domain (low PSORT score) 
makes the last domain be surface-exposed, i.e. located at the extracellular side. Panel A is a reinterpretation of the topology 
representation  of  protein Spy0184 published in  [17]. 
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Table 1 – Summary of organisms in which the “shaving” approach has been applied.
Organism Classification Enzyme Cytoplasmic Viability assay Bioinformatics References
proteins (%) prediction
Streptococcus Gram + bacterium Trypsin, proteinase K 6–27% CFU plate count PSORT, SignalP, [17,20,21]
pyogenes TopPred, LipoP,
TMHMM
Streptococcus Gram + bacterium Trypsin, proteinase K 12% No Psortb v 2.0, LipPred [22]
agalactiae
Streptococcus Gram + bacterium Trypsin, proteinase K 0–70% CFU plate count LocateP [23–26]
suis
Streptococcus Gram + bacterium Trypsin 65% Flow cytometry LocateP [27]
pneumoniae
Streptococcus Gram + bacterium Trypsin 50% CFU plate count Psortb v 2.0, SignalP, [28]
equi LipoP, TMHMM
Bacillus subtilis Gram + bacterium Trypsin (free and 70% CFU plate count; Western No [29]
immobilized) blotting against cytosolic
proteins
Staphylococcus Gram + bacterium Trypsin (free and 40–50% CFU plate count; Western LipoP, TMHMM, [30–35]
aureus immobilized), blotting against cytosolic CWPred, SignalP, Psortb
proteinase K proteins v 2.0, SurfG +
Enterococcus Gram + bacterium Trypsin (free and 18–60% CFU plate count PSORT, LocateP [36,37]
faecalis immobilized)
Lactococcus Gram + bacterium Trypsin 42% DNA detection in culture Augur, LocateP [38,39]
lactis supernatants
Mycobacterium Gram + bacterium Trypsin 37% No Psortb v 2.0, TMHMM [40,41]
avium subsp.
paratuberculosis
Chlamydia Gram − bacterium Trypsin No DNA detection in culture No [42]
trachomatis information supernatants
available
Escherichia coli Gram − bacterium Trypsin, proteinase 10–57% CFU plate count PSORT [43–45]
K, chymotrypsin
Salmonella Gram − bacterium Trypsin, proteinase K No No No [44]
enterica information
available
Capnocytophaga Gram − bacterium Trypsin 22% No Not specified [46]
canimorsus
Borrelia spp. Gram − bacterium Trypsin Around 35% No SignalP, LipoP, TMHMM [47]
(B. Burgdorferi,
B. garinii
and B. afzelii)
Rhodopirellula Gram − bacterium Proteinase K 62% No Psortb v 2.0, TMHMM [48]
baltica (marine
planctomycete)
Saccharomyces Unicellular Trypsin 66% Flow cytometry Gene Ontology [49,50]
cerevisiae eukaryote
Candida Eukaryote (yeast Trypsin 20–80% Flow cytometry Gene Ontology [51,52]
albicans and filamentous
fungus)
Schistosoma Eukaryote Trypsin 41% Confocal microscopy Not specified [53]
mansoni (tremathode
parasite)
Schistosoma Eukaryote Trypsin 45% Optical microscopy Gene Ontology [54]
bovis (tremathode
parasite)
Fasciola Eukaryote Trypsin 60% Optical microscopy Gene Ontology [55]
hepatica (tremathode
parasite)
Taenia solium Eukaryote Trypsin 80% Optical microscopy Gene Ontology [56]
(cesthode parasite)
regarding the total number of these proteins identified, to 
evaluate the efficiency of this procedure, as this will depend 
on some factors, like the presence of a structure (e.g. a 
polysaccharide capsule) that may hinder the action of pro- 
teases. Since the  first  application  of  the  strategy,  this  has 
evolved according to the problems encountered by each 
organism and/or researcher, and to specific requirements 
arisen to cope with them. The following sections will sum up 
the aspects that have been considered for the improvement of 
such  a  protocol:  the  redigestion  of  the  already  generated 
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peptides; the use of unspecific proteases; and the use of 
immobilized enzymes. We will also discuss an intriguing 
aspect found when applying this approach (which is also 
present when other proteomic approaches are employed for 
the analysis of surface protein samples): the presence of 
predicted cytoplasmic proteins in the “surfomics” analyses. 
As will be discussed throughout this text, especially in 
Section 4, many works have shown that these proteins are 
found on the surface of many cells, or are present in the 
secreted fractions (so that they are referred to as “non- 
classical secreted proteins”). Numerous publications even 
demonstrate both immunogenic and protective activities of 
theoretically cytoplasmic proteins, so the concept of “subcel- 
lular localization” must be revised: rather than thinking of 
cells in terms of “snapshots”, mobility and trafficking among 
different compartments must be taken into account, i.e. pro- 
teins can be localized in different parts (even simultaneously). 
We present to the reader different hypotheses to explain this 
phenomenon. In our opinion, none of them are corroborated nor 
can be yet definitely rejected. However, to simplify the writing of 
this text, every time the term “cytoplasmic protein(s)” appears, it 
must be interpreted as “protein(s) for which algorithms of 
subcellular location predict to be in the cytoplasm, because 
lacking exporting/retention  signals”,  which,  according  to 
their presence in surfomes or secretomes, may be named as 
“non-classical secreted proteins”. 
3.1. Redigestion of “surfomes” 
In the original protocol described by Rodríguez-Ortega et al. 
[17], the digestion of surface-exposed moieties with proteases 
was carried out at relative short times (30 min), after which 
the peptides recovered were analyzed by LC/MS/MS. This 
rendered 72 proteins identified, of which 51 were found by 
trypsin treatment and 29 after proteinase K digestion. Only 11 
proteins were exclusively identified by this unspecific 
enzyme, and 18 were found in common with trypsin digestion. 
In total, 278 peptides were identified (172 tryptic peptides and 
106 coming from proteinase K treatment), which represents an 
average of less than 3.9 peptides/protein. The efficiency of the 
protease activities can vary by several factors: the abundance of 
their substrates, the accessibility of their cleavage sites or the 
environment in which the reactions take place. The protease 
treatment of live cells is carried out in a physiological buffer in 
which surface proteins (the target substrates of the analysis) are 
folded in their in vivo configuration and not necessarily exhibit 
the cleavage sites of the (specific) proteases. Although not 
discussed in the original article, review of the identified 
peptides reveals that a significant proportion of them were 
quite long (some of them reaching more than 50 amino acid 
residues). Moreover, a remarkably high number of tryptic 
peptides (56 out of 172, that is around 33%) had at least one 
trypsin missed cleavage site. Of them, 10 peptides had 2 missed 
cleavage sites, there were 5 peptides with 3 cleavage sites and 1 
peptide each for both 4 and 5 cleavage sites. This indicates that 
trypsin had not worked at its highest efficiency in the 
conditions used. Moreover, as very long peptides were identi- 
fied, even without missed cleavage sites, it cannot be discarded 
that longer peptides, with a mass out of the measurement range 
of  the  instruments,  would  have  been  excluded  from  the 
analysis, thus losing a very valuable information. The incom- 
plete digestion of proteins after “shaving” has been shown in 
E. faecalis [37] and S. pneumoniae [27], as revealed by the presence 
of high molecular-weight bands in “surfome” fractions exam- 
ined by SDS-PAGE. 
The first substantial modification to the original protocol 
came in 2008, when a redigestion step of the already generated 
“surfome” was added to the procedure. Tjalsma et al. [29], in 
B. subtilis, allowed the redigestion of the peptide-containing 
supernatant for 18 h by adding more trypsin. In S. suis, 
Rodríguez-Ortega et al. [26] carried out the redigestion of the 
“surfome” for 2 h. However, none of these works described 
whether this modification affected the number of identified 
peptides. 
In 2009, Doro and coworkers [22] “shaved” S. agalactiae with 
trypsin and proteinase K, and then carried out an overnight 
redigestion of the  “surfomes” using  newly  added  trypsin 
(2 μ g). Compared to the original protocol described in 
2006, 
the average number of identified peptides per protein was 
increased (5.5 vs 3.9). In addition, 5 out of the 43 proteins 
identified were only found after this double digestion. These 5 
proteins were identified each from 1 peptide, thus indicating 
that the procedure improves the identification of surface 
proteins. As expected, the presence of trypsin missed cleavages 
was considerably reduced: 27 peptides (12% of total) presented 
some missed cleavage, and only one had more than one missed 
cleavage (compared to the 17 peptides with 2–5 missed 
cleavages in the S. pyogenes study). 
Other organisms in which the redigestion of surfomes has 
been performed are: M. avium subsp. paratuberculosis [40], for 
which tryptic surfomes were allowed to continue the digestion 
for 12–14 h, but without adding new enzyme; E. faecalis [37], with 
1 μ g newly added trypsin overnight; S. pneumoniae [27], with 2 μ g 
newly added trypsin overnight; S. equi [28], without new 
enzyme, and for 20 min; and S. aureus for 4 h more after adding 
1 μ g new trypsin [35], or 30 min more after a very brief initial 
1-min “shaving” [34]. 
3.2. “Shaving” with unspecific proteases 
Trypsin is the chosen enzyme for digesting proteins in almost 
all the proteomic analyses, both for in-gel and in-solution 
samples, for several reasons: i) it is quite specific, as it cleaves 
always at the C-side of K or R residues, unless they are 
followed by P; ii) it works very well either in gel or in solution; 
iii) due to its specificity, it generates peptide fragments whose
length are ideal for mass spectrometry analysis; and iv) the 
peptides generated will have at least one extra positively 
charged group, because of ending either in K or R. Consequently, 
tryptic peptides generally are well ionized in the mass 
spectrometers. 
However, the use of a protease that cleaves after a specific 
recognition site implies that, for loops without a free end 
(i.e. loops corresponding to domains between two transmem- 
brane helices), two cleavage sites are needed in order to 
generate some peptide. In addition, these sites must be 
accessible to the protease. Therefore, it is expected that 
multitransmembrane proteins, with multiple inter-TMH loops, 
would protrude less from the underlying membrane than other 
motifs  with  the  same  length.  Moreover,  the  presence  of  a 
Ph. D. Thesis – Alfonso Olaya Abril  Appendix I
223
J  O U R N A L  O F  P R O T E O M I C S  9 7  ( 2 0 1 4 )  1 6 4 – 1 7 6 171 
covering structure like a capsule would make even more 
difficult the surface exposure of such domains, and then their 
accessibility to proteolytic enzymes. 
To overcome this potential problem, the original protocol 
included the use of an unspecific protease, the proteinase K. 
As it does not require the presence of any specific recognition 
sequence to cleave proteins, theoretically it should generate a 
plethora of fragments of a wide range of amino acid residues 
from a given substrate protein, supposed that it worked at its 
maximum activity. However, this great avidity for the sub- 
strates may become a problem, as it would be able to degrade to 
single amino acids a protein, working at its highest level. Then, 
the activity of this enzyme must be carefully controlled to have 
peptides that can be detected by the mass spectrometers. 
Proteinase K is active in a pH range of 4–12, being 8 the 
optimum pH [57]. For it to work at its maximum activity in vitro, 
Ca2+ is required. Removal  of this ion reduces the catalytic 
activity by around 80% [58]. Originally, a qualitative optimiza- 
tion was carried out in which the activity was controlled by 
lowering substantially the pH and eliminating the Ca2+ from the 
buffer [17]. It was found that a reasonable number of peptides of 
m/z values 500–3000 were generated after 30 min digestion at 
pH 6. However, the use of this enzyme presents a few problems: 
i) the reproducibility among both biological and analytical
replicates is low, due to the non-specific proteolytic activity of 
the enzyme (Rodríguez-Ortega, unpublished data); and ii) the 
quality of the MS/MS spectra of proteinase-K peptides is 
generally lower than that of tryptic peptides, as they lack the 
extra positively charged group in C-term (unless they end in a 
basic amino acid residue by chance). As a consequence, the 
number of proteinase-K peptides identified was lower than that 
of trypsin (38% vs 62%). In addition, it is impossible to use this 
enzyme for false-positive controls, because of its non-specific 
proteolysis [32]. 
But proteinase K “shaving” has also provided some 
advantages: i) the identification of some proteins exclusively 
by this enzyme: of the 11 proteins identified only after 
proteinase K treatment in S. pyogenes, 6 had transmembrane 
domains not sufficiently exposed to be “shaved” by trypsin; 
ii) two identifications corresponded to pilin proteins carrying
the LPXTG peptidoglycan-anchoring motif to the cell wall. Pili 
in Gram-positive bacteria are long filaments with adhesion 
functions, and are constituted by several protein subunit 
types [59–61]. These proteins have been previously described 
as T antigens, because of their resistance to trypsin digestion 
[62]. 
In other works, proteinase K has proven to provide 
additional information to trypsin: in S. agalactiae, 2 proteins 
were exclusively identified by the first enzyme [22]; in S. aureus, 
the number of exclusively proteinase-K digested proteins was 
14, one of them generating 28 peptides [32]. More recently, up to 
79 proteins have been identified by “shaving” the marine 
planctomycete R. baltica with proteinase K [48]. 
3.3. “Shaving” with immobilized enzymes 
An unresolved question derived from the “shaving” approach 
is, as will be discussed in the next section, the presence of 
predicted cytoplasmic proteins in the “surfomes”. Several 
hypotheses have been proposed to explain this phenomenon. 
One of them is based on the possibility that cleaving proteins 
embedded in biological membranes may destabilize cells and 
cause a decrease in viability or integrity. In the case of Gram- 
positive bacteria, the peptidoglycan cell wall does not consti- 
tute a compact, non-permeable web, but a kind of “fabric” 
allowing molecules up to 50 kDa to pass through [29]. Trypsin 
and proteinase K are relatively small proteases (around 23 kDa), 
so that they could penetrate, by passive diffusion, into the cell 
wall and reach the inner layers in contact with the underlying 
plasma membrane. Therefore, it has been proposed the use of 
immobilized proteases to avoid this issue, and to “shave” only 
domains at the outer plane of the cell surface. 
In 2008, Tjalsma and coworkers [29] used trypsin immobilized 
on agarose beads to “shave” B. subtilis, and compared these 
results with the  digestion by free  trypsin.  They  found  tens 
of proteins, both in the  “shaving”  and  in  the  “shedding” 
(i.e. material released to the incubation buffer and then 
trypsinized) fractions, and observed the following: i) in general, 
less proteins were identified from the immobilized trypsin 
treatment, and for those identified in both free- and 
immobilized-trypsin digestions, the number of peptides per 
identified protein was lower in the latter case; and ii) predicted 
cytoplasmic proteins were identified in both treatments, and in 
both fractions (“shaving” and “shedding”), thus indicating that 
their presence is not due to destabilization caused by trypsin 
treatment. 
Dreisbach et al. [30] also applied immobilized trypsin to 
S. aureus, followed by redigestion of the generated “surfome” 
with free trypsin, finding also proteins without any predicted 
exporting/retention signal. 
Similarly to that obtained for B. subtilis, Bøhle et al. found in 
E. faecalis [37] that treatment of cells with immobilized trypsin 
resulted in less proteins and peptides identified than in the case 
of free trypsin digestion, and also that predicted cytoplasmic 
proteins were found in both cases. However, the proportion of 
these proteins compared to the total was lower in the case of 
immobilized trypsin digestion. Nevertheless, it must be taken 
into account that immobilized enzymes have usually lower 
activity than their free versions. This can explain that treat- 
ments with agarose-bead trypsin originate less identified pro- 
teins than free-trypsin digestions. This might be a reason why 
this modification has not widely applied so far. 
4. Concerning the presence of proteins without
classical exporting/retention signals 
Perhaps the main concern of this approach derives from one 
of the theoretical advantages postulated when described the 
first time: the possibility of identifying in a fast and reliable 
way a set of surface proteins (by combining proteomic and 
bioinformatics analysis, complemented with validation by 
another experimental means like immunochemical studies) 
without the interference of proteins from other subcellular 
fractions, mainly the cytoplasm, in the “surfome”. Thus, when 
first applied in S. pyogenes M1_SF370, only 4 out of 72 proteins 
(i.e. 6%) were predicted as cytoplasmic. However, authors 
realized that the presence of these proteins would not be 
easily explained if they were too abundant, especially for 
projects with a clear applied purpose (e.g. searching protein 
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vaccine candidates). Actually, the proportion of predicted 
cytoplasmic proteins present in “surfome” analyses vary not 
only depending on the organism, but even among different 
strains of the same species. Thus, in S. pyogenes the 
percentages of  such  proteins  in  the  “pan-surfomic”  analysis 
of 16 different strains ranged from 6 to 35% (Rodríguez-Ortega, 
unpublished results), and in an integrative multi high- 
throughput approach, they represented 27% of total identified 
proteins   by   proteomics   in   a   more   reduced   number   of 
S. pyogenes strains [20]. Therefore, authors assumed from the 
beginning the following rationale: in the search of novel 
proteins with vaccine potential (those predicted as surface- 
localized or exported), the selection criteria would be that 
such proteins should be identified by a combination of 
proteomics and bioinformatics, and their real surface exposure 
experimentally validated in  terms of antibody accessibility. 
Predicted cytoplasmic proteins would be considered as 
remaining contamination from residual cell lysis, and therefore 
discarded for entering the pipeline of vaccine discovery and 
development. As lysis would be the limiting factor for the 
success of this approach, it was assumed that its application 
would be most suitable for Gram-positive bacteria, because of 
the cell wall  that,  in principle, should protect cells against 
osmotic lysis, contrarily to the soft cell surface of Gram- 
negative microorganisms. 
To explain the intriguing presence of predicted cytoplasmic 
proteins in the “surfomes”, at least three hypotheses might be 
considered: i) they come from cell lysis, which may be even very 
residual, thus contaminating the “surfome” fraction; ii) cyto- 
plasmic proteins have reached the surface by any exporting/ 
secretory machinery that does not use the canonical pathways; 
and iii) cytoplasmic proteins are released by shedding 
membrane-vesicle structures in which they are trapped. 
4.1. Hypothesis one: predicted cytoplasmic proteins come 
from cell lysis 
This is perhaps the simplest hypothesis to think of in order to 
explain the presence of this type of proteins. As said above, 
even a very minimum rate of cells undergoing lysis might be 
enough to find them in a “surfome”, as mass spectrometry is 
extremely sensitive, being able to detect peptides of mole- 
cules that are present in minor proportions. And, as also said 
previously, it was assumed to have the best suitability of the 
approach for Gram-positive organisms, because of the theo- 
retical protection against osmotic lysis provided by the cell 
wall. However, in this group of organisms the percentage of 
identified predicted cytoplasmic proteins is extremely vari- 
able (Table 1): from 0% in some clinical isolates of S. suis
(although it is true that in such isolates the absolute number 
of proteins found was very low) until 70% in some clinical 
isolates of the same bacterium [24] and B. subtilis [29]. The 
supposedly disadvantageous nature of Gram-negatives 
because of their greater fragility against osmotic changes is 
not reflected in the “surfomic” analyses carried out so far: the 
range of cytoplasmic proteins is between 10% (only 9 out of 86 
proteins in E. coli) [43] and 62% for R. baltica [48], figures that 
are even below the average compared to Gram-positive 
analyses. Moreover, many works have carried out assays of 
cell viability or integrity by different techniques (most of them 
by CFU plate counting, although this is not very precise; but 
also by flow cytometry, microscopy or DNA detection in 
surfomes or culture supernatants), and a significant reduction 
of cell viability/integrity after protease treatment has never 
been found, either in relative or absolute terms (Table 1). And, 
what is most difficult to explain, for multicellular, quasi- 
macroscopically visible particles like helminth parasite 
larvae, optical microscopy has revealed that these organisms 
are intact before and after protease treatment, and predicted 
cytoplasmic proteins have  been found up to 80% [53–56]. 
However, in these cases it cannot be discarded that during 
manipulation, some cells of the most external layers break up 
and release their cytoplasmic content to the protease incuba- 
tion buffer. 
In most cases, the “shaving” approach has been applied on 
cultures in the exponential phase of the growth curve. In this 
phase, cells undergo an active division, and the rate of cell 
death is very low. During the preparation of cells or organisms 
for protease digestion, samples are normally washed 2–3 times 
with a buffer. This should eliminate any remaining protein(s) 
retained on the surface by non-covalent interactions. In 
pneumococcus, the proteomic analysis of the washes revealed 
that, after the second one, no more predicted cytoplasmic 
proteins were present (Olaya-Abril, unpublished results). This 
indicates that such proteins must come out after resuspending 
cells in the protease incubation buffer. Time-course experi- 
ments have shown that cytoplasmic proteins are found either 
at shorter or longer incubation times, and that is independent 
on trypsin, as they are also found on the negative controls (cells 
incubated in the digestion buffer without the proteolytic 
enzyme) [27]. This has also been demonstrated in B. subtilis
[29] and S. aureus [30]. In addition, flow cytometry has revealed 
in pneumococcus that, for relative short trypsin incubation 
times (up to 30 min), around 99% of cells are viable and not 
lysed, both in non-trypsin controls and trypsin-treated bacteria. 
Therefore, it is possible that this very residual lysis of ca. 1% 
could explain at least in part the presence of predicted 
cytoplasmic proteins in surfomic analyses. Nevertheless, fur- 
ther research is needed to corroborate this hypothesis, and their 
presence could be explained also by other reasons. 
4.2. Hypothesis two: predicted cytoplasmic proteins are 
exported by non-canonical secretion pathways 
This hypothesis considers the possibility that lysis is not (at 
least in major terms) the source for finding surface-associated 
cytoplasmic proteins, but the existence of a secretion/exporting 
mechanism different from classical ones (type-I and -II signal 
peptides, transmembrane helices) able to translocate proteins 
with still unknown retention signals. Therefore, these proteins 
without any known secretion/exporting or retention motif are 
referred to as “anchorless” proteins, to which multiple func- 
tions are attributed (“moonlighting proteins”) [63–67]. 
In principle, the biological sense of the presence of predicted 
cytoplasmic proteins on the cell surface can be questioned. In 
pathogenic microorganisms, it could be an evolutionary mech- 
anism to expose universally conserved proteins (such as 
enolase, glyceraldehyde-3-phosphate dehydrogenase, many 
ribosomal proteins, etc.) to evade the host immune system, as 
they would not be recognized as foreign molecules by either 
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antibodies or T cells [30]. But also their presence on the surface 
could be correlated with the fact that those found are normally 
the most abundant proteins in the cells, like enolase [68]. 
Whether cytoplasmic proteins without any canonical 
secretion/exporting or retention signal are really translocated 
across the membrane to be extracellularly located or not, is 
still unresolved, although there are many evidences both in 
prokaryotes and eukaryotes [69–71]. About their possible 
anchoring on the surface, it has been proposed that  they 
could be surface-associated by non-covalent, electrostatic 
interactions with negatively charged molecules like the teichoic 
acids of Gram-positive bacteria [72], because many cytoplasmic 
proteins, like those ribosomal, have a positive net charge. 
Surface location of many of them has been demonstrated by 
immunochemical techniques [73,74], but there is also some 
literature demonstrating that some very abundant cytoplasmic 
proteins like EF-Tu, frequently found in “shaving” analyses, are 
not recognized by polyclonal sera in viable bacterial cells [75]. 
In addition to the apparent surface location of many  of 
them, some proteins such as enolase and glyceraldehyde-3- 
phosphate dehydrogenase have been described also as viru- 
lence factors [76,77], and to protect both against bacterial 
infection [73,78–85] and infectious diseases caused by fungal 
microorganisms [86–88]. 
4.3. Hypothesis three: predicted cytoplasmic proteins are 
released within membrane vesicles shed from the surface 
It is well known since nearly five decades that Gram-negative 
bacteria produce membrane vesicles that are released from 
the outer membrane. These structures may have different 
roles, as releasing material (even wastes from metabolic 
activity) in response to a stress on the cell [89,90], or serving 
as offensive weapons against the infected host, via toxins 
enclosed in the vesicles or causing pathogenic cells to avoid 
the immune system by an evasion mechanism (membrane 
vesicles would be the targets of both antibodies and T cells, 
thus allowing microbial cells to escape) [89,91]. 
Very recently, production of membrane vesicles has also 
been described for Gram-positive microorganisms. However, 
the mechanism by which vesicles are produced and released 
in this group of organisms is still unknown, as the cell wall 
constitutes an important physical barrier that theoretically 
hampers the release of such vesicles from the underlying 
plasma membrane. In 2009, Lee and coworkers [92] published 
the proteomic characterization of membrane vesicles produced 
by S. aureus. They identified 90 proteins, and almost 60% were 
predicted as cytoplasmic. The vesicles were also demonstrated 
to be produced in vivo in a mouse pneumonia model, and to 
induce apoptosis of host cells [93]. Rivera et al. [94] have 
demonstrated that also Bacillus anthracis produces membrane 
vesicles, and that their composition differs from that of plasma 
membrane at both protein and fatty acid levels, thus indicating 
that, although related, membrane vesicles are not likely to be an 
artifact derived from residual cell lysis. These vesicles contain 
also many predicted cytoplasmic proteins, apart from proteins 
with retention signals that act as toxins in an in vivo model. In 
addition, the B. anthracis membrane vesicles protect against 
infection in an animal model, thus indicating that they can be 
used as vaccinating agents. Prados-Rosales and coworkers [95] 
have also demonstrated the production of membrane vesicles 
in several species of the Mycobacterium genus, and these vesicles 
induce an inflammatory response both in vitro to macrophages 
and in vivo in a mouse lung infection model. Membrane vesicles 
have been demonstrated also to be produced by fungi, and 
proteomic analyses have revealed the presence of proteins 
predicted as cytoplasmic within such structures [96–99]. 
Release of vesicle structures in the incubation buffer after 
culturing and washing the cells might explain the identification 
of predicted cytoplasmic proteins, even in controls in which a 
protease has not been added. However, further research is 
needed to understand whether the presence of these proteins in 
“surfome” analyses may be due to shedding such membrane 
vesicles during the brief period of incubation in a buffer with the 
protease, as the kinetics of vesicle production and release is not 
yet clear. 
5. Future perspectives and challenges
Although the “shaving” approach can be used to confirm 
experimentally the expression of some protein(s) on the 
surface without depicting the whole “surfome” [39], the almost 
exclusive objective has been to describe the sets of surface- 
associated proteins of the organisms in which it has been 
carried out. When this has an applied aim as is to find novel 
vaccine candidates, the best option consists of carrying out a 
“pan-surfomic” analysis, i.e. to determine the “surfomes” of a 
collection of strains/clinical isolates, as broad as possible, in 
order to cover the most prevalent and/or virulent forms of a 
given pathogen. Therefore, the flowchart for novel vaccine 
candidate selection should be to select those proteins expressed 
on the surface, being immunogenic (which must be demon- 
strated by reaction with antibodies), sequence-conserved and 
common to all or most strains analyzed, in order to generate a 
broad cross-protection. However, meeting all these criteria is 
not always easy. Either when analyzing a low number of strains 
[27,30], moderate [20] or high (almost 40 in S. suis) [24], the 
common proteins to all the analyzed isolates is generally low. 
Then, other criteria may be defined, as the presence of a protein 
in at least 75% of the most prevalent/virulent isolates [24,27]. 
These same criteria can be applied to other aims: searching 
protein markers for developing serology-based diagnostic 
tools or epidemiological surveillance of populations. Our 
group has shown recently that “surfomics” serves for discover- 
ing proteins that are immunoreactive using sera from infected 
patients, both for early detection of infection (measuring the 
presence of IgM antibodies) or in advanced/convalescent 
phases (measuring the presence of IgG) [27]. 
Therefore, future programs for vaccine discovery of the 
most important microbial pathogens, as well as developing 
new diagnostic tools, can be based on the “shaving” strategy, 
complemented by other “omics” and bioinformatics analysis. 
A promising variation that has been recently described 
consists of the study of host proteins interacting with surface 
proteins  of  a  given  pathogen.  This  has  been  applied  in 
S. aureus [100] and Streptococcus gallotycus [101]. In both works, 
authors have identified proteins from host sera attached to 
surface proteins. This can open a new era in the study of host– 
pathogen   interactomes. 
Ph. D. Thesis – Alfonso Olaya Abril  Appendix I
226
174 J  O U R N A L  O F  P R O T E O M I C S  9 7  ( 2 0 1 4 )  1 6 4 – 1 7 6 
6. Concluding remarks
“Shaving” live organisms with proteases has proven as a fast 
and reliable way to identify a set of surface-associated 
proteins, which can enter the pipeline of discovery of novel 
therapeutic or diagnostic tools. In this sense, pan-surfomics is 
an adequate strategy to find candidates fulfilling the criteria 
of ideal molecules. Further research is needed to understand 
the source of predicted cytoplasmic proteins in the “surfomes”, 
so that the term “contamination” to refer to them must be 
revised. Proteomics contributes to shedding light on the new 
vision of biology, in particular on the growing field of Systems 
Biology, as it reveals the cell and any biological system as a 
dynamic structure, thus changing our conception of biological 
compartments. A promising new application of the “shaving” is 
the study  of host–pathogen interactomics. This may aid to 
understand the molecular and physiological mechanisms by 
which microorganisms infect and invade hosts. 
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Strain156 2 3 0 0 0 1.0 56% 14% 
Strain162 1 2 1 0 0 1.33 5% 0% 
Strain838 1 2 1 0 0 1.33 10% 0% 
Strain557 1 1 2 0 0 1.66 0% 0% 
Appendix III. Evolutionary relationship in pneumococcal clinical isolates used 
 No. isolates = 40 | No. STs = 29 | No. re-samplings for bootstrapping = 1000 No. 
loci per isolate = 7 | No. identical loci for group def = 6 | No. groups = 3 
Group 1: No. Isolates = 5 |  No. STs = 4 | Predicted Founder = 9 
Average ST Bootstrap 
ST FREQ SLV DLV TLV SAT Distance Group  Subgrp 
Group 2: No. Isolates = 2 |  No. STs = 2 | Predicted Founder = None 
ST FREQ SLV DLV TLV SAT Distance 
Strain94 1 1 0 0 0 1.0 
Strain2204 1 1 0 0 0 1.0 
Group 3: No. Isolates = 3 |  No. STs = 2 | Predicted Founder = None 
ST FREQ SLV DLV TLV SAT Distance 
Strain1223 2 1 0 0 0 1.0 
Strain289 1 1 0 0 0 1.0 
Singletons: size 21 
Strain386 Strain53 Strain2480 
Strain1876 
Strain81 
Strain1221 
Strain1201 
Strain88 Strain180 
Strain202 Strain7340 
Strain276 Strain260 
Strain113 Strain228 
Strain62 Strain433 
Strain989 Strain306 
Strain191 Strain304 247
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